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Abstract: 
A debilitating degenerative autoimmune disease, Multiple Sclerosis (MS) is characterised by 
demyelination of neurons in the central nervous system (CNS). The exact cause of MS is 
unknown; though MS is thought to arise in genetically susceptible individuals, elicited by 
environmental factors. Around 32% of disease risk is due to genetic factors; HLA-DR has the 
strongest association with MS. Other MS risk genes of interest here are CD40, a member of the 
TNFR superfamily, transcription factors ZFP36L2, EOMES and TBX2, the transcription factor 
regulator ZMIZ1, and RPS6KB1, which phosphorylates ribosomal protein S6 (RPS6). As 70% of MS 
risk cannot be explained by genetics; a large portion must be due to environmental factors. Here, 
we focus on two main environmental factors influencing MS risk; the Epstein Barr Virus (EBV) 
and Multiple sclerosis associated retrovirus (MSRV). Virtually all MS patients are seroconverted 
to EBV, and MS patients are found to have increased levels of anti EBNA-1 IgGs, an EBV latency 
protein. Sodium serum levels will also be investigated. 
In this project, we confirm that anti EBNA-1 IgGs are increased in MS patients, independent of 
total IgG levels in the blood, alongside a significant association between anti EBNA-1 IgG levels 
with rs2516049, an MS risk SNP for HLA-DR. We found no significant association of the SNP most 
associated in MS; rs9271366. ZMIZ1, RPS6 and ZFP36L2 were associated with anti EBNA-1 titres 
and may contribute to the immune response to EBV.  The MS protective allele of CD40 is 
associated with higher expression of CD40 in lymphoblastic cell lines (LCLs) derived by EBV 
transformation of B-cells, and culture of LCLs in the presence of CD40L reduces their proliferation 
a genotype dependant manner. This suggests that the protective allele of CD40 reduces MS risk 
by reducing EBV susceptibility. MSRVenv was previously found to be overexpressed in MS 
lymphocytes, were found to be expressed at very low levels in MS and healthy controls, with no 
statistically significant differences between them. No correlation between MSRVenv mRNA and 
anti EBNA-1 IgG titres suggests a lack of association between MSRVenv, MS and EBV. Here, we 
show that EBV is likely to contribute to MS risk by way of the MS risk genes of ZMIZ1, RPS6, 
ZFP36L2 and particularly, CD40. MSRV is unlikely to contribute to MS risk through EBV. 
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Chapter 1: Introduction: 
Multiple Sclerosis (MS) is the most common neurological disease of the central nervous system 
(CNS) in young adults (Ramagopalan and Sadovnick 2011), affecting more than 2.3 million people 
worldwide, mainly in North America, Europe, Australia and New Zealand [Figure 1.1] (Browne, 
Chandraratna et al. 2013). It is a degenerative autoimmune disease characterised by 
demyelination of neurons in the CNS (Sospedra and Martin 2005, Pender 2010). Disease onset 
typically occurs between the ages of 15 and 50 years old, resulting in permanent heterogeneous 
disability; including but not limited to loss of sensation, motor, autonomic, and neurocognitive 
ability (Sospedra and Martin 2005, Haahr and Hollsberg 2006).  
 
Figure 1.1: Global Prevalence of MS in 2013 (Browne, Chandraratna et al. 2013) 
 
Despite the common themes of inflammation, demyelination and subsequent neurodegeneration, 
with little consistency between patients, the aetiology of MS remains elusive due to its complexity 
and heterogeneity (Feinstein, Freeman et al. 2015). MS is an extremely polysymptomatic disease, 
presenting with a broad range of symptoms ranging from loss of vision due to optic neuritis to loss 
of mobility, hand function, fatigue, sensory problems, loss of cognition, spasticity, loss of bladder 
and/or bowel function, pain, depression and tremors (Kister, Bacon et al. 2013). Patients can have 
any number and any combination of these symptoms depending on the location of the 
demyelinated lesions, but characteristic to MS is the Lhermitte’s symptom (an electrical sensation 
upon neck flexion), and Uhthoff phenomenon (transient worsening of symptoms when core body 
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temperature rises) (Compston and Coles 2008). The pathology of lesions also shows heterogeneity, 
with variations in demyelination patterns between individuals; some showing patterns similar to 
T cell mediated or T cell and antibody mediated EAE, and others showing primary oligodendrocyte 
dystrophy, possibly virus or toxin induced (Lucchinetti, Bruck et al. 2000).  
 
The first presentation of MS is usually as a clinically isolated syndrome (CIS), where a single episode 
of neurological deficit occurs in isolation from any other neurological events, with 63% eventually 
progressing to MS; this number rising to 82% if accompanied with abnormal MRI at time of CIS 
(Fisniku, Brex et al. 2008). The most common form of MS; relapsing-remitting MS (RRMS) which 
affects approximately 85% of all MS patients, is characterised by recurring bouts of neurological 
dysfunction coinciding with CNS inflammation and demyelination, followed by a period of 
symptomatic recovery (Dendrou, Fugger et al. 2015). This recovery eventually wanes as the disease 
progresses; resulting in accumulating neurological disability. Most RRMS patients go on to develop 
secondary progressive MS (SPMS), where disease progression is constant and accompanied by CNS 
atrophy (Dendrou, Fugger et al. 2015).   
 
Approximately 10% of all MS patients are diagnosed with primary progressive MS (PPMS), which 
mimics SPMS in its constant disease progression (Dendrou, Fugger et al. 2015). MS causes major 
personal and socioeconomic burden costing approximately $41 866 per patient annually in 
Australia (Trisolini, Honeycutt et al. 2010). Current treatments include immunomodulatory drugs, 
which can abate further progression of the disease; some with severe side effects (Wingerchuk 
and Carter 2014, Dendrou, Fugger et al. 2015), and symptomatic based treatments such as 
physiotherapy, botulinum toxin and cognitive therapy (Feinstein, Freeman et al. 2015). Currently, 
there are two treatments on offer that can halt disease progression, but none that can recover lost 
neurological function.  Alemtuzumab is an anti CD52 monoclonal antibody that results in a ~90% 
relapse reduction, with most adverse events relating to opportunistic infections (67-77%) and 
thyroid autoimmune disease (35-41%) (Willis and Robertson 2016). Autologous hematopoietic 
stem cell transplant can halt the disease in some patients (Atkins, Bowman et al. 2016), but this 
procedure is fraught with risks due to high toxicity involved in both full and partial immunoablation 
(von Wunster, Bailey et al. 2018). Additionally, as the transplant is autologous, the inherent MS 
genetic risks would still be present (von Wunster, Bailey et al. 2018). The need for more effective 
and specific therapy that can halt disease progression with minimal side effects is clear, for which 
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a better understanding of MS pathogenesis is crucial (Dendrou, Fugger et al. 2015, Feinstein, 
Freeman et al. 2015). 
 
1.1: MS Pathogenesis 
 
To date, MS pathogenesis is known to involve the breakdown of autoreactive T cell tolerance 
mechanisms (Dendrou, Fugger et al. 2015),  followed by the disruption of the blood-brain barrier 
(BBB) to allow migration and infiltration of autoreactive CD4+ and CD8+ T cells that mediate CNS 
damage (Huseby, Liggitt et al. 2001, McFarland and Martin 2007). While MS pathogenesis was 
traditionally considered to be T cell-mediated, genetic evidence suggests that a complex network 
of immune mechanisms involving both innate and adaptive immunity is likely to be involved (Kaur, 
Trowsdale et al. 2013). However, it is unclear what events lead to the demyelination and 
subsequent neuron damage. Multiple hypotheses attempt to elucidate further the complex 
mechanisms that underlie MS pathogenesis. These include molecular mimicry (Fujinami and 
Oldstone 1985, Munz, Lunemann et al. 2009), bystander activation (Munz, Lunemann et al. 2009), 
autoreactive T cell and B cell activation and persistence resulting from defective immune 
regulation (McFarland and Martin 2007) and CNS-intrinsic events (Dendrou, Fugger et al. 2015).  
 
Molecular mimicry  
Some microbial antigens exhibit homology to self-antigens resulting in T cell receptor cross-
reactivity to self (Munz, Lunemann et al. 2009). Exposure to the microbe triggers an inflammatory 
cascade directed against self-antigen resulting in the tissue damage seen in inflammatory 
autoimmune diseases (Figure 1.2 [A]) (Munz, Lunemann et al. 2009). In the case of MS, many viral 
antigens share homology with Myelin Basic Protein (MBP); such as Hepatitis-B virus polymerase, 
Influenza Haemagglutinin (Oldstone 1998) and Epstein Barr Virus Nuclear Antigen-1 (EBNA-1) 
(Bray, Luka et al. 1992). These EBNA-1 cross-reactive T cells produce interferon- (IFN) (Munz, 
Lunemann et al. 2009); associated with promoting relapse in MS (Panitch, Haley et al. 1987), and 
interleukin -2, which stimulates proliferation of activated T cells and whose receptor is abnormally 
found in the MS brain (Hofman, von Hanwehr et al. 1986).  
 
Bystander activation  
Antigen presenting cells that become activated in the inflammatory setting of a pathogenic 
infection may stimulate the activation of autoreactive or cross-reactive T or B cells (Figure 1.2 [B]) 
(Munz, Lunemann et al. 2009). This can be done by presentation of self-antigen released due to 
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tissue damage or via microbial superantigens, resulting in non-specific or auto-antigen-specific T 
cell activation (Munz, Lunemann et al. 2009). Other myelin components including myelin 
oligodendrocyte glycoprotein (MOG) and proteolipid proteins have also been identified as 
potential targets for autoreactive T cells (Munz, Lunemann et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Cross-reactivity and Bystander Activation (Munz, Lunemann et al. 2009) 
A | Molecular mimicry: autoreactive T cells can be activated involving cross-reactive 
recognition of a viral antigen that has similarity to self-antigen. Ba | Microbial infection 
stimulates TLRs and other PAMPs on APCs, leading to the production of pro-inflammatory 
mediators and tissue damage. Bb | Bystander activation: Self antigen released from damaged 
tissue can be taken up by activated APCs, processed and presented to autoreactive T cells. 
Alternatively, an infection can lead to microbial superantigen-induced activation of some T 
cells, which could be autoreactive. TLR, Toll-like receptors; PAMP, pathogen-associated 
molecular pattern; APC, antigen presenting cells; TCR, T cell receptor (Munz, Lunemann et al. 
2009). 
 
Defective immune regulation 
One of the most studied hypotheses to account for autoimmunity in MS is defective immune 
regulation, where a breakdown of tolerance to self-antigens has occurred. Two non-mutually 
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exclusive T-cell signalling pathways have been identified; defective immune suppression involving 
T-regulatory (T-reg) cells, and effector cell resistance to these suppressive mechanisms (McFarland 
and Martin 2007, Dendrou, Fugger et al. 2015).  Defective immune suppression involves mainly 
CD4+ T-reg cells expressing Forkhead box P3; a transcription factor often downregulated in 
autoimmune disease, along with type I T-reg cells that produce IL-10 (McFarland and Martin 2007, 
Dendrou, Fugger et al. 2015), a cytokine that ameliorates effector T cell responses (Couper, Blount 
et al. 2008). These cells are often decreased in MS patients and/or have reduced suppressive 
capacity (Dendrou, Fugger et al. 2015) which may be improved with treatment, as in the case of 
Glatiramer Acetate and IFN-β, increasing the number of circulating naïve CD4+ T-reg cells (Venken, 
Hellings et al. 2008). Increased resistance to immunosuppression is suggested to involve increased 
IL-6 induced STAT3 mediated signalling, inhibiting the function of T-reg cells (McFarland and 
Martin 2007, Dendrou, Fugger et al. 2015).  
 
Experimental Autoimmune Encephalomyelitis (EAE) 
One of the most commonly used animal models of multiple sclerosis is experimental autoimmune 
encephalomyelitis (EAE), in which brain emulsion or myelin antigens are used to stimulate a CNS-
specific immune response. This model induces inflammatory CNS disease in all vertebrates tested. 
Various models of disease induction are used, and each have been useful in informing specific 
aspects of inflammatory CNS pathology (Pöllinger, Krishnamoorthy et al. 2009). One of the most 
used protocols is active immunisation, in which brain antigens are injected with a strong adjuvant 
such as Complete Freund’s adjuvant. This results in an inflammatory encephalopathy in which 
auto-reactive CD4+ T cells drive axonal injury, resulting in secondary demyelination, which is quite 
different to the primary demyelination seen in MS (Nikić, Merkler et al. 2011). In addition, 
pathology is largely restricted to the spinal cord. Passive transfer of autoreactive T cell clones (CD4 
or CD8), or co-transfer of T cells and pathogenic autoantibodies are alternative methods of disease 
induction, as well as focal injury/inflammatory stimulus in animals pre-sensitised with CNS 
antigens (Pöllinger, Krishnamoorthy et al. 2009).  
 
While the EAE model is an imperfect replicate of the human disease, it has facilitated identification 
and characterisation of aspects in immune surveillance, inflammation and immune mediated 
tissue injury. It was also used in developing three immunotherapies for MS; glatiramer acetate, 
mitoxantrone and natalizumab (Baxter 2007).  More recently, EAE models have been developed 
using transgenic TCR variants recognizing specific myelin epitopes. These are arguably one of the 
most human MS-like models, in that they exhibit spontaneous disease onset, with both relapsing-
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remitting and primary progressive MS phenotypes and require MOG-specific B cell involvement 
for disease manifestation (Lassmann and Bradl 2017). It is hoped that the development of 
humanised, and of B-cell dependent EAE models will shed light on further facets of the human 
disease (Pöllinger, Krishnamoorthy et al. 2009). 
 
T cells in MS 
Historically, MS has been known to be primarily a T cell disease, with emphasis on CD4+ 
autoreactive T cells, due to findings based on experimental autoimmune encephalomyelitis (EAE), 
the main animal model of MS (Ramagopalan, Dobson et al. 2010). However, human studies have 
shown that while CD4+ T cells may be important to disease development and/or progression, 
depletion of CD4+ T cells alone is not efficacious clinically (Van Oosten, Lai et al. 1997, Dendrou, 
Fugger et al. 2015). One subset of CD4+ T cells implicated in MS is Th17, T-helper cells that produce 
Interleukin 17 (IL-17), a pro-inflammatory cytokine that appears to be essential for the disease 
process in EAE (Kasper and Shoemaker 2010). However, it must be considered that EAE is a murine 
model, and it has significant differences to MS, not least due to the differences between mice and 
humans. In humans, the presence of IL-17 producing T cells, astrocytes and oligodendrocytes in 
active MS lesions further supports the role of IL-17 in MS pathogenesis (Tzartos, Friese et al. 2008).  
 
Another major subset of CD4+T cells implicated in MS are Th1 cells, in part due to studies with EAE, 
where the disease is mediated by Th1 cells (Sospedra and Martin 2005). Additionally, acute lesions 
are thought to be induced by Th1 cells (McFarland and Martin 2007). The Th1 phenotype is 
characterised by the proinflammatory cytokines IFN-γ, TNF-α, IL-1 and IL-2, cytokines that are 
found to be upregulated in MS (McFarland and Martin 2007). Some treatments such as glatiramer 
acetate are thought to work by shifting Th1 cytokine profiles into a more Th2/Th3 phenotype that 
is thought to be more anti-inflammatory, elevating IL-4 and IL-10, along with TGF-β (Duda, Schmied 
et al. 2000). 
 
More recently, CD8+ T cells have been implicated in both EAE and MS (Friese and Fugger 2005). 
CD8+ T cells have been found to outnumber CD4+ T cells in MS lesions by almost tenfold (Neumann, 
Medana et al. 2002) and their clonal expansion also outnumbers the CD4+ T cell expansion in active 
brain lesions by at least a factor of three (Babbe, Roers et al. 2000). In addition to this, autoreactive 
CD8+ T cells specific for neuroantigens have been found in MS patients (Crawford, Yan et al. 2004).  
Given the main functions of CD8+ T cells as cytotoxic lymphocytes (CTLs), it can be hypothesised 
that these cells mediate and amplify the damage initiated by CD4+T cells (McFarland and Martin 
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2007). Conversely, it has also been hypothesised that the damage to neurons in MS are initiated 
by autoreactive CD8+ T cells, causing mild disease, followed by CD4+ T cells that mediate the 
damage characteristic in MS (Friese and Fugger 2009). This is supported by the enrichment of CD8+ 
Tc17 cells in the CSF in early-stage MS patients (Huber, Heink et al. 2013). CD8 and CD4 T cells have 
been shown to work synergistically in EAE, with CD8+-derived IL-17A required to allow CD4 T cell 
infiltration of the CNS and Th17-mediated induction of disease (Huber, Heink et al. 2013).  
 
It has been hypothesised that CD8 Tc17 cells activate antigen-presenting cells (APCs) to polarise 
CD4 T cells towards a pathogenic Th17 phenotype, initiating a first wave of CNS infiltration of CD4 
T cells. These Th17 cells subsequently facilitate migration of Tc17 cells into CNS – the second wave 
of infiltration (Huber, Heink et al. 2013). Further study is required to dissect the CD4-CD8 interplay 
in disease propagation, especially in human disease (Legroux and Arbour 2015).       
 
B cells in MS 
B cells closely interact with T cells both in and out of the immune privileged CNS, and are thought 
to contribute to MS mainly via autoreactive antibody production, cytokine production and T cell 
activation (Archelos, Storch et al. 2000).  Despite the emphasis on T cell interactions in MS, the 
humoral immune system is known to be involved in MS since 1948, when Kabat et al reported 
increased cerebrospinal fluid (CSF) immunoglobulins in 8 out of 14 MS patients tested (Kabat, 
Glusman et al. 1948, Archelos, Storch et al. 2000). These immunoglobulins can be seen as 
oligoclonal bands under protein electrophoresis, and are regarded as a hallmark and diagnostic 
tool for MS, with a prevalence of 88-90% (Compston and Coles 2008, Dobson, Ramagopalan et al. 
2013). A high frequency of clonally expanded B cells can be found within the CSF of MS patients, 
indicative of antigen driven B cell activation (Serafini, Rosicarelli et al. 2004), either through cross-
reactivity with pathogens or self-antigen presentation. It is likely that this process occurs locally 
within the CNS, as ectopic germinal centres composed of B cells, T cells, plasma cells and follicular 
dendritic cells (DCs) have been found in SPMS (Serafini, Rosicarelli et al. 2004). Furthermore, a 
predominance of B cells over monocytes in the CSF of patients is associated with faster disease 
progression (Cepok, Jacobsen et al. 2001). 
 
Despite the presence of oligoclonal bands in most MS patients, their role in disease pathogenesis 
remains controversial, with many recombinant antibodies generated from clonally expanded CSF 
plasma cells from MS patients failing to bind to probable autoantigens such as MBP and myelin 
oligodendrocyte protein (MOG) (Disanto, Morahan et al. 2012). On the other hand, MS patients 
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that do not produce oligoclonal bands progress slower and have better prognosis than those who 
do (Joseph, Hirst et al. 2009). Anti-MOG and -MBP antibodies can be found in the serum of some 
MS patients but are not predictive of conversion from CIS to MS, (Kuhle , Pohl  et al. 2007). The 
Epstein Barr virus (EBV), as will be discussed later, is a B cell virus capable of maintaining B cells in 
an immortal/ memory state. Thus it has been hypothesised that one of the ways that EBV 
contributes to MS pathogenesis is by ‘rescuing’ B cells from central negative selection, resulting in 
persistence of autoreactive plasma and memory B cells (Taylor, Long et al. 2015).  
 
Perhaps the strongest evidence for B cell involvement in MS is the success of rituximab and 
ocrelizumab, monoclonal antibodies against CD20 (expressed in most B cells), in suppressing 
relapses (Kappos, Li et al. , Hauser , Waubant  et al. 2008). A recent Phase III trial of ocrelizumab 
also demonstrated effectiveness in PPMS patients (Montalban, Hemmer et al. 2016), indicating 
that B cells play a vital role in disease progression. On the other hand, it is also possible that the 
anti-CD20 drugs prevent the differentiation of autoreactive B cells into plasma cells, thus 
ameliorating disease progression (Montalban, Hemmer et al. 2016). Another drug that may exert 
clinical effects via B cells in MS is IFNβ, as therapy correlates with an increase of transitional B cells 
in patients (Schubert, Hu et al. 2015). These cells produce IL-10 in much greater numbers 
compared to other B cells (Schubert, Hu et al. 2015), a cytokine known to dampen 
immunopathology, particularly effector T cell responses (Couper, Blount et al. 2008). Another 
cytokine implicated in MS is B cell attractant CXCL13, which is elevated in the CSF of MS and CIS 
patients and also correlated with CSF total leukocyte and B cell counts, MRI activity and relapse 
rate (Disanto, Morahan et al. 2012).  
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Figure 1.3: Some B and T cells interactions in MS pathogenesis  
Probable B and T cell interactions for MS involvement via cytokine secretion, antigen 
presentation and antibody production, with EBV rescue of autoreactive B cells leading to 
inflammation and demyelination. Red arrows represent events that promote 
inflammation/demyelination, green arrows represent protective mechanisms. 
 
1.2: Risk Factors for Multiple Sclerosis 
MS is thought to arise in genetically susceptible individuals, elicited by environmental factors. 
Though the precise cause of MS is unknown, evidence has shown that gender, age, genetic and 
environmental factors play a crucial role (Ramagopalan, Dobson et al. 2010). Environmental 
factors associated with MS include smoking, vitamin D levels and latitude, sodium intake, and viral 
infections, in particular the Epstein-Barr virus (EBV) and endogenous retroviruses (Ramagopalan, 
Dobson et al. 2010). We hypothesise that a subset of MS risk genes mediate susceptibility through 
interaction with the Epstein-Barr virus, or the associated retrovirus, MSRV.   
 
Genetic Factors 
Genetic factors were first hypothesised to have a role in MS in the 1890s, when it was noted that 
there is a degree of familial aggregation in MS (Dyment, Ebers et al. 2004). Since then, it has been 
long recognised that MS prevalence is mostly concentrated in those of Caucasian descent, with 
migration studies pointing towards a strong genetic influence (Kurtzke, Beebe et al. 1979). On the 
other hand, new studies have shown that African Americans are not at a reduced risk of developing 
MS, and are more likely to have a more severe disease course compared to Americans with 
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European ancestry (Hollenbach and Oksenberg 2015). Female monozygotic twin studies show that 
approximately 30- 34% of disease risk is due to genetic factors (Dyment, Ebers et al. 2004, Marrie 
2004, Dendrou, Fugger et al. 2015), with first degree relatives having a 3-5% recurrence risk as 
compared to the global prevalence of approximately 0.2% (Dyment, Ebers et al. 2004). While these 
numbers are still comparatively small, this equates to more than 15-35 times greater risk 
compared to the general population (Dyment, Ebers et al. 2004, Ramagopalan and Sadovnick 
2011). Adoption and half sibling studies show those with no genetic relation to MS patients have 
the same recurrence risk as compared to the general population, suggesting that most, if not all 
familial aggregation in MS is due to genetics (Dyment, Ebers et al. 2004, Ramagopalan and 
Sadovnick 2011).  
 
Despite the drastically increased recurrence rates in families, it is highly unlikely that the genetic 
basis of MS follows a simple model of inheritance, rather, the general consensus is of a complex 
and multifactorial model of many genes each exerting small effects (Hollenbach and Oksenberg 
2015). More than 200 genetic MS risk variants as single nucleotide polymorphisms (SNPs) have 
been identified by international genome wide association studies (GWAS) (Beecham and IMSGC 
2013, Patsopoulos, Baranzini et al. 2017). The current study focuses on a subset of these MS risk 
variants that we hypothesise may mediate MS risk via interaction with the Epstein Barr virus, as 
described in the following sections. These include the HLA-DRB1*1501 and DRB5*0101 variants 
(Schmidt, Williamson et al. 2007), and SNPs within or in close proximity to genes encoding 
Eomesodermin (EOMES) and T-box transcription factor (TBX21), ZMIZ-1 and CD40 (The 
International Multiple Sclerosis Genetics Consortium (IMSGC), Wellcome Trust Case Control 
Consortium 2 (WTCCC2) et al. 2011, Beecham and IMSGC 2013). The strongest genetic risk factors 
in MS are HLA-DR and DQ, in particular, HLA-DRB1*1501 which confers a dose effect (Sospedra 
and Martin 2005).  
 
HLA-DR  
Also known as the major histocompatibility complex (MHC), the Human Leukocyte Antigen (HLA) 
is heavily involved in antigen presentation on the surface of antigen presenting cells (Schmidt, 
Williamson et al. 2007). Its genes are located on chromosome 6 in a dense cluster containing 
greater than 130 protein coding genes (Shiina, Hosomichi et al. 2009). These genes are crucial in 
the regulation of the immune system, and some are involved in CNS development, plasticity and 
neurological cell interactions (Shiina, Hosomichi et al. 2009). HLA-DR in particular is located in the 
class II region, contains 669 alleles and is highly polymorphic (Shiina, Hosomichi et al. 2009). HLA 
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genes and their products play a critical role in immune responses and histocompatibility, with 
more than 100 disease phenotypes associated with variations in these genes (Hollenbach and 
Oksenberg 2015). Class II regions encode the HLA-DR, DQ and DP molecules found on the surface 
of antigen presenting cells such as B cells, DCs and macrophages (Hollenbach and Oksenberg 
2015). 
 
Of all of the MS risk genes, HLA-DR has the strongest association with MS, and of its variants, the 
DRB1*1501 allele confers the highest risk with an odds ratio of 3.1 followed by DRB1*1303 at an 
odds ratio of 2.4 (The International Multiple Sclerosis Genetics Consortium (IMSGC), Wellcome 
Trust Case Control Consortium 2 (WTCCC2) et al. 2011). HLA-DRB1 *15:01 confers a dose effect 
(Sospedra and Martin 2005), and is mostly associated with DQA1*0102 and DQB1*0602 in relation 
to MS, but most of these studies were conducted in European populations where the three alleles 
are most often inherited together (Schmidt, Williamson et al. 2007). Studies in other populations 
show other alleles may be involved, including the DRB1*0801, *1303, *0405, *1503 and 
DRB5*0101 (Lang, Jacobsen et al. 2002, Hollenbach and Oksenberg 2015). Table 1.1 lists in further 
detail HLA-DR and DQ alleles associated with MS.  
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Table 1.1: HLA class I and II alleles associated with Multiple Sclerosis 
Adapted from Sospedra and Martin (2004)  
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HLA-DRB1 is also associated with EBV infection, a known environmental risk factor for MS (page 9 
- 10), where titre of antibodies to the viral EBNA-1 gene expressed by latently infected B cells, is 
associated with SNPs rs477515 and rs2516049 found within the HLA-DRB1 gene (Rubicz, Yolken et 
al. 2013). In addition, HLA-DRB1*15:01 and HLADRB5*0101  restricted peptides derived from MBP 
and EBV respectively, were found to be recognised by the T cell receptor of an MS patient with a 
very similar crystal structure, supporting the hypothesis of molecular mimicry (Lang, Jacobsen et 
al. 2002). 
 
EOMES 
EOMES and TBX21 are paralogue genes that encode the highly homologous transcription factors 
Eomesodermin (Eomes) and T-bet, which drive differentiation of NK cell and CD8+ memory cells 
(Intlekofer, Takemoto et al. 2005). Both Eomes and T-bet are required for the cytotoxic capabilities 
of CD8+ T cells, however, ectopic expression of EOMES alone is sufficient to trigger enzymes 
required for cytotoxic activity such as IFN-γ, perforin and granzyme- B (Pearce, Mullen et al. 2003, 
Lazarevic, Glimcher et al. 2013). Mice deficient in T-bet and Eomes are deficient in NK  cells and 
memory CD8+ T cells (Intlekofer, Takemoto et al. 2005). Our group has shown previously that MS 
patients exhibit lower expression of EOMES and TBX21 compared to healthy controls in peripheral 
blood (Parnell, Gatt et al. 2014, McKay, Gatt et al. 2016), and lower expression of Eomes and T-bet 
proteins within NK cells and CD8 T cells (McKay, Gatt et al. 2016). Given the reduced expression of 
Eomes and T-bet (and their respective genes) in peripheral blood, we questioned whether the 
cytotoxic capacity pf NK cells and CD8+ T cells may be impaired in MS.   
 
NK cells are the first line of immune defence against EBV infection.  Recently a humanised mouse 
model has demonstrated the critical role of human NK cells in control of lytic EBV infection, with 
NK cell depletion associated with enhanced symptoms of infectious mononucleosis and EBV 
tumorigenesis.  (Chijioke, Muller et al. 2013). CD8+ memory T cells are critical to ongoing immune 
control of established EBV infection (Pender 2012) and their reduced frequency and cytotoxic 
capacity against EBV in MS has been hypothesised to be associated with loss of control of EBV 
infection in MS (Pender, Csurhes et al. 2014, Pender, Csurhes et al. 2017). These data have led us 
to question whether there is any relationship between EBV infection control (as measured by anti-
EBNA-1 titres) and Eomes and T-bet expression or genotype (MS risk SNPs).    
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1.3: CD40 
CD40 is 48-kDa type I transmembrane protein, part of the Tumour Necrosis Factor Receptor (TNFR) 
superfamily and is found on chromosome 20 (Elgueta, Benson et al. 2009). Mainly expressed on B 
cells, it can also be expressed on DCs, monocytes, macrophages and platelets, along with 
myofibroblasts, fibroblasts, epithelial, and endothelial cells (Elgueta, Benson et al. 2009). The 
ligand for CD40, CD40L, also known as CD154, is usually found transiently expressed on activated 
T cells, but can also be found on activated B cells, and platelets, monocytes, natural killer (NK) cells 
(Carbone, Ruggiero et al. 1997), mast cells and basophils (Elgueta, Benson et al. 2009).  
 
CD40-CD40L interaction results in CD40 binding to TNF receptor-associated factors (TRAFs) that 
mediate signal transduction. CD40 binds TRAFs 2, 3, 5 and 6, along with an indirect association 
with TRAF1 (Peters, Stunz et al. 2009). TRAF2, 5 and 6 are required for nuclear factor κB (NF-κB) 
activation; TRAF3 downregulates CD40, and TRAF5 and 6 are also involved in c-Jun N-terminal 
kinases (JNK) activation and IL-6 production (Ishida, Mizushima et al. 1996, Peters, Stunz et al. 
2009). Engagement of CD40 by CD40L results in activation of pathways such as NF-κB, mitogen 
activated protein kinases (MAPKs), JNK, phosphoinositide 3 Kinase and phospholipase Cγ (Elgueta, 
Benson et al. 2009, Peters, Stunz et al. 2009). The downstream effects of CD40 activation include 
but are not limited to T cell dependent B cell activation, differentiation into plasma cells and 
memory B cells, Ig isotype switching, germinal centre formation and somatic hypermutation to 
enhance Ig affinity (Elgueta, Benson et al. 2009, Peters, Stunz et al. 2009). CD40 signalling also 
stimulates production of cytokines, adhesion molecules and matrix metalloproteinases (MMPs) 
(Chatzigeorgiou, Lyberi et al. 2009). Unsurprisingly, given its crucial and varied role in immune 
regulation, genetic variation in CD40 is implicated in susceptibility to many autoimmune diseases 
other than MS, including Grave’s disease, type 1 diabetes mellitus, psoriasis, inflammatory bowel 
disease, rheumatoid arthritis and systemic lupus erythematosus (Peters, Stunz et al. 2009). 
 
The CD40 paradox in MS 
Several single nucleotide polymorphisms (SNPs) in the CD40 gene confer risk of MS, including 
rs1883832, located 1 base pair prior to the CD40 transcription start site (Australia New Zealand 
Multiple Sclerosis Genetics Consortium 2009, Beecham and IMSGC 2013). For rs1883832, the MS 
risk is allele is T, a minor allele that is also associated with increased risk of Crohn’s disease (Blanco-
Kelly, Matesanz et al. 2010). The MS protective allele, C, is associated with an increased risk of 
Graves’ disease and rheumatoid arthritis (Blanco-Kelly, Matesanz et al. 2010, Field, Shahijanian et 
- 15 - 
 
al. 2015). The minor T MS risk allele is associated with decreased CD40 mRNA expression in B cells 
and differentiated DCs of healthy controls (Field, Shahijanian et al. 2015), indicating a protective 
function of CD40 in MS. In addition, MS patient B cells are found to have lower levels of CD40, at 
both the mRNA and protein levels, when compared to healthy controls (Field, Shahijanian et al. 
2015). However, this finding is controversial, with other studies finding either no difference or 
increased CD40 levels in MS patients (Huang, Huang et al. 2000, Buck, Kroner et al. 2006). 
 
Both T cell and B cell infiltration into the brain is associated with demyelinating lesion activity in 
MS (Frischer, Bramow et al. 2009), and integral to these interactions are CD40 and CD40L 
(Archelos, Storch et al. 2000). CD40-CD40L interaction increases T and B cell activation along with 
proinflammatory cytokine production, among which is IL-6, a cytokine implicated in MS 
pathogenesis (Bush and Bishop 2008, Dendrou, Fugger et al. 2015). Given the role of CD40-CD40L 
in inflammation, the finding of lower CD40 expression associated with MS and MS risk SNPs was 
unexpected; and we have called the “CD40 paradox” A possible explanation for the 
downregulation of CD40 in MS is that it is a homeostatic response to the heightened chronic 
inflammatory state in MS.  
 
Alternatively, in addition to the role of CD40-CD40L in inflammatory pathways,   
CD40 - CD40L interaction has other complex downstream effects; including anti-inflammatory 
processes that may be protective in MS. CD40 is involved in activation and expansion of T-reg cells, 
along with B cell production of IL-10, an anti-inflammatory cytokine that can inhibit symptoms in 
EAE (Tu, Lau et al. 2008, Yoshizaki, Miyagaki et al. 2012). Thus, lower expression of the CD40 risk 
allele may reduce T-reg and anti-inflammatory B cell pathways.  Finally, we propose that the “CD40 
paradox” may arise due to higher CD40 expression conferring protection from EBV “hijacking” of 
the cell signalling pathways, discussed in a subsequent section.   This EBV hypothesis will be tested 
in this thesis.  
1.4: Environmental Risk Factors: 
Despite the large role that genetic factors play in MS pathogenesis, around 70% of MS risk cannot 
be explained by genetics (Ebers 2008); of which a large portion must then be due to environmental 
factors, in addition to other unknown events. There are two main environmental factors 
influencing MS risk, the first being Vitamin D/UV, and the second; infectious disease involvement, 
particularly, the Epstein Barr Virus. Viruses as a contributory factor to the development of MS is 
supported by the evidence that demyelination in humans can be associated with viral infections 
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as in the cases of: Human T-lymphotropic virus type 1 associated myelopathy, subacute sclerosing 
panencephalitis with the measles virus, and progressive multifocal leukoencephalopathy with the 
John Cunningham virus (Scarisbrick and Rodriguez 2003). Candidate viruses for pathogens 
contributing to MS are mainly the herpes viruses EBV and human herpesvirus 6 (HHV-6), along 
with human endogenous retroviruses, specifically the Multiple sclerosis associated retrovirus 
(Scarisbrick and Rodriguez 2003). 
 
1.5: The Epstein Barr Virus 
EBV is a gamma-herpes virus, and is almost ubiquitous in 
the population, with a seroconversion rate of 90-94% 
(Ramagopalan, Dobson et al. 2010, Jørgensen, Livbjerg et 
al. 2012). EBV infects humans via the oral route, causing 
acute inflammation and subsequent latent infection, 
present throughout lifetime with occasional reactivation 
(Pender 2010).  EBV infection presents as asymptomatic or 
mild flu-like illness in childhood (Fields, Knipe et al. 2013). 
In adolescence or adulthood, primary EBV infection can 
result in infectious mononucleosis (IM), a self-limiting 
lymphoproliferative disease (Kuppers 2003).  
 
Entering the body by infecting naïve B cells in the tonsil, EBV 
virions bind to B cells via Glycoprotein 350 attaching with CD21, present on B cells and follicular 
DCs (Speck, Haan et al. 2000). Entry/fusion into B cells is dependent upon a complex of 3 
glycoproteins; gp85, gp25 and gp42, binding to HLA-DR and DQ (MHC class II) (Speck, Haan et al. 
2000). EBV uses different transcriptional programs to pass through various stages of its lifecycle. 
After entry into B cells, the virus moves into the latency III “growth” program and expresses EBNA 
1, 2, 3a, 3b, 3c and LP, along with LMP1, 2a and 2b (Figure 3) (Tsurumi, Fujita et al. 2005). This 
complement of proteins activates the B cells and resulting in their migration to the tonsillar 
germinal centre, where the virus enters Latency II (Tsurumi, Fujita et al. 2005). Here, there is a 
down regulation of all latency proteins except for EBNA1 and LMP 1, 2a and 2c, directing infected 
B cells to move through a germinal centre reaction becoming infected memory B cells (Tsurumi, 
Fujita et al. 2005).  
Figure 1.4: Electron 
Micrograph of EBV (Young and 
Rickinson 2004) 
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Figure 1.5: The life cycle of the Epstein-Barr Virus (Taylor, Long et al. 2015). In Primary 
infection with EBV, virions enter naïve B cells in the oropharynx, establishing a lytic 
infection in throat epithelial cells.  The infected B cells move into latency III and moves to the 
tonsillar germinal center (GC), where it enters Latency II, then latency 1 to become infected 
memory B cells and finally into Latency 0. In this phase, EBV can stay dormant for many 
years, occasionally reactivating by returning to the lytic phase in the tonsil. 
 
In latency I, the infected memory B cells exit the germinal centre into the blood, expressing no viral 
proteins with the exception of EBNA-1 only during cell division (Tsurumi, Fujita et al. 2005). A phase 
called latency 0 occurs when the infected memory cells become non-replicative and thus not 
produce any viral proteins (Taylor, Long et al. 2015). In this phase, EBV can stay dormant for many 
years, occasionally reactivating by returning to the lytic phase (Taylor, Long et al. 2015). To return 
to the lytic phase, the infected memory B cells returns to tonsil germinal centres, and if immunity 
to EBV wanes, the virus returns to the lytic phase to infect surrounding epithelial cells for extensive 
replication (Tsurumi, Fujita et al. 2005). Unfortunately, not much is known about the virus in the 
lytic phase, in part due to difficulties with infecting epithelial cell lines with EBV (Speck, Haan et al. 
2000). 
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EBV is thought to be implicated in MS pathogenesis as virtually all MS patients are seroconverted 
to EBV compared to the general population with a seroconversion rate of 90-94% (Ramagopalan, 
Dobson et al. 2010, Jørgensen, Livbjerg et al. 2012). It is theorised that primary EBV infection at an 
early age dose not increase risk of MS, but conversely may trigger the development of MS in 
genetically susceptible individuals if primary infection occurs around or post-puberty (Haahr and 
Hollsberg 2006). This is supported by the epidemiology, as risk of MS decreases if a person moves 
from a high-risk to a low-risk area during the first two decades of life, especially before puberty 
(Gale and Martyn 1995, Haahr and Hollsberg 2006). Furthermore, late-age infection with EBV leads 
to infectious mononucleosis, a risk factor in the development of MS, which is more common in 
areas with higher MS prevalence (Sospedra and Martin 2005).  
 
Perhaps the strongest evidence for EBV involvement in MS is that increased levels of IgG antibodies 
to EBV Nuclear Antigen-1 (EBNA-1) after the age of 25 is associated with increased MS risk by 2 to 
3 fold (Levin, Munger et al. 2005, DeLorenze, Munger et al. 2006). Additionally, MS patients are 
found to have increased levels of anti-EBNA-1 IgGs, a finding that has been replicated across many 
cohorts (Munger, Levin et al. 2011, McKay, Gatt et al. 2016). Anti EBNA-1 IgG levels have also been 
found to correlate with the Expanded Disability Status Scale (EDSS), a measure of disability in MS, 
with the levels of the protein EBNA-1 on peripheral blood cells correlating with gadolinium 
enhancing lesions on MRI and T2 lesion volume (Farrell, Antony et al. 2009, Lunemann, Tintore et 
al. 2010). Moreover, both anti EBNA-1 and EBNA-2 IgG levels are increased in the years preceding 
the onset of MS (Ascherio, Munger et al. 2001, Sundström, Juto et al. 2004). Oligoclonal CSF IgG 
from MS patients have been found to bind to EBNA-1 (Bray, Luka et al. 1992), along with increased 
number of EBV specific CD8+ T cells in MS peripheral blood (Cepok, Zhou et al. 2005), further 
supporting the role of EBV in MS.  
 
It is possible that one of the ways by which EBNA-1 contributes to disease risk is via molecular 
mimicry, as there are some similarities between peptide sequences of EBNA-1 and MBP (Fujinami 
and Oldstone 1985, Bray, Luka et al. 1992, Lang, Jacobsen et al. 2002). It has been found that MS 
patients have a two-fold higher number of EBNA-1 specific T cells with increased capacity to 
proliferate and produce IFN-γ (Lunemann, Edwards et al. 2006). Interestingly, in addition to this 
Lunemann et al. (2006) have also discovered that these EBNA-1 specific T cells from MS patients 
have diversified epitope recognition patterns, increasing the risk of cross reactivity with 
autoantigens such as MBP. IFN-β therapy is commonly used as a first line drug for MS patients, and 
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for some, it is an effective therapy able to slow disease progression (Comabella, Kakalacheva et al. 
2012). In these patients, an absence of relapse on therapy is associated with decreased T cell 
responses to EBNA-1, supporting the theory of molecular mimicry with EBV propagating disease 
(Comabella, Kakalacheva et al. 2012).  
 
In addition to EBNA-1, the EBV Early Antigen (EA) has also been implicated in MS, with a study 
reporting nearly double the number of MS patients producing stable titres of antibodies against it 
compared to healthy controls (Buljevac, van Doornum et al. 2005). As EA is only produced during 
viral replication, this indicates that the anti-EA positive patients have chronic active EBV infection 
or reactivation. Interestingly, this group of patients also have more active disease as indicated by 
MRI (Buljevac, van Doornum et al. 2005). 
 
B cells from MS patients have a higher tendency to transform spontaneously into Lymphoblastoid 
Cell Lines (LCLs) carrying EBV antigens when compared to healthy controls (Fraser, Millar et al. 
1979, Munch, Møller-Larsen et al. 1995), suggesting a higher rate or efficiency of prior EBV 
infection. In vitro infection of EBV in B cells causes upregulation of alpha-B-crystallin expression, a 
heat shock protein targeted by autoimmune T cell responses (van Sechel, Bajramovic ̀et al. 1999) 
and overexpressed in the CNS lesions of MS patients (Bajramović, Lassmann et al. 1997). In 
addition, LMP-1, a pro-inflammatory protein described previously (page 14) as a CD40 mimic, is 
upregulated in LCLs, which manifests as the third stage of latency (Young and Rickinson 2004). 
Interestingly, human genetic variants have been found to exert an effect on copy number of EBV 
present in EBV-immortalised LCLs (Houldcroft, Petrova et al. 2014).  
 
1.6: MS susceptibility and EBV 
Our group has taken multiple approaches to understanding the functional significance of genetic 
variation in MS risk. We have examined the interactions between individual genetic variants with 
environmental risk factors such as CY27B1 with Vitamin D (Shahijanian, Parnell et al. 2014). The 
level of MS risk gene expression in whole blood has also been examined; identifying stable gene 
expression signatures or “Molecular Phenotypes”, that are up or down-regulated in MS compared 
to healthy controls (Parnell, Gatt et al. 2014, Parnell, Gatt et al. 2014, McKay, Gatt et al. 2016, 
Fewings, Gatt et al. 2017). In this project we examine the hypothesis that a subset of MS risk genes, 
and the MS molecular phenotypes, may confer susceptibility to MS due to interactions with EBV 
or the associated MSRV retrovirus. 
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Gene-environment interactions in MS have been examined by Mechelli et al. (2013), utilising 
“candidate interactomes”; defined as a group of genes whose products are known to interact with 
environmental factors that may contribute to disease pathogenesis. Out of the 8 viruses examined, 
only the EBV interactome is suspected to be involved in the pathogenesis of MS, based on 
statistically significant enrichment of MS risk SNPs, with the caveat that type-1 interferons are 
unlikely to mediate the MS-EBV interaction (Mechelli, Umeton et al. 2013). SNPs with the highest 
association with both MS and anti EBNA-1 are found mostly within the HLA locus, particularly HLA-
DR, denoted by rs2516049 (Zhou, Zhu et al. 2016), rs3129860, rs3135388 and rs9271366 (Rubicz, 
Yolken et al. 2013). Aside from the HLA locus, other shared genetic risk factors that influence both 
anti EBNA-1 titres and MS risk are EOMES, EVI5, IL2RA and ILDR1 (Zhou, Zhu et al. 2016). Of these, 
EOMES will be examined in this project based on these genetic associations, downregulation in an 
MS “Molecular Phenotype”, as well as proposed role in EBV control as discussed subsequently.        
 
CD40 risk alleles and EBV 
As introduced in section 1.3, the MS protective allele of CD40 is associated with higher CD40 
expression; an unexpected relationship given the role of CD40 in costimulation. It has been 
suggested that in the context of EBV infection, CD40 may compete with EBV latent membrane 
protein 1 (LMP-1) for signalling molecules. LMP-1 is a functional mimic of CD40, with downstream 
effects similar to CD40, but signalling in an amplified and sustained manner (Kilger, Kieser et al. 
1998, Graham, Moore et al. 2009). LMP-1 signals result in activation of the same pathways, namely 
NF-κB, JNK and STAT, but employing different TRAFs in different ways (Figure 1.7). While TRAF3 
downregulates CD40 mediated NF-κB signalling (Hauer, Püschner et al. 2005) and is subsequently 
degraded along with TRAF2, TRAF3 is used by LMP-1 as a positive mediator for its downstream 
signalling, without any degradation (Graham, Moore et al. 2009). It may then be postulated that 
those with high CD40 levels exhibit greater TRAF3 degradation, thus decreasing its availability to 
LMP-1, leading to decreased EBV activity and subsequently, MS risk. 
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Figure 1.6: Signaling relationships between LMP1 and CD40 (Thorley-Lawson 2001) 
While the downstream signaling between LMP-1 and CD40 remains the same, the two 
proteins employs the use of TRAFs in different ways along with direct recruitment of the 
TNFR-1 associated death domain protein (TRADD) and receptor interacting protein 
(Thorley-Lawson 2001). 
 
  
- 22 - 
 
1.7: Human Endogenous Retroviruses: 
 
In addition to EBV, human retroviruses have been suggested as a potential environmental 
infectious risk factor in MS pathogenesis. Comprising approximately 1-8% of the human genome, 
Human Endogenous Retroviruses (HERV) can be described as the “footprints” of previous retroviral 
infections that have been transmitted vertically through the germline (Nelson, Carnegie et al. 
2003, Perron and Lang 2010). Though the majority of HERVs are defective through accumulation 
of mutations, some do transcribe viral products that are implicated in illnesses or provide a benefit 
(Nelson, Carnegie et al. 2003). There are many different classifications for HERVs, including 
function and morphology, copy number and tRNA primer binding site (Antony, Deslauriers et al. 
2011). Of these, the last has become the most prevalent despite difficulties with the classification 
of new HERVs (Nelson, Carnegie et al. 2003). Despite the replication deficiency of the majority of 
HERVs, they can still produce viral proteins and modulate or disrupt genes by way of DNA insertion, 
allowing them to play a role in the development of diseases by way of molecular mimicry, 
neurotoxin production or release, cytokine modulation and host gene manipulation (Antony, 
Deslauriers et al. 2011). HERVs are implicated in cancers and autoimmune diseases by way of 
immunomodulation with immunosuppressive peptides, disruption of/insertion into oncogenes, 
superantigen activity resulting in bystander activation and insertion into long terminal repeats 
located near HLA genes (Nelson, Carnegie et al. 2003). 
 
 A beneficial HERV product is the HERV group W envelope protein, syncytin, believed to be 
important in human placental morphogenesis (Mi, Lee et al. 2000). Syncytin-1 bears close 
homology with Multiple Sclerosis associated Retrovirus envelope protein (MSRVenv) (Machnik, 
Skudrzyk et al. 2015), a viral element repeatedly found in the cerebrospinal fluid (CSF), EBV-
immortalised LCLs (Perron, Garson et al. 1997), serum (Garson, Tuke et al. 1998) and the brain 
tissue of MS patients (Schmitt, Richter et al. 2013). Other than the human placenta, syncytin-1 can 
also be found expressed in astrocytes, perivascular macrophages, and activated microglia (Antony, 
Deslauriers et al. 2011). Whether syncytin plays a role in MS is debatable; with conflicting findings 
suggesting that it is both immunoreactive and immunosuppressive (Mi, Lee et al. 2000, Antony, 
van Marle et al. 2004). Syncytin-1 contains an amino acid sequence known to be 
immunosuppressive; inhibiting leukocyte proliferation (Knerr, Huppertz et al. 2004). On the other 
hand, there is evidence that syncytin upregulates cytokines and reactive oxygen species 
production in astrocytes that can mediate oligodendrocyte damage (Antony, van Marle et al. 2004) 
and is upregulated in the MS brain. Evolutionarily speaking, it is beneficial for syncytin as first a 
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viral protein and later in human genetic history, as a placental syncytiotrophoblast protein, to be 
immunosuppressive, evading the immune system and promoting tolerance towards the foetus. 
 
The presence of MSRV in the CSF of MS patients is also observed to be associated with increased 
disease severity (Sotgiu, Serra et al. 2002). However, the role of MSRV in the pathogenesis of MS 
is unclear and controversial, with conflicting reports of MSRV upregulation or lack of in the MS 
brain (Antony, Zhu et al. 2007, Mameli, Astone et al. 2007, Antony, Deslauriers et al. 2011). MSRV 
can be detected in only 7-20% of controls (Garson, Tuke et al. 1998, Arru, Mameli et al. 2007), but 
in 50- 100% off MS patients depending on the population tested (Antony, Deslauriers et al. 2011). 
MSRV is thought to be compiled from multiple loci in the human genome; and is thought to be 
derived from the same HERV-W loci, indicating that MSRV is possibly a mutated version of HERV-
W that has become replication competent (Laufer, Mayer et al. 2009). It also has been suggested 
that the differences between the two may be a PCR related error and that they are the same 
virus/viral proteins (Christensen and Giovannoni 2012). 
 
Seropositivity of MSRV is associated with a worse disease activity as measured by EDSS and 
number of relapses (Sotgiu, Serra et al. 2002). Additionally, the MSRV positive group had a much 
larger proportion of those presenting with OCB (Sotgiu, Serra et al. 2002), which is also associated 
with greater disease progression. However, this was a small study consisting of only 6 MSRV 
negative MS and 9 MSRV positive MS patients, precluding the examination of OCB-MSRV 
interactions. 
 
A recent model proposes Human Endogenous Retrovirus-W (HERV-W) as the link between high 
EBV titre and MS (Mameli, Poddighe et al. 2012). Here, super-antigenic HERV-W is activated by 
EBV infection in the brain, triggering toxic mechanisms against oligodendrocytes, contributing to 
the neuropathology of MS (Mameli, Poddighe et al. 2012). The first MSRV virions were isolated 
from LCLs which are either spontaneous transforming or in-vitro EBV-infected and transformed 
from MS lymphocytes (Antony, Deslauriers et al. 2011), indicating that B cell activation by EBV 
results in activation and increased expression of HERV-W and/or MSRV (Mameli, Poddighe et al. 
2012). It is possible that MSRV acts as a mediator of EBV related damage in MS, as anti EBNA-1 IgG 
is found to be correlated with MSRV mRNA accumulation (Mameli, Madeddu et al. 2013). 
Interestingly, MSRV is not only expressed in brain lesion sites and LCLs, but also in endothelial cells 
and microglia (Perron, Lazarini et al. 2005).  
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Figure 1.7: MSRV virion particles visualized by electron microscopy.  Extracellular 
virion particles at the surface of leptomeningeal cells (a), EBV-transformed B-
lymphoblastoid cell lines (b and d), or macrophage cells (c) from patients with MS. Negative 
staining of purified virion particles pelleted by ultracentrifugation (e) (Perron and Lang 
2010). 
 
1.8: MS risk genes, EBV and HERV-W.  
To determine the functional relevance of MS risk genes, one strategy used by our group has been 
to examine the expression of these in peripheral blood in MS, with special focus on transcriptional 
regulators of immune response. This has resulted in identification of three immune gene 
expression signatures (“Molecular Phenotypes”) in the blood in MS compared to healthy controls: 
these are 1. low EOMES and TBX21, 2. low ZMIZ1 and 3. high RPS6 (Parnell, Gatt et al. 2014, Parnell, 
Gatt et al. 2014). EOMES and TBX21 are found to be under-expressed in whole blood in MS (Parnell, 
Gatt et al. 2014); both are crucial for the stability and maturation of NK cells (Gordon, Chaix et al. 
2012) and long-term renewal of memory CD8+ T cells (Intlekofer, Takemoto et al. 2005).  Both NK 
and CD8+ T cells work synergistically to keep EBV infection under tight control, with cytotoxic CD8+ 
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T cells eliminating proliferating and lytically infected B cells (Pender 2012, Chijioke, Muller et al. 
2013). Consequently, we questioned whether low expressions of EOMES and TBX21 may be 
reflective of low CD8+ and NK cell activity and proportions in MS (De Jager, Rossin et al. 2008), and 
therefore associated with impaired EBV control in MS. 
 
The second MS Molecular phenotype to be investigated in this study is the low expression of 
ZMIZ1; correlated with high expression of ZPF36L2; in MS peripheral blood. An androgen receptor 
coactivator, Zinc Finger MIZ-Type Containing 1 (ZMIZ1) is a protein that shares homology to protein 
inhibitors of activated STATs (PIAS) (Rogers, Riordan et al. 2013). ZMIZ1 can bind to Notch-1 
(Pinnell, Yan et al. 2015), which if activated starts a cascade resulting in the promotion of 
transcription (Bray 2006). ZFP36L2 is a putative transcription factor that is fatal in knockout mice 
due to defective haematopoiesis, similar to ZMIZ1 (Stumpo, Broxmeyer et al. 2009). In addition, 
ZFP36L2 also interacts with Notch-1 (Hodson, Janas et al. 2010) and helps the genomic integrity of 
B-cells by maintaining quiescence after VDJ recombination (Galloway, Saveliev et al. 2016). It is 
found to be downregulated in MS patients and positively correlated with ZFP36L2 expression 
(Fewings, Gatt et al. 2017). Along with MS risk, ZMIZ1 is also implicated in vitiligo (Sun, Zuo et al. 
2014). The role of ZMIZ1 is poorly understood, and to our knowledge its expression in whole blood 
had not previously been examined in the context of MS, nor has it been studied in EBV infection. 
Given its involvement in MS risk and downregulation in MS, we will examine its interaction with 
the putative MS environmental risk factors, EBV and MSRV. 
 
Finally, this study will examine the higher expression of RPS6 in MS and relationship to 
viral/retroviral risk factors. RPS6 is a ribosomal protein associated with many downstream effects, 
including but not limited to; cell proliferation, PI3K, Ras/MAPK, Phospholipase D and cytokine 
signalling along with cell proliferation (Magnuson, Ekim et al. 2012), all of which may play a role in 
MS pathogenesis. Phosphorylation and activity of RPS6 is regulated by RPS6KB1, an MS risk gene 
(Parnell, Gatt et al. 2014). RPS6 can be used as a marker of a T cell activation gene expression 
signature that predicts the likelihood of MS and is found to be lowered by IFN-β treatment in 
responders (Parnell, Gatt et al. 2014). In addition, our group has demonstrated that the proportion 
of phosphorylated (p235/236) RPS6+ B cells are increased in untreated MS (n = 38) compared to 
healthy controls (n = 35; p = 0.003, Mann-Whitney, unpublished). Of note, our group has found a 
significant correlation between the gene encoding the envelope protein of HERV-W and expression 
of RPS6, in whole blood of MS patients, (n = 32; r = 0.55, p = 0.001, Spearman’s) but not in controls 
- 26 - 
 
(n = 40; unpublished data).This is of particular interest, given the reported interaction of RPS6 with 
other viruses. Knockdown of RPS6 preferentially suppresses translation of hepatitis C virus 
proteins, but not general translation within infected cells (Huang, Su et al. 2012). RPS6 also 
interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus, 
which is hypothesised to contribute to the extraordinary nuclear stability of this antigen that is 
critical for viral maintenance and the survival of infected cells (Chen and Dittmer 2011).   To our 
knowledge, association of EBV infection with RPS6 expression has not previously been examined. 
In this study we will examine whether RPS6, as a viral activity-associated, and MS risk gene-
regulated protein, is also associated with EBV in MS patients and controls.  
 
1.9: Sodium as an environmental risk factor for MS 
The role of dietary sodium intake in the pathogenesis of MS is far less studied than genetics, EBV 
and vitamin D, however, dietary sodium has been suggested to play a role in the increase in MS 
incidence worldwide (Kleinewietfeld, Manzel et al. 2013). In fact, hypertonicity has been long 
associated with proinflammatory cytokine production (Shapiro and Dinarello 1995) and increased 
T cell proliferation (Junger, Liu et al. 1994). Recent studies have shown that high levels of sodium 
chloride induces CD4 naive T cells to develop a Th17 phenotype, and that this effect is dependent 
upon the MAPK, NAT5 and SGK1 pathways (Kleinewietfeld, Manzel et al. 2013). Th17 cells are 
strongly implicated in EAE pathogenesis (Kasper and Shoemaker 2010, Dendrou, Fugger et al. 
2015), and EAE mice fed a high sodium diet have increased numbers of Th17 cells, accompanied 
with a severe worsening of symptoms (Kleinewietfeld, Manzel et al. 2013) Additionally, a high 
sodium environment prevents immunosuppression due to anti-inflammatory cytokines such as 
TGF-β, IL-4 and IL-10 by increasing secretion of the pro-inflammatory IL-2 by T cells (Loomis, Namiki 
et al. 2001). Additionally, high dietary sodium intake has been implicated in EBV associated gastric 
carcinoma, a finding replicated in multiple cohorts (Zheng, Yan et al. 1994, Koriyama, Akiba et al. 
2005, Campos, Koriyama et al. 2006). While there are a range of homeostatic controls to maintain 
serum sodium levels in humans, large population studies indicate an effect of dietary sodium on 
serum sodium (He, Markandu et al. 2005, Goldstein and Leshem 2014). In this study, I will 
investigate whether there is an interaction between 2 environmental risk factors, sodium levels 
and EBV infection, in MS, under the hypothesis that a high sodium intake may contribute to the 
autoreactive inflammatory processes initiated by EBV in MS.  
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1.10: Aims and Hypothesis: 
 
Aims: 
The overall aim of this project is to determine if there are associations between EBV, sodium, MSRV 
and the MS risk genes/MS risk gene-regulated genes HLA-DR, CD40, RPS6, EOMES and TBX21 in 
the context of multiple sclerosis. The specific aims are: 
 
1. To determine if MS risk variants of HLA-DR, CD40, RPS6KB1, EOMES and TBX21; or whole 
blood expression of the genes CD40, RPS6, EOMES, TBX21, ZMIZ1 and ZFP36L2, are 
associated with EBV anti EBNA-1 IgG levels in healthy controls and people with MS. 
 
2. To determine if sodium serum levels, a putative environmental risk factor, are associated 
with MS, and with another environmental risk factor, EBV, in our cohort.  
 
3. To determine if the MS protective allele of CD40 (SNP rs1883832) is upregulated in B cells 
as previously described; affects CD40 gene expression similarly in LCLs; and associates with 
levels of proliferation in response to CD40-CD40L signalling in LCLs, or with anti-EBNA-1 
titres.  
 
4. To determine if MS risk variants and anti-EBNA-1 IgG levels are associated with MSRVenv 
expression levels in healthy controls and people with MS. 
 
Hypotheses 
The overall hypothesis is that MS genetic variants interact with EBV or MSRV to increase risk of 
developing MS.  
 
Specifically, the hypotheses are:  
1. That MS risk variants of HLA-DR, CD40, RPS6KB1, EOMES and TBX21; and whole blood 
expression of the genes CD40, RPS6, EOMES, TBX21, ZMIZ1 and ZFP36L2, are associated 
with EBV anti EBNA-1 IgG levels in healthy controls and people with MS. 
 
2. That high serum sodium levels are associated with MS correlated with higher EBV anti-
EBNA-1 titres. 
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3. The CD40 protective allele has higher expression (mRNA, protein) in LCLs; increasing its 
response to CD40L so that signalling increases through this pathway competitively 
inhibiting the viral LMP1 pathway. Consequently, proliferation is reduced in the presence 
of CD40L, especially for the protective genotype. Those with the protective genotype have 
better control of EBV infection, as indicated by lower anti-EBNA-1 antibody levels. 
 
4. That MS risk variants and anti-EBNA-1 IgG levels are associated with MSRVenv expression 
levels in people with MS but not in healthy controls. 
 
 
 
 
 
 
 
 
  
- 30 - 
 
References: 
Antony, J. M., A. M. Deslauriers, R. K. Bhat, K. K. Ellestad and C. Power (2011). "Human 
endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?" 
Biochim Biophys Acta 1812(2): 162-176. 
Antony, J. M., G. van Marle, W. Opii, D. A. Butterfield, F. Mallet, V. W. Yong, J. L. Wallace, R. M. 
Deacon, K. Warren and C. Power (2004). "Human endogenous retrovirus glycoprotein-mediated 
induction of redox reactants causes oligodendrocyte death and demyelination." Nat Neurosci 
7(10): 1088-1095. 
Antony, J. M., Y. Zhu, M. Izad, K. G. Warren, M. Vodjgani, F. Mallet and C. Power (2007). 
"Comparative expression of human endogenous retrovirus-W genes in multiple sclerosis." AIDS 
research and human retroviruses 23(10): 1251-1256. 
Archelos, J. J., M. K. Storch and H. P. Hartung (2000). "The role of B cells and autoantibodies in 
multiple sclerosis." Annals of neurology 47(6): 694-706. 
Arru, G., G. Mameli, V. Astone, C. Serra, Y.-M. Huang, H. Link, E. Fainardi, M. Castellazzi, E. 
Granieri and M. Fernandez (2007). "Multiple sclerosis and HERV-W/MSRV: a multicentric study." 
International journal of biomedical science: IJBS 3(4): 292. 
Ascherio, A., K. L. Munger, E. T. Lennette and et al. (2001). "Epstein-barr virus antibodies and risk 
of multiple sclerosis: A prospective study." JAMA 286(24): 3083-3088. 
Atkins, H. L., M. Bowman, D. Allan, G. Anstee, D. L. Arnold, A. Bar-Or, I. Bence-Bruckler, P. Birch, 
C. Bredeson, J. Chen, D. Fergusson, M. Halpenny, L. Hamelin, L. Huebsch, B. Hutton, P. Laneuville, 
Y. Lapierre, H. Lee, L. Martin, S. McDiarmid, P. O'Connor, T. Ramsay, M. Sabloff, L. Walker and M. 
S. Freedman (2016). "Immunoablation and autologous haemopoietic stem-cell transplantation 
for aggressive multiple sclerosis: a multicentre single-group phase 2 trial." The Lancet 
388(10044): 576-585. 
Australia New Zealand Multiple Sclerosis Genetics Consortium (2009). "Genome-wide association 
study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20." Nat Genet 
41(7): 824-828. 
Babbe, H., A. Roers, A. Waisman, H. Lassmann, N. Goebels, R. Hohlfeld, M. Friese, R. Schröder, M. 
Deckert and S. Schmidt (2000). "Clonal expansions of CD8+ T cells dominate the T cell infiltrate in 
active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain 
reaction." The Journal of experimental medicine 192(3): 393-404. 
Bajramović, J. J., H. Lassmann and J. M. van Noort (1997). "Expression of αB-crystallin in glia cells 
during lesional development in multiple sclerosis." Journal of Neuroimmunology 78(1–2): 143-
151. 
Beecham, A. H. and IMSGC (2013). "Analysis of immune-related loci identifies 48 new 
susceptibility variants for multiple sclerosis." Nat Genet 45(11): 1353-1360. 
Blanco-Kelly, F., F. Matesanz, A. Alcina, M. Teruel, L. M. Díaz-Gallo, M. Gómez-García, M. A. 
López-Nevot, L. Rodrigo, A. Nieto and C. Cardeña (2010). "CD40: novel association with Crohn's 
disease and replication in multiple sclerosis susceptibility." PloS one 5(7): e11520. 
- 31 - 
 
Bray, P. F., J. Luka, P. F. Bray, K. Culp and J. Schlight (1992). "Antibodies against Epstein-Barr 
nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities 
between EBNA and myelin basic protein." Neurology 42(9): 1798-1798. 
Bray, S. J. (2006). "Notch signalling: a simple pathway becomes complex." Nature reviews. 
Molecular cell biology 7(9): 678. 
Browne, P., D. Chandraratna, C. Angood, H. Tremlett, C. Baker, B. V. Taylor and A. J. Thompson 
(2013). "Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity." 
Neurology 83(11): 1022-1024. 
Buck, D., A. Kroner, P. Rieckmann, M. Mäurer and H. Wiendl (2006). "Analysis of the C/T− 1 single 
nucleotide polymorphism in the CD40 gene in multiple sclerosis." Tissue Antigens 68(4): 335-338. 
Buljevac, D., G. J. van Doornum, H. Z. Flach, J. Groen, A. D. Osterhaus, W. Hop, P. A. van Doorn, F. 
G. van der Meche and R. Q. Hintzen (2005). "Epstein-Barr virus and disease activity in multiple 
sclerosis." J Neurol Neurosurg Psychiatry 76(10): 1377-1381. 
Bush, T. J. V. and G. A. Bishop (2008). "TLR7 and CD40 cooperate in IL-6 production via enhanced 
JNK and AP-1 activation." European Journal of Immunology 38(2): 400-409. 
Campos, F. I., C. Koriyama, S. Akiba, G. Carrasquilla, M. Serra, E. Carrascal, T. Itoh, Y. Minakami 
and Y. Eizuru (2006). "Environmental factors related to gastric cancer associated with Epstein-
Barr virus in Colombia." Asian Pac J Cancer Prev 7(4): 633-637. 
Carbone, E., G. Ruggiero, G. Terrazzano, C. Palomba, C. Manzo, S. Fontana, H. Spits, K. Kärre and 
S. Zappacosta (1997). "A New Mechanism of NK Cell Cytotoxicity Activation: The CD40–CD40 
Ligand Interaction." The Journal of Experimental Medicine 185(12): 2053-2060. 
Cepok, S., M. Jacobsen, S. Schock, B. Omer, S. Jaekel, I. Böddeker, W. H. Oertel, N. Sommer and 
B. Hemmer (2001). "Patterns of cerebrospinal fluid pathology correlate with disease progression 
in multiple sclerosis." Brain 124(11): 2169-2176. 
Cepok, S., D. Zhou, R. Srivastava, S. Nessler, S. Stei, K. Bussow, N. Sommer and B. Hemmer (2005). 
"Identification of Epstein-Barr virus proteins as putative targets of the immune response in 
multiple sclerosis." J Clin Invest 115(5): 1352-1360. 
Chatzigeorgiou, A., M. Lyberi, G. Chatzilymperis, A. Nezos and E. Kamper (2009). "CD40/CD40L 
signaling and its implication in health and disease." Biofactors 35(6): 474-483. 
Chijioke, O., A. Muller, R. Feederle, M. H. Barros, C. Krieg, V. Emmel, E. Marcenaro, C. S. Leung, O. 
Antsiferova, V. Landtwing, W. Bossart, A. Moretta, R. Hassan, O. Boyman, G. Niedobitek, H. J. 
Delecluse, R. Capaul and C. Munz (2013). "Human natural killer cells prevent infectious 
mononucleosis features by targeting lytic Epstein-Barr virus infection." Cell Rep 5(6): 1489-1498. 
Christensen, T. and G. Giovannoni (2012). "HERVs: have we been here before?" Mult Scler 
18(12): 1670-1672. 
Comabella, M., K. Kakalacheva, J. Rio, C. Munz, X. Montalban and J. D. Lunemann (2012). "EBV-
specific immune responses in patients with multiple sclerosis responding to IFNbeta therapy." 
Mult Scler 18(5): 605-609. 
- 32 - 
 
Compston, A. and A. Coles (2008). "Multiple sclerosis." The Lancet 372(9648): 1502-1517. 
Couper, K. N., D. G. Blount and E. M. Riley (2008). "IL-10: The Master Regulator of Immunity to 
Infection." The Journal of Immunology 180(9): 5771-5777. 
Crawford, M. P., S. X. Yan, S. B. Ortega, R. S. Mehta, R. E. Hewitt, D. A. Price, P. Stastny, D. C. 
Douek, R. A. Koup and M. K. Racke (2004). "High prevalence of autoreactive, neuroantigen-
specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay." Blood 
103(11): 4222-4231. 
De Jager, P. L., E. Rossin, S. Pyne, P. Tamayo, L. Ottoboni, V. Viglietta, M. Weiner, D. Soler, E. 
Izmailova, L. Faron-Yowe, C. O’Brien, S. Freeman, S. Granados, A. Parker, R. Roubenoff, J. P. 
Mesirov, S. J. Khoury, D. A. Hafler and H. L. Weiner (2008). Cytometric profiling in multiple 
sclerosis uncovers patient population structure and a reduction of CD8low cells. 
DeLorenze, G. N., K. L. Munger, E. T. Lennette, N. Orentreich, J. H. Vogelman and A. Ascherio 
(2006). "Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective 
study with long-term follow-up." Arch Neurol 63(6): 839-844. 
Dendrou, C. A., L. Fugger and M. A. Friese (2015). "Immunopathology of multiple sclerosis." Nat 
Rev Immunol 15(9): 545-558. 
Disanto, G., J. M. Morahan, M. H. Barnett, G. Giovannoni and S. V. Ramagopalan (2012). "The 
evidence for a role of B cells in multiple sclerosis." Neurology 78(11): 823-832. 
Dobson, R., S. Ramagopalan, A. Davis and G. Giovannoni (2013). "Cerebrospinal fluid oligoclonal 
bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, 
prognosis and effect of latitude." Journal of Neurology, Neurosurgery & Psychiatry 84(8): 909-
914. 
Dyment, D. A., G. C. Ebers and A. Dessa Sadovnick (2004). "Genetics of multiple sclerosis." The 
Lancet Neurology 3(2): 104-110. 
Ebers, G. C. (2008). "Environmental factors and multiple sclerosis." The Lancet Neurology 7(3): 
268-277. 
Elgueta, R., M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo and R. J. Noelle (2009). "Molecular 
mechanism and function of CD40/CD40L engagement in the immune system." Immunol Rev 
229(1): 152-172. 
Farrell, R., D. Antony, G. Wall, D. Clark, L. Fisniku, J. Swanton, Z. Khaleeli, K. Schmierer, D. Miller 
and G. Giovannoni (2009). "Humoral immune response to EBV in multiple sclerosis is associated 
with disease activity on MRI." Neurology 73(1): 32-38. 
Feinstein, A., J. Freeman and A. C. Lo (2015). "Treatment of progressive multiple sclerosis: what 
works, what does not, and what is needed." The Lancet Neurology 14(2): 194-207. 
Fewings, N. L., P. N. Gatt, F. C. McKay, G. P. Parnell, S. D. Schibeci, J. Edwards, M. A. Basuki, A. 
Goldinger, M. J. Fabis-Pedrini, A. G. Kermode, C. P. Manrique, J. L. McCauley, D. Nickles, S. E. 
Baranzini, T. Burke, S. Vucic, G. J. Stewart and D. R. Booth (2017). "The autoimmune risk gene 
ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis." Journal 
of Autoimmunity 78: 57-69. 
- 33 - 
 
Field, J., F. Shahijanian, S. Schibeci, Australia, M. S. G. C. New Zealand, L. Johnson, M. Gresle, L. 
Laverick, G. Parnell, G. Stewart, F. McKay, T. Kilpatrick, H. Butzkueven and D. Booth (2015). "The 
MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen 
Presenting Cells: Implications for Gene Function." PLoS One 10(6): e0127080. 
Fields, B. N., D. M. Knipe and P. M. Howley (2013). Fields virology. Philadelphia, Wolters Kluwer 
Health/Lippincott Williams & Wilkins. 
Fisniku, L., P. Brex, D. Altmann, K. Miszkiel, C. Benton, R. Lanyon, A. Thompson and D. Miller 
(2008). "Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of 
multiple sclerosis." Brain 131(3): 808-817. 
Fraser, K. B., J. H. D. Millar, M. Haire and S. McCrea (1979). "Increased tendency to spontaneous 
in-vitro Lymphocyte transformation in clinically active Multiple Sclerosis." The Lancet 314(8145): 
715-717. 
Friese, M. A. and L. Fugger (2005). "Autoreactive CD8+ T cells in multiple sclerosis: a new target 
for therapy?" Brain 128(8): 1747-1763. 
Frischer, J. M., S. Bramow, A. Dal-Bianco, C. F. Lucchinetti, H. Rauschka, M. Schmidbauer, H. 
Laursen, P. S. Sorensen and H. Lassmann (2009). "The relation between inflammation and 
neurodegeneration in multiple sclerosis brains." Brain 132(5): 1175-1189. 
Fujinami, R. S. and M. B. A. Oldstone (1985). "Amino Acid Homology between the 
Encephalitogenic Site of Myelin Basic Protein and Virus: Mechanism for Autoimmunity." Science 
230(4729): 1043-1045. 
Gale, C. R. and C. N. Martyn (1995). "Migrant studies in multiple sclerosis." Progress in 
Neurobiology 47(4–5): 425-448. 
Galloway, A., A. Saveliev, S. Łukasiak, D. J. Hodson, D. Bolland, K. Balmanno, H. Ahlfors, E. 
Monzón-Casanova, S. C. Mannurita, L. S. Bell, S. Andrews, M. D. Díaz-Muñoz, S. J. Cook, A. 
Corcoran and M. Turner (2016). "RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell 
quiescence." Science 352(6284): 453-459. 
Garson, J. A., P. W. Tuke, P. Giraud, G. Paranhos-Baccala and H. Perron (1998). "Detection of 
virion-associated MSRV-RNA in serum of patients with multiple sclerosis." The Lancet 351(9095): 
33. 
Gordon, S. M., J. Chaix, L. J. Rupp, J. Wu, S. Madera, J. C. Sun, T. Lindsten and S. L. Reiner (2012). 
"The transcription factors T-bet and Eomes control key checkpoints of natural killer cell 
maturation." Immunity 36(1): 55-67. 
Graham, J. P., C. R. Moore and G. A. Bishop (2009). "Roles of the TRAF2/3 binding site in 
differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1." The Journal of 
Immunology 183(5): 2966-2973. 
Haahr, S. and P. Hollsberg (2006). "Multiple sclerosis is linked to Epstein-Barr virus infection." Rev 
Med Virol 16(5): 297-310. 
Hauer, J., S. Püschner, P. Ramakrishnan, U. Simon, M. Bongers, C. Federle and H. Engelmann 
(2005). "TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-
- 34 - 
 
mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs." Proceedings of 
the National Academy of Sciences of the United States of America 102(8): 2874-2879. 
Hauser , S. L., E. Waubant , D. L. Arnold , T. Vollmer , J. Antel , R. J. Fox , A. Bar-Or , M. Panzara , 
N. Sarkar , S. Agarwal , A. Langer-Gould  and C. H. Smith (2008). "B-Cell Depletion with Rituximab 
in Relapsing–Remitting Multiple Sclerosis." New England Journal of Medicine 358(7): 676-688. 
Hodson, D. J., M. L. Janas, A. Galloway, S. E. Bell, S. Andrews, C. M. Li, R. Pannell, C. W. Siebel, H. 
R. MacDonald, K. De Keersmaecker, A. A. Ferrando, G. Grutz and M. Turner (2010). "Deletion of 
the RNA-binding proteins Zfp36l1 and Zfp36l2 leads to perturbed thymic development and T-
lymphoblastic leukaemia." Nature immunology 11(8): 717-724. 
Hofman, F. M., R. I. von Hanwehr, C. A. Dinarello, S. B. Mizel, D. Hinton and J. E. Merrill (1986). 
"Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain." The 
Journal of Immunology 136(9): 3239-3245. 
Hollenbach, J. A. and J. R. Oksenberg (2015). "The immunogenetics of multiple sclerosis: A 
comprehensive review." Journal of Autoimmunity 64: 13-25. 
Houldcroft, C. J., V. Petrova, J. Z. Liu, D. Frampton, C. A. Anderson, A. Gall and P. Kellam (2014). 
"Host Genetic Variants and Gene Expression Patterns Associated with Epstein-Barr Virus Copy 
Number in Lymphoblastoid Cell Lines." PloS one 9(10): e108384. 
Huang, W.-X., P. Huang and J. Hillert (2000). "Systemic upregulation of CD40 and CD40 ligand 
mRNA expression in multiple sclerosis." Multiple Sclerosis Journal 6(2): 61-65. 
Huseby, E. S., D. Liggitt, T. Brabb, B. Schnabel, C. Öhlén and J. Goverman (2001). "A pathogenic 
role for myelin-specific CD8+ T cells in a model for multiple sclerosis." The Journal of 
experimental medicine 194(5): 669-676. 
Intlekofer, A. M., N. Takemoto, E. J. Wherry, S. A. Longworth, J. T. Northrup, V. R. Palanivel, A. C. 
Mullen, C. R. Gasink, S. M. Kaech and J. D. Miller (2005). "Effector and memory CD8+ T cell fate 
coupled by T-bet and eomesodermin." Nature immunology 6(12): 1236-1244. 
Ishida, T., S.-i. Mizushima, S. Azuma, N. Kobayashi, T. Tojo, K. Suzuki, S. Aizawa, T. Watanabe, G. 
Mosialos and E. Kieff (1996). "Identification of TRAF6, a novel tumor necrosis factor receptor-
associated factor protein that mediates signaling from an amino-terminal domain of the CD40 
cytoplasmic region." Journal of Biological Chemistry 271(46): 28745-28748. 
Jørgensen, P. B., A. H. Livbjerg, H. J. Hansen, T. Petersen and P. Höllsberg (2012). "Epstein-Barr 
virus peptide presented by HLA-E is predominantly recognized by CD8bright cells in multiple 
sclerosis patients." PloS one 7(9): e46120. 
Joseph, F. G., C. L. Hirst, T. P. Pickersgill, Y. Ben-Shlomo, N. P. Robertson and N. J. Scolding (2009). 
"CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 
patients." Journal of Neurology, Neurosurgery & Psychiatry 80(3): 292-296. 
Junger, W. G., F. C. Liu, W. H. Loomis and D. B. Hoyt (1994). "Hypertonic saline enhances cellular 
immune function." Circulatory shock 42(4): 190-196. 
- 35 - 
 
Kabat, E. A., M. Glusman and V. Knaub (1948). "Quantitative estimation of the albumin and 
gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods." The 
American Journal of Medicine 4(5): 653-662. 
Kappos, L., D. Li, P. A. Calabresi, P. O'Connor, A. Bar-Or, F. Barkhof, M. Yin, D. Leppert, R. 
Glanzman, J. Tinbergen and S. L. Hauser "Ocrelizumab in relapsing-remitting multiple sclerosis: a 
phase 2, randomised, placebo-controlled, multicentre trial." The Lancet 378(9805): 1779-1787. 
Kasper, L. H. and J. Shoemaker (2010). "Multiple sclerosis immunology The healthy immune 
system vs the MS immune system." Neurology 74(1 Supplement 1): S2-S8. 
Kaur, G., J. Trowsdale and L. Fugger (2013). "Natural killer cells and their receptors in multiple 
sclerosis." Brain 136(Pt 9): 2657-2676. 
Kilger, E., A. Kieser, M. Baumann and W. Hammerschmidt (1998). "Epstein–Barr virus‐mediated 
B‐cell proliferation is dependent upon latent membrane protein 1, which simulates an activated 
CD40 receptor." The EMBO journal 17(6): 1700-1709. 
Kister, I., T. E. Bacon, E. Chamot, A. R. Salter, G. R. Cutter, J. T. Kalina and J. Herbert (2013). 
"Natural history of multiple sclerosis symptoms." International journal of MS care 15(3): 146-156. 
Kleinewietfeld, M., A. Manzel, J. Titze, H. Kvakan, N. Yosef, R. A. Linker, D. N. Muller and D. A. 
Hafler (2013). "Sodium Chloride Drives Autoimmune Disease by the Induction of Pathogenic Th17 
Cells." Nature 496(7446): 518-522. 
Knerr, I., B. Huppertz, C. Weigel, J. Dötsch, C. Wich, R. L. Schild, M. W. Beckmann and W. Rascher 
(2004). "Endogenous retroviral syncytin: compilation of experimental research on syncytin and 
its possible role in normal and disturbed human placentogenesis." Molecular Human 
Reproduction 10(8): 581-588. 
Koriyama, C., S. Akiba, Y. Minakami and Y. Eizuru (2005). "Environmental factors related to 
Epstein-Barr virus-associated gastric cancer in Japan." Journal of experimental & clinical cancer 
research: CR 24(4): 547-553. 
Kuhle , J., C. Pohl , M. Mehling , G. Edan , M. S. Freedman , H.-P. Hartung , C. H. Polman , D. H. 
Miller , X. Montalban , F. Barkhof , L. Bauer , S. Dahms , R. Lindberg , L. Kappos  and R. Sandbrink 
(2007). "Lack of Association between Antimyelin Antibodies and Progression to Multiple 
Sclerosis." New England Journal of Medicine 356(4): 371-378. 
Kuppers, R. (2003). "B cells under influence: transformation of B cells by Epstein-Barr virus." Nat 
Rev Immunol 3(10): 801-812. 
Kurtzke, J. F., G. W. Beebe and J. E. Norman (1979). "Epidemiology of multiple sclerosis in US 
veterans 1. Race, sex, and geographic distribution." Neurology 29(9 Part 1): 1228-1228. 
Lang, H. L., H. Jacobsen, S. Ikemizu, C. Andersson, K. Harlos, L. Madsen, P. Hjorth, L. Sondergaard, 
A. Svejgaard, K. Wucherpfennig, D. I. Stuart, J. I. Bell, E. Y. Jones and L. Fugger (2002). "A 
functional and structural basis for TCR cross-reactivity in multiple sclerosis." Nat Immunol 3(10): 
940-943. 
- 36 - 
 
Laufer, G., J. Mayer, B. F. Mueller, N. Mueller-Lantzsch and K. Ruprecht (2009). "Analysis of 
transcribed human endogenous retrovirus W env loci clarifies the origin of multiple sclerosis-
associated retrovirus envsequences." Retrovirology 6(1): 37. 
Levin, L. I., K. L. Munger, M. V. Rubertone, C. A. Peck, E. T. Lennette, D. Spiegelman and A. 
Ascherio (2005). "Temporal relationship between elevation of Epstein-Barr virus antibody titers 
and initial onset of neurological symptoms in multiple sclerosis." Jama 293(20): 2496-2500. 
Loomis, W. H., S. Namiki, D. B. Hoyt and W. G. Junger (2001). "Hypertonicity rescues T cells from 
suppression by trauma-induced anti-inflammatory mediators." American Journal of Physiology - 
Cell Physiology 281(3): C840-C848. 
Lucchinetti, C., W. Bruck, J. Parisi, B. Scheithauer, M. Rodriguez and H. Lassman (2000). 
"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination." 
Annals of neurology 47(6): 707-717. 
Lunemann, J. D., N. Edwards, P. A. Muraro, S. Hayashi, J. I. Cohen, C. Munz and R. Martin (2006). 
"Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in 
multiple sclerosis." Brain 129(Pt 6): 1493-1506. 
Lunemann, J. D., M. Tintore, B. Messmer, T. Strowig, A. Rovira, H. Perkal, E. Caballero, C. Munz, X. 
Montalban and M. Comabella (2010). "Elevated Epstein-Barr virus-encoded nuclear antigen-1 
immune responses predict conversion to multiple sclerosis." Ann Neurol 67(2): 159-169. 
Machnik, G., E. Skudrzyk, L. Buldak, K. Labuzek, J. Ruczynski, M. Alenowicz, P. Rekowski, P. J. 
Nowak and B. Okopien (2015). "A Novel, Highly Selective RT-QPCR Method for Quantification of 
MSRV Using PNA Clamping Syncytin-1 (ERVWE1)." Mol Biotechnol 57(9): 801-813. 
Magnuson, B., B. Ekim and Diane C. Fingar (2012). "Regulation and function of ribosomal protein 
S6 kinase (S6K) within mTOR signalling networks." Biochemical Journal 441(1): 1-21. 
Mameli, G., V. Astone, G. Arru, S. Marconi, L. Lovato, C. Serra, S. Sotgiu, B. Bonetti and A. Dolei 
(2007). "Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients 
hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human 
herpesvirus 6." J Gen Virol 88(Pt 1): 264-274. 
Mameli, G., G. Madeddu, A. Mei, E. Uleri, L. Poddighe, L. G. Delogu, I. Maida, S. Babudieri, C. 
Serra, R. Manetti, M. S. Mura and A. Dolei (2013). "Activation of MSRV-type endogenous 
retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with 
multiple sclerosis?" PLoS ONE 8(11): e78474. 
Mameli, G., L. Poddighe, A. Mei, E. Uleri, S. Sotgiu, C. Serra, R. Manetti and A. Dolei (2012). 
"Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood 
cells and astrocytes: inference for multiple sclerosis." PloS one 7(9): e44991. 
Marrie, R. A. (2004). "Environmental risk factors in multiple sclerosis aetiology." The Lancet 
Neurology 3(12): 709-718. 
McFarland, H. F. and R. Martin (2007). "Multiple sclerosis: a complicated picture of 
autoimmunity." Nature immunology 8(9): 913-919. 
- 37 - 
 
McKay, F. C., P. N. Gatt, N. Fewings, G. P. Parnell, S. D. Schibeci, M. A. I. Basuki, J. E. Powell, A. 
Goldinger, M. J. Fabis-Pedrini, A. G. Kermode, T. Burke, S. Vucic, G. J. Stewart and D. R. Booth 
(2016). "The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56 + cell 
dysregulation and is affected by immunomodulatory therapies." Clinical Immunology 163: 96-
107. 
Mechelli, R., R. Umeton, C. Policano, V. Annibali, G. Coarelli, V. A. G. Ricigliano, D. Vittori, A. 
Fornasiero, M. C. Buscarinu, C. International Multiple Sclerosis Genetics, C. Wellcome Trust Case 
Control, S. Romano, M. Salvetti and G. Ristori (2013). "A “Candidate-Interactome” Aggregate 
Analysis of Genome-Wide Association Data in Multiple Sclerosis." PLOS ONE 8(5): e63300. 
Mi, S., X. Lee, X.-p. Li, G. M. Veldman, H. Finnerty, L. Racie, E. LaVallie, X.-Y. Tang, P. Edouard, S. 
Howes, J. C. Keith and J. M. McCoy (2000). "Syncytin is a captive retroviral envelope protein 
involved in human placental morphogenesis." Nature 403(6771): 785-789. 
Montalban, X., B. Hemmer, K. Rammohan, G. Giovannoni, J. De Seze, A. Bar-Or, D. Arnold, A. 
Sauter, D. Masterman and P. Fontoura (2016). "Efficacy and Safety of Ocrelizumab in Primary 
Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled 
ORATORIO Study (S49. 001)." Neurology 86(16 Supplement): S49. 001. 
Munch, M., A. Møller-Larsen, T. Christensen, N. Morling, H. J. Hansen and S. Haahr (1995). "B–
lymphoblastoid cell lines from multiple sclerosis patients and a healthy control producing a 
putative new human retrovirus and Epstein–Barr virus." Multiple Sclerosis 1(2): 78-81. 
Munger, K. L., L. I. Levin, E. J. O’Reilly, K. I. Falk and A. Ascherio (2011). "Anti-Epstein-Barr virus 
antibodies as serological markers of multiple sclerosis: a prospective study among United States 
military personnel." Multiple sclerosis (Houndmills, Basingstoke, England) 17(10): 1185-1193. 
Munz, C., J. D. Lunemann, M. T. Getts and S. D. Miller (2009). "Antiviral immune responses: 
triggers of or triggered by autoimmunity?" Nat Rev Immunol 9(4): 246-258. 
Nelson, P. N., P. R. Carnegie, J. Martin, H. Davari Ejtehadi, P. Hooley, D. Roden, S. Rowland-Jones, 
P. Warren, J. Astley and P. G. Murray (2003). "Demystified . . . Human endogenous retroviruses." 
Molecular Pathology 56(1): 11-18. 
Neumann, H., I. M. Medana, J. Bauer and H. Lassmann (2002). "Cytotoxic T lymphocytes in 
autoimmune and degenerative CNS diseases." Trends in neurosciences 25(6): 313-319. 
Oldstone, M. B. A. (1998). "Molecular mimicry and immune-mediated diseases." The FASEB 
Journal 12(13): 1255-1265. 
Panitch, H. S., A. S. Haley, R. L. Hirsch and K. P. Johnson (1987). "Exacerbations of Multiple 
Sclerosis in patients treated with Gamma Interferon." The Lancet 329(8538): 893-895. 
Parnell, G. P., P. N. Gatt, M. Krupa, D. Nickles, F. C. McKay, S. D. Schibeci, M. Batten, S. Baranzini, 
A. Henderson and M. Barnett (2014). "The autoimmune disease-associated transcription factors 
EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of 
disease." Clinical Immunology 151(1): 16-24. 
Parnell, G. P., P. N. Gatt, M. Krupa, D. Nickles, F. C. McKay, S. D. Schibeci, M. Batten, S. Baranzini, 
A. Henderson, M. Barnett, M. Slee, S. Vucic, G. J. Stewart and D. R. Booth (2014). "The 
- 38 - 
 
autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in 
multiple sclerosis and define a molecular subtype of disease." Clinical Immunology 151(1): 16-24. 
Parnell, G. P., P. N. Gatt, F. C. McKay, S. Schibeci, M. Krupa, J. E. Powell, P. M. Visscher, G. W. 
Montgomery, J. Lechner-Scott, S. Broadley, C. Liddle, M. Slee, S. Vucic, G. J. Stewart and D. R. 
Booth (2014). "Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, 
downregulated by interferon treatment, and affected by season." Mult Scler 20(6): 675-685. 
Pender, M. P. (2010). "The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple 
Sclerosis." The Neuroscientist. 
Pender, M. P. (2012). "CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, 
and Steps to Autoimmunity: A Unifying Hypothesis." Autoimmune Dis 2012: 189096. 
Perron, H., J. A. Garson, F. Bedin, F. Beseme, G. Paranhos-Baccala, F. Komurian-Pradel, F. Mallet, 
P. W. Tuke, C. Voisset, J. L. Blond, B. Lalande, J. M. Seigneurin, B. Mandrand and t. C. R. G. o. M. 
Sclerosis (1997). "Molecular identification of a novel retrovirus repeatedly isolated from patients 
with multiple sclerosis." Proceedings of the National Academy of Sciences 94(14): 7583-7588. 
Perron, H. and A. Lang (2010). "The Human Endogenous Retrovirus Link between Genes and 
Environment in Multiple Sclerosis and in Multifactorial Diseases Associating Neuroinflammation." 
Clinical Reviews in Allergy & Immunology 39(1): 51-61. 
Perron, H., F. Lazarini, K. Ruprecht, C. Pechoux-Longin, D. Seilhean, V. Sazdovitch, A. Creange, N. 
Battail-Poirot, G. Sibai, L. Santoro, M. Jolivet, J. L. Darlix, P. Rieckmann, T. Arzberger, J. J. Hauw 
and H. Lassmann (2005). "Human endogenous retrovirus (HERV)-W ENV and GAG proteins: 
physiological expression in human brain and pathophysiological modulation in multiple sclerosis 
lesions." J Neurovirol 11(1): 23-33. 
Peters, A. L., L. L. Stunz and G. A. Bishop (2009). "CD40 and autoimmunity: the dark side of a 
great activator." Semin Immunol 21(5): 293-300. 
Pinnell, N., R. Yan, Hyo J. Cho, T. Keeley, Marcelo J. Murai, Y. Liu, Amparo S. Alarcon, J. Qin, Q. 
Wang, R. Kuick, Kojo S. J. Elenitoba-Johnson, I. Maillard, Linda C. Samuelson, T. Cierpicki and 
Mark Y. Chiang (2015). "The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of 
Notch1 in T Cell Development and Leukemia." Immunity 43(5): 870-883. 
Ramagopalan, S. V., R. Dobson, U. C. Meier and G. Giovannoni (2010). "Multiple sclerosis: risk 
factors, prodromes, and potential causal pathways." The Lancet Neurology 9(7): 727-739. 
Ramagopalan, S. V. and A. D. Sadovnick (2011). "Epidemiology of multiple sclerosis." Neurol Clin 
29(2): 207-217. 
Rubicz, R., R. Yolken, E. Drigalenko, M. A. Carless, T. D. Dyer, L. Bauman, P. E. Melton, J. W. Kent, 
Jr., J. B. Harley, J. E. Curran, M. P. Johnson, S. A. Cole, L. Almasy, E. K. Moses, N. V. Dhurandhar, E. 
Kraig, J. Blangero, C. T. Leach and H. H. H. Göring (2013). "A Genome-Wide Integrative Genomic 
Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 
1 (EBNA-1)." PLOS Genetics 9(1): e1003147. 
Scarisbrick, I. and M. Rodriguez (2003). "Hit-Hit and hit-Run: viruses in the playing field of 
multiple sclerosis." Current neurology and neuroscience reports 3(3): 265-271. 
- 39 - 
 
Schmidt, H., D. Williamson and A. Ashley-Koch (2007). "HLA-DR15 Haplotype and Multiple 
Sclerosis: A HuGE Review." American Journal of Epidemiology 165(10): 1097-1109. 
Schmitt, K., C. Richter, C. Backes, E. Meese, K. Ruprecht and J. Mayer (2013). "Comprehensive 
Analysis of Human Endogenous Retrovirus Group HERV-W Locus Transcription in Multiple 
Sclerosis Brain Lesions by High-Throughput Amplicon Sequencing." Journal of Virology 87(24): 
13837-13852. 
Schubert, R. D., Y. Hu, G. Kumar, S. Szeto, P. Abraham, J. Winderl, J. M. Guthridge, G. Pardo, J. 
Dunn and L. Steinman (2015). "IFN-β treatment requires B cells for efficacy in 
neuroautoimmunity." The Journal of Immunology 194(5): 2110-2116. 
Serafini, B., B. Rosicarelli, R. Magliozzi, E. Stigliano and F. Aloisi (2004). "Detection of Ectopic B-
cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive 
Multiple Sclerosis." Brain Pathology 14(2): 164-174. 
Shahijanian, F., G. P. Parnell, F. C. McKay, P. N. Gatt, M. Shojoei, K. S. O'Connor, S. D. Schibeci, F. 
Brilot, C. Liddle, M. Batten, A. M. S. G. Consortium, G. J. Stewart and D. R. Booth (2014). "The 
CYP27B1 variant associated with an increased risk of autoimmune disease is underexpressed in 
tolerizing dendritic cells." Human Molecular Genetics 23(6): 1425-1434. 
Shapiro, L. and C. A. Dinarello (1995). "Osmotic regulation of cytokine synthesis in vitro." 
Proceedings of the National Academy of Sciences 92(26): 12230-12234. 
Shiina, T., K. Hosomichi, H. Inoko and J. K. Kulski (2009). "The HLA genomic loci map: expression, 
interaction, diversity and disease." J Hum Genet 54(1): 15-39. 
Sospedra, M. and R. Martin (2005). "Immunology of multiple sclerosis." Annu Rev Immunol 23: 
683-747. 
Sospedra, M. and R. Martin (2005). "Immunology of multiple sclerosis*." Annu. Rev. Immunol. 
23: 683-747. 
Sotgiu, S., C. Serra, G. Mameli, M. Pugliatti, G. Rosati, G. Arru and A. Dolei (2002). "Multiple 
sclerosis–associated retrovirus and MS prognosis An observational study." Neurology 59(7): 
1071-1073. 
Speck, P., K. M. Haan and R. Longnecker (2000). "Epstein-Barr virus entry into cells." Virology 
277(1): 1-5. 
Stumpo, D. J., H. E. Broxmeyer, T. Ward, S. Cooper, G. Hangoc, Y. J. Chung, W. C. Shelley, E. K. 
Richfield, M. K. Ray, M. C. Yoder, P. D. Aplan and P. J. Blackshear (2009). "Targeted disruption of 
Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective 
hematopoiesis." Blood 114(12): 2401-2410. 
Sun, Y., X. Zuo, X. Zheng, F. Zhou, B. Liang, H. Liu, R. Chang, J. Gao, Y. Sheng and H. Cui (2014). "A 
comprehensive association analysis confirms ZMIZ1 to be a susceptibility gene for vitiligo in 
Chinese population." Journal of medical genetics 51(5): 345-353. 
Sundström, P., P. Juto, G. Wadell, G. Hallmans, A. Svenningsson, L. Nyström, J. Dillner and L. 
Forsgren (2004). "An altered immune response to Epstein-Barr virus in multiple sclerosis A 
prospective study." Neurology 62(12): 2277-2282. 
- 40 - 
 
Taylor, G. S., H. M. Long, J. M. Brooks, A. B. Rickinson and A. D. Hislop (2015). "The immunology 
of Epstein-Barr virus-induced disease." Annu Rev Immunol 33: 787-821. 
The International Multiple Sclerosis Genetics Consortium (IMSGC), Wellcome Trust Case Control 
Consortium 2 (WTCCC2), S. Sawcer, G. Hellenthal, M. Pirinen, C. C. A. Spencer, N. A. Patsopoulos, 
L. Moutsianas, A. Dilthey, Z. Su, C. Freeman, S. E. Hunt, S. Edkins, E. Gray, D. R. Booth, S. C. 
Potter, A. Goris, G. Band, A. B. Oturai, A. Strange, J. Saarela, C. Bellenguez, B. Fontaine, M. 
Gillman, B. Hemmer, R. Gwilliam, F. Zipp, A. Jayakumar, R. Martin, S. Leslie, S. Hawkins, E. 
Giannoulatou, S. D’alfonso, H. Blackburn, F. M. Boneschi, J. Liddle, H. F. Harbo, M. L. Perez, A. 
Spurkland, M. J. Waller, M. P. Mycko, M. Ricketts, M. Comabella, N. Hammond, I. Kockum, O. T. 
McCann, M. Ban, P. Whittaker, A. Kemppinen, P. Weston, C. Hawkins, S. Widaa, J. Zajicek, S. 
Dronov, N. Robertson, S. J. Bumpstead, L. F. Barcellos, R. Ravindrarajah, R. Abraham, L. 
Alfredsson, K. Ardlie, C. Aubin, A. Baker, K. Baker, S. E. Baranzini, L. Bergamaschi, R. Bergamaschi, 
A. Bernstein, A. Berthele, M. Boggild, J. P. Bradfield, D. Brassat, S. A. Broadley, D. Buck, H. 
Butzkueven, R. Capra, W. M. Carroll, P. Cavalla, E. G. Celius, S. Cepok, R. Chiavacci, F. Clerget-
Darpoux, K. Clysters, G. Comi, M. Cossburn, I. Cournu-Rebeix, M. B. Cox, W. Cozen, B. A. C. Cree, 
A. H. Cross, D. Cusi, M. J. Daly, E. Davis, P. I. W. de Bakker, M. Debouverie, M. B. D’hooghe, K. 
Dixon, R. Dobosi, B. Dubois, D. Ellinghaus, I. Elovaara, F. Esposito, C. Fontenille, S. Foote, A. 
Franke, D. Galimberti, A. Ghezzi, J. Glessner, R. Gomez, O. Gout, C. Graham, S. F. A. Grant, F. R. 
Guerini, H. Hakonarson, P. Hall, A. Hamsten, H.-P. Hartung, R. N. Heard, S. Heath, J. Hobart, M. 
Hoshi, C. Infante-Duarte, G. Ingram, W. Ingram, T. Islam, M. Jagodic, M. Kabesch, A. G. Kermode, 
T. J. Kilpatrick, C. Kim, N. Klopp, K. Koivisto, M. Larsson, M. Lathrop, J. S. Lechner-Scott, M. A. 
Leone, V. Leppä, U. Liljedahl, I. L. Bomfim, R. R. Lincoln, J. Link, J. Liu, Å. R. Lorentzen, S. Lupoli, F. 
Macciardi, T. Mack, M. Marriott, V. Martinelli, D. Mason, J. L. McCauley, F. Mentch, I.-L. Mero, T. 
Mihalova, X. Montalban, J. Mottershead, K.-M. Myhr, P. Naldi, W. Ollier, A. Page, A. Palotie, J. 
Pelletier, L. Piccio, T. Pickersgill, F. Piehl, S. Pobywajlo, H. L. Quach, P. P. Ramsay, M. Reunanen, R. 
Reynolds, J. D. Rioux, M. Rodegher, S. Roesner, J. P. Rubio, I.-M. Rückert, M. Salvetti, E. Salvi, A. 
Santaniello, C. A. Schaefer, S. Schreiber, C. Schulze, R. J. Scott, F. Sellebjerg, K. W. Selmaj, D. 
Sexton, L. Shen, B. Simms-Acuna, S. Skidmore, P. M. A. Sleiman, C. Smestad, P. S. Sørensen, H. B. 
Søndergaard, J. Stankovich, R. C. Strange, A.-M. Sulonen, E. Sundqvist, A.-C. Syvänen, F. Taddeo, 
B. Taylor, J. M. Blackwell, P. Tienari, E. Bramon, A. Tourbah, M. A. Brown, E. Tronczynska, J. P. 
Casas, N. Tubridy, A. Corvin, J. Vickery, J. Jankowski, P. Villoslada, H. S. Markus, K. Wang, C. G. 
Mathew, J. Wason, C. N. A. Palmer, H. E. Wichmann, R. Plomin, E. Willoughby, A. Rautanen, J. 
Winkelmann, M. Wittig, R. C. Trembath, J. Yaouanq, A. C. Viswanathan, H. Zhang, N. W. Wood, R. 
Zuvich, P. Deloukas, C. Langford, A. Duncanson, J. R. Oksenberg, M. A. Pericak-Vance, J. L. Haines, 
T. Olsson, J. Hillert, A. J. Ivinson, P. L. De Jager, L. Peltonen, G. J. Stewart, D. A. Hafler, S. L. 
Hauser, G. McVean, P. Donnelly and A. Compston (2011). "Genetic risk and a primary role for 
cell-mediated immune mechanisms in multiple sclerosis." Nature 476(7359): 214-219. 
Thorley-Lawson, D. A. (2001). "Epstein-Barr virus: exploiting the immune system." Nature 
Reviews Immunology 1(1): 75-82. 
Trisolini, M., A. Honeycutt, J. Wiener and Sarah Lesesne (2010). Global Economic Impact of 
Multiple Sclerosis, Multiple Sclerosis International Federation. 
Tsurumi, T., M. Fujita and A. Kudoh (2005). "Latent and lytic Epstein-Barr virus replication 
strategies." Rev Med Virol 15(1): 3-15. 
Tu, W., Y.-L. Lau, J. Zheng, Y. Liu, P.-L. Chan, H. Mao, K. Dionis, P. Schneider and D. B. Lewis 
(2008). "Efficient generation of human alloantigen-specific CD4<sup>+</sup> regulatory T cells 
from naive precursors by CD40-activated B cells." Blood 112(6): 2554-2562. 
- 41 - 
 
Tzartos, J. S., M. A. Friese, M. J. Craner, J. Palace, J. Newcombe, M. M. Esiri and L. Fugger (2008). 
"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is 
associated with active disease in multiple sclerosis." The American journal of pathology 172(1): 
146-155. 
Van Oosten, B., M. Lai, S. Hodgkinson, F. Barkhof, D. Miller, I. Moseley, A. Thompson, P. Rudge, A. 
McDougall and J. McLeod (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 
antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored 
phase II trial." Neurology 49(2): 351-357. 
van Sechel, A. C., J. J. Bajramovic,̀ M. J. B. van Stipdonk, C. Persoon-Deen, S. B. Geutskens and J. 
M. van Noort (1999). "EBV-Induced Expression and HLA-DR-Restricted Presentation by Human B 
Cells of αB-Crystallin, a Candidate Autoantigen in Multiple Sclerosis." The Journal of Immunology 
162(1): 129-135. 
Venken, K., N. Hellings, T. Broekmans, K. Hensen, J.-L. Rummens and P. Stinissen (2008). "Natural 
Naive CD4+CD25+CD127low Regulatory T Cell (Treg) Development and Function Are Disturbed in 
Multiple Sclerosis Patients: Recovery of Memory Treg Homeostasis during Disease Progression." 
The Journal of Immunology 180(9): 6411-6420. 
von Wunster, B., S. Bailey, A. Wilkins, D. I. Marks, N. J. Scolding and C. M. Rice (2018). "Advising 
patients seeking stem cell interventions for multiple sclerosis." Practical Neurology. 
Willis, M. D. and N. P. Robertson (2016). "Alemtuzumab for Multiple Sclerosis." Current 
Neurology and Neuroscience Reports 16(9): 84. 
Wingerchuk, D. M. and J. L. Carter (2014). Multiple sclerosis: current and emerging disease-
modifying therapies and treatment strategies. Mayo Clinic Proceedings, Elsevier. 
Yoshizaki, A., T. Miyagaki, D. J. DiLillo, T. Matsushita, M. Horikawa, E. I. Kountikov, R. Spolski, J. C. 
Poe, W. J. Leonard and T. F. Tedder (2012). "Regulatory B cells control T-cell autoimmunity 
through IL-21-dependent cognate interactions." Nature 491(7423): 264-268. 
Young, L. S. and A. B. Rickinson (2004). "Epstein-Barr virus: 40 years on." Nat Rev Cancer 4(10): 
757-768. 
Zheng, C. X., L. Yan, B. Nilsson, G. Eklund and B. Drettner (1994). "Epstein-Barr Virus Infection, 
Salted Fish and Nasopharyngeal Carcinoma: A case-control study in Southern." Acta oncologica 
33(8): 867-872. 
Zhou, Y., G. Zhu, J. C. Charlesworth, S. Simpson, R. Rubicz, H. H. Göring, N. A. Patsopoulos, C. 
Laverty, F. Wu and A. Henders (2016). "Genetic loci for Epstein-Barr virus nuclear antigen-1 are 
associated with risk of multiple sclerosis." Multiple Sclerosis Journal: 1352458515626598. 
 
  
- 42 - 
 
Chapter 2: Materials and Methods 
 
Figure 2.1: Flow chart of methods for chapter 3; Anti EBNA-1 IgG, Sodium and MS Risk 
Genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Flow chart of methods for chapter 4; CD40, LMP-1 and MS 
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2.1: Patient and Control demographics: 
All MS patients attended the MS clinic at Westmead Hospital, and gave consent for participation 
in the study, prior to blood collection by Prudence Gatt, Centre for Immunology and Allergy 
Research, Westmead Institute for Medical Research, Westmead, NSW, Australia. All MS patients 
included were untreated; designated as such, if they had not been on any immunomodulatory 
therapies for at least three months.  
Table 2.1: Patient and Healthy control demographics 
 Healthy Controls MS Patients 
Age range 22.75-67.98 24.02-71.95 
Average age 42.78 46.58 
Gender 38 Female, 28 Male 38 Female, 14 Male 
RRMS - 49 
PPMS - 3 
 
2.2: Sample collection and processing: 
All experimental work was completed using whole blood taken from patients and healthy controls; 
collected using either ethylenediaminetetraacetic acid (EDTA) tubes or uncoated tubes for serum 
collection. EDTA blood was used for peripheral blood mononuclear cells (PBMC) and DNA and RNA 
extraction from whole blood using PAXgene tubes (Becton Dickinson, Franklin Lakes, NJ, USA). All 
sample collections were completed by Prudence Gatt, Nicole Fewings or Fiona McKay. Blood 
processing was completed either by the collector (if the sample was collected prior to my 
Flow cytometry of 
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PCR 
(2.15) 
Unsuccessful attempt to replicate 
results from Mameli et. al. (2009): 
Designing new 
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Comparison with 
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Figure 2.3: Flow chart of 
methods for chapter 5. Design 
of new primers explained in 
chapter 5, section 3. 
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commencement), Stephen Schibeci (all from Centre for Immunology and Allergy Research, 
Westmead Institute for Medical Research, Westmead, NSW, Australia, or myself. 
 
Serum processing: 
Bloods intended for serum collection were collected in uncoated tubes and left for 30 minutes to 
coagulate. Once coagulated, blood tubes were spun at 1500 x g for 15 minutes at room 
temperature and the serum was collected using Pasteur pipettes for storage at 4°C for use within 
the week or at -80°C for long term storage. 
 
PBMC processing: 
Bloods intended for PBMC collection were collected in EDTA coated tubes, diluted 1:1 with PBS 
and gently layered on the surface of Ficoll™ Paque (GE Healthcare, Chicago, Ill, USA) at a ratio of 
2:1. The preparation was then spun at 400 x g for 35 mins, with a slow acceleration and 
deceleration. The top layer of plasma and two bottom layers of Ficoll™ and red blood cells was 
then discarded, and the middle layer of PBMCs was washed twice using sterile PBS. The PBMCs 
were then stored at -80°C in a CoolCell Cell Freezing System (Biocision, Mill Valley, CA, USA) after 
suspension in 50% FCS, 10% DMSO and 40% RPMI. 
 
2.3: General materials and methods 
Cell culture 
Unless otherwise specified, all RPMI media is composed of BioWhittaker® RPMI1640 Cat. No. 12-
702F (Lonza, Switzerland) supplemented with 2mM L- glutamine, 50 units/mL penicillin & 50μg/mL 
streptomycin and 10% heat inactivated Foetal Bovine Serum, all from Life Technologies (Carlsbad, 
CA, USA). 
Unless otherwise specified, all cell culture related centrifugation was completed at 300 x g for 5 
minutes. 
Flow cytometry 
Cold FACS wash was composed of 0.05% sodium azide and 0.5% BSA in PBS. All flow cytometry 
was run on a BD FACSCantoII flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), and 
Median Fluorescence Intensity (MFI) analysed using FlowJo (Ashland, OR, USA). 
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Table 2.2: Antibodies for flow cytometry: 
Name Brand Clone Animal of origin Catalog number 
CD40 PE eBioscience™ 5C3 Mouse 12-0409-41 
IgG1 kappa Isotype Control, 
PE  
eBioscience™ P3.6.2.8.1 Mouse 12-4714-81 
CD3 BV241 BD Biosciences SK7 Mouse 563797 
HLA-DR Per-CP BD Biosciences L243 Mouse 347364 
CD19 FITC BD Biosciences 4G7 Mouse 347543 
HERV-W GeneTex Polyclonal Rabbit GTX70327 
Rabbit IgG Isotype GeneTex Polyclonal Rabbit GTX47478 
 
PCR program TD6460 
All PCR experiments were completed using this program: 
 
 
Agarose Gels 
1x TBE buffer is Tris/Borate/EDTA Buffer: 100 mM Tris, 100 mM boric acid, 2mM EDTA in water. 
 
2.4: Anti EBNA-1 IgG: 
Serum anti EBNA-1 IgG was tested by an enzyme linked immunosorbent assay (ELISA) kit; 
ImmunoWELL™ EBNA IgG Immunoassay Test System (GenBio, San Diego, CA, USA), following the 
manufacturer's instructions. As the kit is designed for diagnostic use; where titres are grouped 
under negative, uncertain, medium or high, we adapted its use for quantitative purposes. Serum 
with values above the standard curve limits were diluted in normal EBV seronegative human serum 
10, 50 or 250-fold to within standard curve limits (figure 2.4). 
 
1. 96°C for 10 minutes 
 
2. 96°C for 30 seconds 
3. 64°C for 60 seconds        5x 
4. 72°C for 30 seconds 
 
5. 96°C for 30 seconds 
6. 60°C for 60 seconds       35x 
7. 72°C for 30 seconds 
 
8. 72°C for 5 minutes 
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Figure 2.4: Absorbances for anti EBNA-1 IgG titres, ranked from lowest to highest. 
Green line illustrates the ideal linear curve in healthy controls 
 
2.5: Total IgG 
Serum samples were sent for total IgG measurements to the Serology Department at Pathology 
West, Institute for Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, 
Westmead, NSW, Australia. 
 
2.6: Genotyping PCR 
All genotyping except for CD40 (rs1883832) was completed by Prudence Gatt, Centre for 
Immunology and Allergy Research, Westmead Institute for Medical Research, Westmead, 
Australia. 
DNA was extracted from EDTA blood using the QiaAmp® DNA Blood Mini Kit Cat. No. 51106 
(Qiagen, Germany) according to manufacturer’s protocol. 100ng of each sample was utilised for 
an in-house Taqman PCR or by a commercial provider (Australian Genome Research Facility Ltd.). 
The in-house genotyping protocol included addition of 100ng of DNA to 7.5μL of Applied Biosytems 
TaqMan™ Genotyping Master Mix Cat. No. 4371355 (Life Technologies, Carlsbad, CA, USA) and 
0.7μL of primer and probe mix (Table 2.6.1). 
 
 
 
 
Table 2.1 Genotyping probes 
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Gene SNP Gene SNP 
HLA-DR rs2516049  TBX21 rs4794058 
HLA-DR rs9271366 ZMIZ1 rs1782645 
ZFP36L2 rs2163226 RPS6KB1 rs180515 
EOMES rs11129295 CD40 rs1883832 
 
2.7: Gene Expression (non CD40) 
All measurements of gene expression, except for CD40, were completed by Prudence Gatt (Centre 
for Immunology and Allergy Research, Westmead Institute for Medical Research), University of 
Sydney, Westmead, Australia. 
 
Gene expression by real time PCR was normalised to GAPDH, with mRNA extracted from PAXgene 
blood tubes (Becton Dickinson, Franklin Lakes, NJ, USA) using the manufacturer's kit. Gene 
expression was determined in triplicate by real time PCR using predesigned TaqMan gene 
expression assays (Life Technologies, Carlsbad, CA, USA): EOMES hs00172872_m1; TBX21 
hs00203436_m1; ZMIZ1 hs00393480_m1, RPS6 hs04195024_g1, ZFP36L2 hs00272828_m1, 
GAPDH hs02758991_g1. 
 
2.8: Serum Sodium and Chloride 
Serum samples were sent for sodium and chloride measurements to the Serology Department at 
Pathology West, ICPMR, Westmead Hospital, Westmead, NSW, Australia. 
 
2.9: B cell selection: 
B cell negative selection from PBMCs was completed using the EasySep™ Human Naïve B Cell 
Enrichment kit, Cat. No. 19054 (Stem Cell Technologies, Canada) according to manufacturer’s 
protocol. A purity check by flow cytometry using anti CD20 FITC conjugate (Becton Dickinson, 
Franklin Lakes, NJ, USA) was completed for each sample; only samples with a purity of greater than 
95% were accepted for mRNA extraction. 
 
2.10: LCL transformation 
1ml of B95.8 cell line supernatant was added to 1x107 PBMCs in a 9 mL suspension with RPMI 
media and 1μg/mL of cyclosporin A Cat. No. SML1018 (Sigma Aldrich, St Louis, MO, USA). Cells 
were incubated at 37°C, 5% CO2, in T25 flasks that were kept upright to decrease surface area. 
Media was changed every 7 days, with the addition of cyclosporin stopping at 3 weeks. Flasks were 
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kept vertical until clumps of cells were visible under 20x magnification. Cells were obtained for 
freezing (5x106) and purity checked by flow cytometry (2x105). Purity check by flow cytometry was 
done by the addition of antiCD3 and antiCD56 to check for the presence of T and NK cells. LCLs 
were deemed ready for experimentation once no T or NK cells could be detected by flow 
cytometry. Batches of LCL cells were frozen down to ensure stock levels were maintained. 
 
2.11: Gene expression of CD40 
Extraction of mRNA from B-cells and LCLs was completed using the RNeasy purification kit Cat. No. 
74106 (Qiagen, Germany), following the manufacturer’s protocol. Conversion to cDNA was 
completed using qScript™ cDNA Supermix Cat. No. 95048-100 (Quanta Biosciences, Beverley, MA, 
USA) according to manufacturer’s protocol. Real time PCR was completed using Applied 
Biosystems™ Power SYBR™ Green PCR master mix Cat. No. 4367659 (Life Technologies, Carlsbad, 
CA, USA), using an Illumina™ Eco™ Real Time PCR system (San Diego, CA, USA). The TD6460 
program was used. 
 
2.12: CD40 protein surface expression on LCLs 
LCLs were washed twice prior to flow cytometry treatment, with viability assessed using Trypan 
Blue (Sigma Aldrich, St Louis, MO, USA). 5x105 cells required for each different LCL sample, which 
was split in half into two flow cytometry tubes just prior to blocking and antibody incubation. 
Staining and blocking was done in a 200μL PBS cell suspension. Blocking was completed using 
5μg of mouse IgG per tube, for 10 mins in the dark at room temperature, or 30 min in the dark 
on ice. Staining was completed in the dark on ice, with an antibody cocktail (Table 2.12.1), then 
washed twice with cold FACS wash prior to fixing with 1% paraformaldehyde in PBS. Antibody 
concentrations were as recommended by the manufacturer or previously titrated by Dr. Nicole 
Fewings, Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, 
Westmead, NSW, Australia. 
 
Table 2.3: CD40 Flow Antibody staining conditions 
 CD40 (PE) Isotype (PE) CD3 (BV241) HLA-DR (Per-CP) CD19 (FITC) 
Isotype - 2.5µL 2.5µL 2.5µL 10µL 
CD40 2.5µL - 2.5µL 2.5µL 10µL 
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2.13: LCL stimulation with CD40L 
To determine the optimum stimulation conditions, titration of both concentration of CD40 ligand 
Cat. No. AG-40B-0010-C010 (Adipogen, Switzerland) and incubation time in days was completed, 
where the optimum was found to be 5 days, 250ng/mL of CD40L with a 2x105 cell number in a 96 
well plate (See 2.14 below for full titration protocol). Cell proliferation was measured using 
CellTrace™ Violet Cat. No. C34571 (Life Technologies, Carlsbad, CA, USA) according to 
manufacturer’s flow cytometry protocol. 
 
The experiment proceeded as follows: LCLs were washed twice with PBS, then resuspended in 
PBS with 0.1% BSA. Cell numbers were counted and adjusted to 1x107 per ml. 20μL of 5 mM 
CellTrace™ Violet in DMSO was added, mixed well and incubated at 37°C for 10 mins, shaking 
every 2 mins. 1mL of FCS was added and incubated at room temperature for 5 minutes to stop 
staining. Cells were pelleted, then washed with RPMI. Cells were split, and CD40L was added. 
Cells were incubated for 5 days at 37°C, 5% CO2, with additional medium added at day 3 for 
supplementation purposes and due to evaporative loss. Cells were then washed twice with FACS 
wash, then fixed with 1% paraformaldehyde and stored at 4°C or immediately read by flow 
cytometry. A sample of cells were fixed with 1% paraformaldehyde immediately following 
CellTrace Violet labelling (day 0) for storage at 4°C and run with later time points to establish the 
non-proliferative signal. 
 
2.14: CD40L titration 
The titration proceeded as follows: LCLs were washed twice with PBS, then resuspended in PBS 
with 0.1% BSA. Cell numbers were counted and adjusted to 1x107 per ml. 20μL of varying 
concentrations of CellTrace™ Violet in DMSO was added, mixed well and incubated at 37°C for 10 
mins, shaking every 2 mins. 1mL of FCS was added and incubated at room temperature for 5 
minutes to stop staining. Cells were pelleted, then washed with RPMI. Cells were split, and CD40L 
was added at the appropriate concentration. Cells were incubated for 1-7 days at 37°C, 5% CO2, 
with additional medium added at day 3 for supplementation purposes and due to evaporative 
loss. At each time-point, Cells were then washed twice with FACS wash, then fixed with 1% 
paraformaldehyde and stored at 4°C or immediately read by flow cytometry. A sample of cells 
were fixed with 1% paraformaldehyde immediately following CellTrace Violet labelling (day 0) for 
storage at 4°C and run with later time points to establish the non-proliferative signal. 
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Concentrations CD40L tested were 5, 10, 20, 50, 100, 250, 1000 and 2000ng/L, and the time 
points tested were 24, 48, 72, 96, 120, 144 and 168 hrs (1, 2, 3, 4, 5, 6, 7 days)  
 
2.15: MSRVenv Taqman PCR 
The mRNA used for this PCR was extracted from PBMCs using RNeasy purification kit Cat. No. 
74106 (Qiagen, Germany), following the manufacturer’s protocol. Conversion to cDNA used the 
SuperScript™ First-Strand Synthesis System for RT-PCR Cat. No. 11904018 (ThermoFisher, 
Waltham, MA, USA) .  
 
Taqman PCR was completed using the primer set and probe published by (Mameli, Poddighe et 
al. 2009), forward primer: 5’-CTTCCAGAATTGAAGCTGTAAAGC-3’, reverse primer: 5’-
GGGTTGTGCAGTTGAGATTTCC-3’ and probe: FAM-5’-TTCTTCAAATGGAGCCCCAGATGCAG-3’-
TAMRA, custom ordered from Applied Biosystems, used with Taqman Universal Mastermix II 
with UNG Cat. No. 4440038 (Life Technologies, Carlsbad, CA, USA) according to manufacturer’s 
protocol.  PCR was completed on a ThermoFisher StepOne™ system, using the TD6460 program. 
Two runs were completed, the first using the recommended cDNA concentration, the second 
used undiluted cDNA, 10x more concentrated than the first run (figure 5.3, page 91). 
Extraction of mRNA, conversion to cDNA and the first run was completed by Prudence Gatt, 
Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, 
Westmead, Australia. All subsequent runs used the same cDNA created by Prudence Gatt, but 
the PCR was completed by me. 
2.16: MSRVenv SYBR green PCR 
The cDNA used for this section used the same cDNA as in section 2.14.  
For primer design, see section 5.2 (pages 93 - 95). Primers were checked for self-complementarity 
and melting temperatures using Primer 3 and NCBI’s primer design tool. 
The SYBR green PCR used a different set of primers as explained in section 5.3 (page 96); original 
primer set; MSRVenv160: forward primer: 5’-CTTCCAGAATTGAAGCTGTAAAGC-3’, reverse primer: 
5’-GGGTTGTGCAGTTGAGATTTCC-3’. MSRVenv308: forward: 5’-AGGAGCTTCAAAACACCGAACG-3’, 
reverse primer the same as MSRVenv160. MSRVenv444, forward: 5’-
GCTTTAGACTTGCTAACCGCCA-3’, reverse primer same as MSRVenv160. Real time q-PCR was 
completed using Applied Biosystems™ Power SYBR™ Green PCR master mix Cat. No. 4367659 (Life 
Technologies, Carlsbad, CA, USA), using an Illumina™ Eco™ Real Time PCR system. The TD6460 
program was used. Additionally, products were checked for size, primer dimer formation and non-
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specific binding by running on a 2% agarose gel. Agarose gel used 1 g of agarose (Bioline, United 
Kingdom) in 50mL of 0.5x TBE buffer and 2.5 µL of Ethidium Bromide, then run for 30 mins at 125V. 
 
2.17: Sequencing of MSRVenv308 product 
PCR product was cleaned prior to sequencing using ExoSAP-IT™ PCR Product Cleanup Reagent Cat. 
No. US78201-1ML (GE Healthcare, Chicago, IL, USA) according to the manufacturer’s protocol. 
Samples were then sent to the Australian Genome Research Facility for Sanger Sequencing. 
 
2.18: Flow cytometry of HERV-W 
HERV-W antibody Cat. No. GTX0327 (GeneTex, Irvine, CA, USA) was first conjugated with the 
fluorochrome PE. Cy5 using a PE. Cy5 conjugation kit Cat. No. ab102893 (Abcam, United Kingdom). 
 
PBMCs were washed twice prior to flow cytometry treatment, with cells viability assessed using 
Trypan Blue (Sigma Aldrich, St Louis, MO, USA). 5x105 cells required for each different sample, 
which was split into two flow cytometry tubes just prior to blocking and antibody incubation. 
Staining and blocking was done in a 200μL PBS cell suspension. Blocking for 10 mins in the dark at 
room temperature or 30 min in the dark on ice, and staining was completed in the dark on ice with 
an antibody cocktail (Table 2.17.1), then washed twice with cold FACS wash, prior to fixing with 
1% paraformaldehyde in PBS. 
Table 2.4: Blocking and staining conditions for HERV-W flow cytometry 
Tube Block CD3 (BV421) HERV (PE-Cy5) Iso (PE-Cy5) 
No Block Isotype 5µL sodium azide 2.5µL - 16µL 
No Block HERV 5µL sodium azide 2.5µL 16µL - 
Rabbit IgG Isotype Rabbit IgG block 5µg  2.5µL - 16µL 
Rabbit IgG HERV Rabbit IgG block 5µg  2.5µL 16µL - 
 
 
2.19: Statistical analyses 
All statistical analysis and log transformation of Anti EBNA-1 IgG levels to allow for ease of graphing 
was completed on GraphPad Prism Version 7.00 for Windows, GraphPad Software, La Jolla 
California USA, www.graphpad.com. All datasets were examined for normality using the 
D’Agostino and Pearson normality test. If the data was deemed normal, then an unpaired 2 tailed 
student’s T-test was chosen. If data was not deemed normal, then a Mann-Whitney test was 
chosen. The only exception to this is with the LCL stimulation with CD40L, where paired non-
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parametric test was chosen, the Wilcoxon matched pairs signed rank test, also completed using 
GraphPad Prism version 7.00 as above. 
 
References: 
Mameli, G., L. Poddighe, V. Astone, G. Delogu, G. Arru, S. Sotgiu, C. Serra and A. Dolei (2009). 
"Novel reliable real-time PCR for differential detection of MSRVenv and syncytin-1 in RNA and DNA 
from patients with multiple sclerosis." Journal of Virological Methods 161(1): 98-106. 
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Chapter 3: Anti EBNA-1 IgG, sodium and Multiple Sclerosis 
genetic risk variants  
Introduction: 
Virtually all MS patients are seroconverted to EBV compared to the general population, which have 
a seroconversion rate of 90-94% (Ramagopalan, Dobson et al. 2010, Jørgensen, Livbjerg et al. 
2012). EBV is thought to play a role in MS pathogenesis. Increased levels of IgG antibodies to EBV 
Nuclear Antigen-1 (EBNA-1) after the age of 25 are associated with increased MS risk by 2 to 3 fold 
(Levin, Munger et al. 2005, DeLorenze, Munger et al. 2006), and MS patients are found to have 
increased levels of anti-EBNA-1 IgGs, a finding that has been replicated across many cohorts 
(Munger, Levin et al. 2011, McKay, Gatt et al. 2016). Anti EBNA-1 IgG levels have also been found 
to correlate with Expanded Disability Status Scale (EDSS), a measure of disability in MS, with the 
levels of the protein EBNA-1 itself correlating with gadolinium enhancing lesions on MRI and T2 
lesion volume (Farrell, Antony et al. 2009, Lunemann, Tintore et al. 2010). Moreover, both anti 
EBNA-1 and EBNA-2 IgG levels are increased in the years preceding the onset of MS (Ascherio, 
Munger et al. 2001, Sundström, Juto et al. 2004). In this chapter we examine the relationship of 
anti-EBNA antibodies with MS risk genes HLA-DR, ZFP36L2, EOMES, TBX21, ZMIZ1 and RPS6KB1 
alongside the hypothesised risk factor of high sodium intake. These genes were chosen based on 
studies from both the Australia New Zealand Multiple Sclerosis Genetics Consortium and the 
International Multiple Sclerosis Genetics Consortium to which our group contributed to (ANZMSGC 
2009, IMSGC, WTCCC2 2011). 
 
EBV and EBNA-1 in MS 
EBNA-1 is the main antigen chosen for analysis of EBV levels mainly due to its presence in all stages 
of the EBV life cycle, including the lytic phase (Daikoku, Kudoh et al. 2004, Tsurumi, Fujita et al. 
2005). Additionally, anti EBNA-1 IgGs have been shown to increase with EBV movement from 
latent to lytic infection (activation), therefore it is suitable as a proxy for the measurement of EBV 
activity (Rubicz, Yolken et al. 2013). Seropositivity to IgG antibodies to EBNA-1 are an indication of 
the presence of latent and late primary infection (Nystad and Myrmel 2007); and here, it is utilised 
not only to indicate previous infection, but also reflects a combination of the level of latent 
infection by EBV, along with the strength of the individual’s immune reaction against the antigen 
which influences antibody production. Unsurprisingly, increased anti-EBNA-1 IgGs are also found 
in those who have had Infectious Mononucleosis (IM), also called glandular fever; which is caused 
by an overreaction by CD8+T cells triggered by late age (20’s-30’s) primary infection by EBV (Young 
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and Rickinson 2004). IM is also associated with increased MS risk of approximately 8 fold, though 
it is unknown if EBNA-1 mediates the risk (Martyn, Cruddas et al. 1993).  
 
MS risk genes 
The human leukocyte antigen (HLA) complex is associated with many autoimmune diseases such 
as MS, Type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus and autoimmune 
thyroid disease (Shiina, Hosomichi et al. 2009). The two alleles most strongly associated with MS 
are HLA-DRB1*1501 and HLA-DRB1*1303, conferring risk odds ratios of 3.1 and 2.4, respectively 
(The International Multiple Sclerosis Genetics Consortium (IMSGC), Wellcome Trust Case Control 
Consortium 2 (WTCCC2) et al. 2011). The HLA-DRB1 SNP we used, rs2516049, was the most 
associated with anti EBNA-1 IgG titres in two studies (Rubicz, Yolken et al. 2013, Zhou, Zhu et al. 
2016). It is in moderate linkage disequilibrium with rs3135391, the best SNP for HLA DRB1*1501 
SNP. This proxy SNP HLA DRB1*1501 was not studied in the two EBNA-1 GWAS. 
 
In addition to HLA-DRB1*1501, we have chosen to focus on 5 MS risk genes in relation to EBV; 
ZMIZ1, ZFP36L2, RPS6KB1, EOMES and TBX21 (Parnell, Gatt et al. 2014). 
 
An androgen receptor coactivator, Zinc Finger MIZ-Type Containing 1 (ZMIZ1) is a protein that 
shares homology to protein inhibitors of activated STATs (PIAS) (Rogers, Riordan et al. 2013). It is 
found to be downregulated in MS patients and positively correlated with ZFP36L2 expression 
(Fewings, Gatt et al. 2017). Along with MS risk, ZMIZ1 is also implicated in vitiligo (Sun, Zuo et al. 
2014). ZMIZ1 can bind to Notch-1 (Pinnell, Yan et al. 2015), which if activated starts a cascade 
resulting in the promotion of transcription (Bray 2006). As ZMIZ1 is crucial for the development of 
T cells (Pinnell, Yan et al. 2015), and given the controversially debated role CD8+ T cell activity in 
MS patients (Pender, Csurhes et al. 2008, Friese and Fugger 2009, Pender 2012), we decided to 
compare anti EBNA-1 IgG titres with ZMIZ1 MS risk SNP and mRNA levels in whole blood. ZFP36L2 
is a putative transcription factor that is fatal in knockout mice due to defective haematopoiesis 
(Stumpo, Broxmeyer et al. 2009), not unlike ZMIZ1. In addition, ZFP36L2 also interacts with Notch-
1 (Hodson, Janas et al. 2010) and helps the genomic integrity of B-cells by maintaining quiescence 
after VDJ recombination (Galloway, Saveliev et al. 2016). As ZFP36L2 is correlated with ZMIZ1 and 
given its involvement in the host cell of EBV (Fewings, Gatt et al. 2017), comparison of anti EBNA-
1 IgG titres as a proxy for EBV activity and ZFP36L2 MS risk SNP and mRNA levels was completed.  
RPS6 is a ribosomal protein overexpressed in whole blood of MS patients, whose phosphorylation 
is regulated by RPS6KB1, an MS risk gene (Parnell, Gatt et al. 2014). RPS6 is part of a T cell activation 
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gene expression signature that predicts the probability of MS (Parnell, Gatt et al. 2014). RPS6 is 
known to interact with the Hepatitis C virus; a knockdown of RPS6 results in a 75% reduction of 
HCV RNA and 20-50% reduction in viral protein translation (Huang, Su et al. 2012). Additionally, 
RPS6 is found to interact with a Kaposi's sarcoma associated herpesvirus protein, called the latency 
associated nuclear antigen, which is central to the survival and maintenance of the virus (Chen and 
Dittmer 2011). As RPS6 is involved in viral control and MS risk, it was included in the comparison 
between its MS risk SNP and mRNA with anti EBNA-1 IgG titres. 
 
EOMES and TBX21 are paralogue genes that encode the highly homologous transcription factors 
Eomesodermin (Eomes) and T-bet, which drive differentiation of NK cell and CD8+ memory cells 
(Intlekofer, Takemoto et al. 2005). Both Eomes and T-bet are required for the cytotoxic capabilities 
of CD8+ T cells, however, ectopic expression of EOMES alone is sufficient to trigger enzymes 
required for cytotoxic activity such as IFN-γ, perforin and granzyme- B (Pearce, Mullen et al. 2003, 
Lazarevic, Glimcher et al. 2013). Mice deficient in T-bet and Eomes are deficient in NK  cells and 
memory CD8+ T cells (Intlekofer, Takemoto et al. 2005). Our group has shown previously that MS 
patients exhibit lower expression of EOMES and TBX21 compared to healthy controls in peripheral 
blood (Parnell, Gatt et al. 2014, McKay, Gatt et al. 2016), and lower expression of Eomes and T-bet 
proteins within NK cells and CD8 T cells (McKay, Gatt et al. 2016). Given the reduced expression of 
Eomes and T-bet (and their respective genes) in peripheral blood, we questioned whether the 
cytotoxic capacity pf NK cells and CD8+ T cells may be impaired in MS.   
 
NK cells are the first line of immune defence against EBV infection.  Recently a humanised mouse 
model has demonstrated the critical role of human NK cells in control of lytic EBV infection, with 
NK cell depletion associated with enhanced symptoms of infectious mononucleosis and EBV 
tumorigenesis.  (Chijioke, Muller et al. 2013). CD8+ memory T cells are critical to ongoing immune 
control of established EBV infection (Pender 2012)- and their reduced frequency and cytotoxic 
capacity against EBV in MS has been hypothesised to be associated with loss of control of EBV 
infection in MS (Pender, Csurhes et al. 2014, Pender, Csurhes et al. 2017). These data have led us 
to question whether there is any relationship between EBV infection control (as measured by anti-
EBNA-1 titres) and Eomes and T-bet expression or genotype (MS risk SNPs).    
 
Dietary sodium (NaCl) has been suggested to play a role in the increase in MS incidence worldwide 
(Kleinewietfeld, Manzel et al. 2013) by way of increased proinflammatory cytokine production 
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(Shapiro and Dinarello 1995) and increased T cell proliferation (Junger, Liu et al. 1994). High dietary 
sodium levels have been shown to correlate with higher disease activity as measured by MRI 
(Farez, Fiol et al. 2015). More recent studies have shown that high levels of sodium chloride can 
induce CD4 naive T cells to develop a Th17 phenotype (Kleinewietfeld, Manzel et al. 2013), cells 
that are strongly implicated in EAE pathogenesis (Kasper and Shoemaker 2010, Dendrou, Fugger 
et al. 2015). When EAE mice are fed a high sodium diet, they have increased numbers of Th17 cells, 
accompanied with severe symptomatic deterioration (Kleinewietfeld, Manzel et al. 2013). Of 
interest, extracts of foods with high sodium content such as salted fish have been shown to 
activate EBV in Raji cells, an early EBV lymphoblastoid cell line (Shao, Poirier et al. 1988). Therefore, 
we decided to examine if the relationship between sodium and MS could be detected in serum, 
and whether this relationship could be associated with EBV. 
 
 
Aims  
The aims of this chapter are: 
To confirm the relationship between HLA-DR MS risk SNP rs2516049 and EBV, along with 
determining if the highly associated HLA-DRB1*1501 MS risk SNP rs9271366 is associated with EBV 
activity, using anti EBNA-1 IgGs as a proxy for viral activity. 
 
To determine if MS risk genes ZMIZ1, ZFP36L2, RPS6KB1, EOMES and TBX21 are associated with 
EBV by way of either MS risk genotype or mRNA levels, using anti EBNA-1 IgGs as a proxy for EBV 
activity. 
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Results: 
3.1: EBNA-1 and total IgG in MS patients and healthy controls 
Many previous studies have found anti EBNA-1 titres are significantly higher in MS.  In the 
Westmead MS cohort this is also true (Fig 3.1).  One possibility is that other IgGs are higher in MS, 
so that it doesn’t indicate an EBV-specific abnormality.  However, I found that total IgGs were not 
different between MS and controls (Fig 3.2).  The ratio of anti EBNA-1 to total IgGs was higher in 
MS (Fig 3.3). Analysis was done before log transformation, as log transformation was done for 
graphing purposes. 
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Figure 3.1: Anti EBNA-1 levels in healthy controls and MS patients 
Anti EBNA-1 levels in healthy controls (HC) (n=67) are lower when compared to untreated 
MS patients (MS) (n=52) as measured by ELISA, P value=0.0013. Seropositivity is defined as 
>300 units/mL, seronegativity is defined as <200 units/mL. Error bars represent median 
and interquartile range.  
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 Figure 3.2: Total IgG levels in heathy controls and MS patients 
Total IgG levels do not differ between healthy controls (HC)(n=56) and untreated MS 
patients (MS) (n=39), no statistical significance reached.  Error bars represent median and 
interquartile range. 
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Figure 3.3: Anti EBNA-1 IgG/ total IgG ratio in healthy controls and MS patients 
Anti EBNA-1 lgG/total IgG ratio in healthy controls (HC) (n=56) are lower when compared to 
untreated MS patients (MS) (n=39), P value=0.0009. Error bars represent interquartile 
range and median. 
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3.2: Anti EBNA-1 IgG and MS risk SNPs 
I then tested if antiEBNA-1 titres are associated with MS risk SNPs, potentially indicating these 
genetic variants affect control of EBV infection. HLA DR SNP rs2516049 A allele was associated with 
higher anti EBNA-1 titre in MS and not HC (Fig 3.4). ZFP36L2 allele C was associated with higher 
antiEBNA-1 titre in HC but not MS.  No significant association was seen with risk SNPs HLA-
DRB1*1501 rs9271366, rs11129295 EOMES, rs4794058 TBX21, rs1782645 ZMIZ1, or rs180515 
RPS6KB1. 
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Figure 3.4: Anti EBNA-1 IgG levels in healthy controls (n=60) and treatment naïve MS 
patients (n=49) divided into HLA-DR SNP rs2516049 alleles. Statistical significance 
reached between AA and GG MS patients, P=0.0162 (Mann-Whitney). Error bars represent 
median and interquartile range 
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Figure 3.5:  Anti EBNA-1 IgG levels in healthy controls (n=60) and treatment naïve MS 
patients (n=49) divided into ZFP36L2 SNP rs2163226 alleles.  
A trend of decreasing anti EBNA-1 IgG levels with the T allele is apparent, statistical 
significance reached between CC and TT healthy controls, P=0.0233. Error bars represent 
median and interquartile range 
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Figure 3.6 Anti EBNA-1 IgG levels in healthy controls and treatment naïve MS patients 
divided into SNP alleles: A=HLA-DR rs9271366, B=rs11129295 EOMES, C=rs4794058 
TBX21, D=rs1782645 ZMIZ1, E=rs180515 RPS6KB1. A: n=58 healthy controls, n=51 MS 
patients. B, C, D & E n=60 healthy controls, n=49 MS patients. There was no statistically 
significant difference between any of the alleles in either group (Mann-Whitney).  
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3.3: Anti EBNA-1 IgG and gene expression 
Next, I tested association of anti EBNA-1 titre with expression of the risk genes in whole blood. A 
negative correlation was observed between ZMIZ1 gene expression (R= -0.346, P=0.004). A 
positive correlation was observed between RPS6 gene expression compared (R= 0.289, P=0.02). 
No correlation was seen with EOMES, TBX21, ZFP36L2. 
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Figure 3.7: No correlation was observed between EOMES whole blood gene expression 
(relative to GAPDH) and anti EBNA-1 IgG levels in healthy controls (blue) (n=36) and 
MS patients (red) (n=31) (Spearman r). 
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Figure 3.8: No correlation was observed between TBX21 whole-blood gene expression 
(relative to GAPDH) and anti EBNA-1 IgG levels in healthy controls (blue) (n=36) and 
MS patients (red) (n=31) (Spearman r).  
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Figure 3.10: No correlation was observed between ZFP36L2 gene expression (relative 
to GAPDH) and Anti EBNA-1 IgG levels in healthy controls (blue) (n=26) and MS 
patients (red) (n=22) R= -0.346, P=0.004 (Spearman r).  
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Figure 3.11: A positive correlation was observed between RPS6 gene expression and 
Anti EBNA-1 IgG levels in healthy controls (blue) (n=36) and MS patients (red) (n=31). 
R= 0.289, P=0.02 (Spearman r). 
 
3.4: Anti EBNA-1 and sodium 
Serum sodium levels has been previously associated with MS (Farez, Fiol et al. 2015), however this 
was not the case in the Westmead cohorts (Fig 3.12). Finally, I tested if anti EBNA-1 titre was 
associated with serum sodium. No association was detected (Fig 3.13). 
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Figure 3.12: Serum sodium levels do not differ between healthy controls (HC)(n=20) 
and untreated MS patients (MS)(n=20) (Student’s T-test).  Error bars represent median 
and interquartile range. 
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Figure 3.13: No correlation was observed between serum sodium levels and anti 
EBNA-1 IgG levels in healthy controls (blue) (n=20) and MS patients (red) (n=20) 
(Spearman r) 
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Discussion 
In this chapter I investigated if the previously described environmental risk factors, EBV, as 
measured by anti EBNA-1 titres; and sodium, as measured by serum sodium levels, were 
associated with MS in the Westmead cohort.  I also tested if these environmental risk factors were 
affected by genotype of MS genetic risk variants. The MS cohort had higher titres of anti EBNA-1 
than controls, but serum sodium was not associated with MS.  HLA-DR SNP rs2516049 A allele was 
associated with higher anti EBNA-1 titre in MS and not HC. ZFP36L2 allele C was associated with 
higher anti EBNA-1 titre in HC but not in MS.  No significant association was seen with risk SNPs 
HLA-DRB1*1501 rs9271366, rs11129295 EOMES, rs4794058 TBX21, rs1782645 ZMIZ1, or rs180515 
RPS6KB1. Higher expression of ZMIZ1 was positively associated with anti EBNA-1, and RPS6 lower 
titres. These data are consistent with EBV contributing to MS pathogenesis, and immune 
regulation of EBV is affected by genetic risk variants HLA DR, ZMIZ1, ZFP36L2, and RPS6. 
 
Anti EBNA-1 IgG and total IgG 
Anti EBNA-1 IgG can be considered as an indicator of the level of latent EBV infection, as EBNA-1 
is the only viral protein consistently expressed throughout all stages of the EBV life cycle (Daikoku, 
Kudoh et al. 2004, Tsurumi, Fujita et al. 2005). Here, we confirm previous findings that MS patients 
have increased anti EBNA-1 IgG compared to healthy controls (Lunemann, Tintore et al. 2010, 
Nociti, Frisullo et al. 2010, Munger, Levin et al. 2011) (p = 0.0013; figure 3.1). Despite the large 
spread of data seen in our results, diagnostic application of EBNA-1 IgG for MS is possible. A 
regression model aimed at discriminating MS patients and healthy controls developed by Strautins 
et. al. in 2014, incorporates MS protective HLA-DR *04/07/09 alleles and a combination of anti- 
EBV antibodies (EBNA-1 and viral capsid antigen), reaching a 92% sensitivity and 64% specificity 
with an odds ratio of 21.9 (Strautins, Tschochner et al. 2014). This diagnostic model has quite a 
low specificity and is aimed as a further discriminatory tool in addition to MS specific criteria 
(Strautins, Tschochner et al. 2014). Additionally, as the study was only completed using a single 
cohort, replication in a different cohort is essential (Strautins, Tschochner et al. 2014). 
 
The large spread of data seen in my results may be explained by differences within both EBV and 
its human host; including B-cell transformation efficiency or mutations in the EBNA-1 gene, and 
variations in each subject’s immune response which may be both genetic and environmental 
(Lucas, Hughes et al. 2011). Variations in individual immune responses can be illustrated to an 
extent via the data spread in total IgG (figure 3.2), data that was acquired to ensure that the anti 
EBNA-1 IgG finding of figure 3.1 was not due to a general over production of antibodies. The 
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amount of anti EBNA-1 IgG in the blood may also be an inaccurate reflection of the level of 
infection if the host if for any reason unable to produce the anti-EBNA-1 antibody in sufficient or 
any quantity at all; a rare but possible outcome (Klutts, Ford et al. 2009). 
 
As figure 3.2 shows no difference between the total IgG produced by MS patients and healthy 
controls, it eliminates the possibility that other IgGs are higher in MS, indicating that the effect is 
of an EBV specific abnormality.  Additionally, as the ratio of anti EBNA-1 to total IgGs was higher in 
MS, this supports the hypothesis that in MS, there is an impaired or decreased control of EBV that 
contribute to MS pathogenesis by way of a combination of bystander damage, molecular mimicry 
and/or autoimmune B-cell survival.  
 
Anti EBNA-1 IgG and MS risk genes 
Approximately 30% of predisposition to MS is thought to arise from genetics, causing variations 
that occur within the immune system that mediate CNS damage (Dyment, Ebers et al. 2004). The 
genes explored here were chosen due to their identification as MS-associated in GWAS studies by 
the International Multiple Sclerosis Genetic Consortium (IMSGC, WTCCC2 2011); along with their 
roles as immune regulators in both viral and non-viral contexts. Additionally, ZMIZ1, EOMES, 
TBX21, and RPS6 are all heavily involved in T cell immune regulation (Pearce, Mullen et al. 2003, 
Parnell, Gatt et al. 2014, Pinnell, Yan et al. 2015, Galloway, Saveliev et al. 2016), with a link to EBV 
by way of CD8+T cell cytotoxic activity is deficiency in MS patients, particularly towards EBV 
infected B cells (Pender, Csurhes et al. 2008, Pender 2012). Furthermore, EOMES, TBX21 and 
ZFP36L2 are also involved in the regulation of B cells, the EBV host cell. Lastly, RPS6 is also known 
to be involved in viral survival and replication in the host cell (Chen and Dittmer 2011, Huang, Su 
et al. 2012). 
 
We found an association between anti-EBNA-1 IgG titres and the HLA-DR SNP rs2516049; where 
the more common A allele, also the MS risk allele, produces a dose effect of increasing anti EBNA-
1 IgG production, and thus, increased MS risk. While the trend is apparent in both, statistical 
significance is only reached in MS patients (figure 3.1); indicating that the additional genetic and/or 
immune characteristics of MS amplifies any effect the A allele may confer. A likely explanation for 
the amplification of the trend is the increased inflammatory state of MS patients, but to investigate 
this, pre-MS serum would need to be collected as a baseline. Without a standardised collection of 
blood samples such as is done by the US military upon commencement, such a study is 
impracticable as the study would need to collect extremely large numbers of subject serum 
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prospectively. The association between MS, anti EBNA-1 IgG titres and the rs2516049 SNP is 
further supported by the much larger GWAS study published by Zhou et al (2016), with this SNP 
giving the strongest P value (p= 4.11x10-9) out of all the HLA SNPs tested.  
 
The ZFP36L2 SNP, tagged by rs2163226 suggests a trend of lower anti EBNA-1 IgGs with the T allele 
in healthy controls, which is also the risk allele for MS (Figure 3.5). As increased anti EBNA-1 IgG is 
a known risk factor for MS, it was expected that the opposite trend would occur, with the T allele 
resulting in higher anti EBNA-1 IgGs. Both ZFP36L1 and ZFP36L2 are thought to enforce quiescence 
in B cells, and mice deficient in both have decreased B cell numbers (Galloway, Saveliev et al. 2016). 
Therefore, if the T allele is associated with lower ZFP36L2 expression, then a likely explanation for 
this trend in healthy controls is the decreased ZFP36L2 protein levels leads to lower levels of 
mature B- cells, and consequently, less EBNA-1 expression and production of its antibody. In MS 
patients, this effect is absent, which may be due to the increased inflammatory state in MS. As a 
higher anti EBNA-1 IgG is associated with higher MS risk, it is unlikely that the MS risk conferred 
by rs2163226 is mediated through levels of EBV infection in the host. The absence of a correlation 
between anti EBNA 1 IgG levels with ZFP36L2 mRNA expression further suggests a lack of 
relationship between EBV and MS risk conferred by ZFP36L2 that is evident in peripheral blood 
(figure 3.10).  
 
A weak negative correlation was observed between ZMIZ1 gene expression and anti EBNA-1 IgG 
levels in healthy controls, indicating that higher levels of ZMIZ1 expression is associated with lower 
levels of EBV infection. Often studied in the context of cancer, ZMIZ1 is a member of the protein 
inhibitor of activated STAT (PIAS)-like family of transcriptional coactivators which bind to STAT, 
Notch-1, NF-κB, SMAD and androgen receptors (Sharma, Li et al. 2003, Shuai and Liu 2005). Like 
ZFP36L2, it is difficult to develop specific hypotheses to explain how lower ZMIZ1 expression 
confers disease risk due to its many probable interactions and downstream effects as a 
transcriptional coactivator. However, as ZMIZ1 inactivation is also known to result in inhibition of 
T-cell development (Pinnell, Yan et al. 2015), it is possible that decreased ZMIZ1 expression leads 
to decreased T-cell maturation, and thus decreased control of EBV infection, leading to increased 
MS risk.   
 
RPS6KB1, an MS risk gene, controls the phosphorylation of ribosomal protein 6 (RPS6), a protein 
involved in the regulation of cell growth, and proliferation. It is known to be upregulated in MS 
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(Parnell, Gatt et al. 2014, Fewings, Gatt et al. 2017), and as RPS6 expression has a weak positive 
correlation with anti EBNA-1 (figure 3.11), it is possible that the MS risk conferred by RPS6 is in 
some way mediated by EBV infection. The upregulation of RPS6 in MS patients may have increased 
the cell growth and proliferation of EBV infected B-cells, leading to increased levels of EBV 
infection, and thus increased MS risk. On the other hand, it may also be interpreted that the 
increased levels of EBV infection is a side effect of increased RPS6, and that the MS risk conferred 
by RPS6KB1 has little to do with EBV, supported by the lack of association between the MS risk 
SNP and anti EBNA-1 IgG. As not much is known about RPS6 and autoimmune diseases in general, 
it is very difficult to determine whether the interaction between RPS6 and EBV is relevant to the 
MS risk conferred by RPS6KB1. 
 
While it is clear that EBV activity, as assayed by anti EBNA-1 antibody titre, is likely to be involved 
in MS pathogenesis, the role it plays in mediating the risk conferred by MS risk genes is not as clear 
cut. It is possible that EBV may contribute to the MS risk conferred by ZMIZ1 and RPS6, and 
perhaps, to a lower extent, ZFP36L2. ZMIZ1 is positively correlated with ZFP36L2; both are 
upregulated in MS patients and ZMIZ1 is also negatively correlated with RPS6, which is 
downregulated in MS patients (Fewings, Gatt et al. 2017). As ZMIZ1, RPS6 and ZFP36L2 seem to 
interact with each other, a relationship between EBV and any one of the three genes may be 
reflected less prominently in the other two. We saw no evidence in whole blood other MS risk 
variants conferred altered regulation of EBV infection; HLA-DR SNP rs9271366, EOMES SNP 
rs11129295, TBX21 SNP rs4794058, ZMIZ1 SNP rs1782645 and RPS6KB1 SNP rs180515 when 
compared to anti-EBNA-1 IgG titres did not result in statistical significance, although this may be 
due to a lack of statistical power. 
 
As a transcription factor that is expressed in many immune cells; including NK, B, and both CD4+ 
and CD8+ T cells (Lazarevic and Glimcher 2011), it is difficult to formulate a specific hypothesis to 
why and how TBX21 and its protein T-Bet contributes to MS risk and/or pathogenesis. The 
expression of TBX21 is also debated in MS patients, where some studies state it is upregulated, 
while others state it is downregulated (Lazarevic and Glimcher 2011). While T-bet is found to be 
upregulated in the CD4+ and CD8+ T cells in RRMS, a previous study published by our lab found that 
TBX21 is downregulated in the whole blood, including CD4 and CD8+ T cells of MS patients, the 
majority of whom are RRMS (McKay, Gatt et al. 2016). Notably, the cells that express the highest 
amounts T-Bet in PBMCs are NK cells (McKay, Gatt et al. 2016), so the downregulation of T-bet in 
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these cells indicate deficiency in cytotoxicity capacity and therefore a lower capacity for EBV 
control.  Another possibility is the downregulation of TBX21 mRNA is part of the homeostasis of T-
bet in response to higher T-bet protein levels, though to my knowledge, no data exists to support 
this hypothesis. NK cells from MS patients are deficient in cytotoxic capacity (Benczur, Petranyl et 
al. 1980) and therefore less able to control EBV. This may be a susceptibility factor, and perhaps 
even involved in ongoing EBV control.  
 
T-bet deficiency is known to increase the expression of the immunosuppressive interleukin IL-10 
(Lazarevic and Glimcher 2011), a point that contradicts with the finding that MS patients have 
lower TBX21 mRNA levels. This can be in part explained if EBV does indeed play a part in mediating 
the MS risk conferred by rs4794058, where a decrease in T-bet protein levels result in increased 
IL-10, and a lower immune response against the always present EBV infection. A lack of 
suppression of the EBV can then result in increased MS pathology. However, another possible 
explanation is the lower TBX21 mRNA levels is a response of the body against the inflammatory 
state of MS; an attempt to increase levels of IL-10 or other immunosuppressive cytokines. As no 
correlation was observed between TBX21 mRNA expression and anti EBNA-1 IgG levels (figure 
3.3.2), which suggests that either it is unlikely that EBV mediates the MS risk conferred by 
rs4794058, that such a relationship is cell-subset-specific, or that anti EBNA-1 IgG levels are not a 
good proxy of the levels of EBV infection in MS. 
 
Anti EBNA-1 IgG and blood sodium levels 
Despite the literature evidence that dietary sodium levels may be involved in MS pathology as 
measured by urinary sodium output and T2 total lesion load (Farez, Fiol et al. 2015), we did not 
find that serum sodium levels are increased in MS; and thus no evidence to support that defective 
sodium regulation in MS is present. It is likely that the tight regulation of sodium levels in the blood 
as part of fluid homeostasis by way of urinary output is not reflective of dietary sodium intake, 
where any high sodium intake into the body is adjusted to normal levels before the blood samples 
used in this study can be taken (Spitzer 1982). Because serum sodium levels are so tightly and 
quickly regulated, any effect sodium can have on MS pathology must occur short, frequent bursts. 
Furthermore, serum sodium levels are not correlated with anti EBNA-1 IgG levels, indicating that 
EBV infection levels is unlikely to play a role in any sodium involvement of MS pathology 
Unfortunately, the absence of urinary samples collected for the patients in our cohort means that 
we are unable to investigate the role of dietary sodium any further. Further studies with urinary 
sodium levels as a measure of dietary sodium compared with anti EBNA-1 IgG levels may be 
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considered, as sodium is known to activate EBV in Raji cells (Shao, Poirier et al. 1988) and is 
implicated in nasopharyngeal carcinoma, a cancer with EBV involvement (Zheng, Yan et al. 1994). 
 
 
 
 
Conclusion: 
We can confirm that anti EBNA-1 IgGs are increased in MS patients, independent of total IgG levels 
in the blood, as MS patients have very similar levels of total IgG to healthy controls. However, the 
spread of the data overlap of MS and controls precludes the use of anti EBNA-1 levels are 
predictors of MS risk. We found a significant association between anti EBNA-1 IgG levels with 
rs2516049, an MS risk SNP for HLA-DR, the gene most strongly associated with MS risk. However, 
we found no significant association of the SNP most associated in MS; rs9271366. ZMIZ1, RPS6 and 
ZFP36L2 were associated with anti EBNA1 titres, and may contribute to the immune response to 
EBV. 
Serum sodium is not associated with anti EBNA-1 IgG levels, though as the human body seems to 
keep a very tight homeostasis on sodium, it may not be the best measure of dietary sodium intake 
and that urinary sodium output should be done instead. It must be considered however, that while 
anti EBNA-1 IgG is the main antibody associated with latent EBV infection and is used in many 
studies, it may not be the best measure of EBV dysregulation in the body as it only measures levels 
of EBNA-1, a protein only expressed during latency. If EBV has reactivated in MS patients, then 
other antigens need to be considered as markers EBV dysregulation. 
 
Acknowledgements: 
All SNP genotyping and gene expression was completed by Prudence Gatt, Centre for Immunology 
and Allergy Research, Westmead Institute for Medical Research, Westmead, NSW, Australia. 
  
- 71 - 
 
References 
Ascherio, A., K. L. Munger, E. T. Lennette and et al. (2001). "Epstein-barr virus antibodies and risk 
of multiple sclerosis: A prospective study." JAMA 286(24): 3083-3088. 
 
Australia New Zealand Multiple Sclerosis Genetics Consortium (2009). "Genome-wide association 
study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20." Nat Genet 
41(7): 824-828. 
 
Bray, S. J. (2006). "Notch signalling: a simple pathway becomes complex." Nature reviews. 
Molecular cell biology 7(9): 678. 
 
Chen, W. and D. P. Dittmer (2011). "Ribosomal Protein S6 Interacts with the Latency-Associated 
Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus." Journal of Virology 85(18): 9495-
9505. 
 
Chijioke, O., A. Muller, R. Feederle, M. H. Barros, C. Krieg, V. Emmel, E. Marcenaro, C. S. Leung, O. 
Antsiferova, V. Landtwing, W. Bossart, A. Moretta, R. Hassan, O. Boyman, G. Niedobitek, H. J. 
Delecluse, R. Capaul and C. Munz (2013). "Human natural killer cells prevent infectious 
mononucleosis features by targeting lytic Epstein-Barr virus infection." Cell Rep 5(6): 1489-1498. 
 
DeLorenze, G. N., K. L. Munger, E. T. Lennette, N. Orentreich, J. H. Vogelman and A. Ascherio 
(2006). "Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study 
with long-term follow-up." Arch Neurol 63(6): 839-844. 
 
Dendrou, C. A., L. Fugger and M. A. Friese (2015). "Immunopathology of multiple sclerosis." Nat 
Rev Immunol 15(9): 545-558. 
 
Dyment, D. A., G. C. Ebers and A. Dessa Sadovnick (2004). "Genetics of multiple sclerosis." The 
Lancet Neurology 3(2): 104-110. 
 
Farez, M. F., M. P. Fiol, M. I. Gaitán, F. J. Quintana and J. Correale (2015). "Sodium intake is 
associated with increased disease activity in multiple sclerosis." J Neurol Neurosurg Psychiatry 
86(1): 26-31. 
- 72 - 
 
 
Farrell, R., D. Antony, G. Wall, D. Clark, L. Fisniku, J. Swanton, Z. Khaleeli, K. Schmierer, D. Miller 
and G. Giovannoni (2009). "Humoral immune response to EBV in multiple sclerosis is associated 
with disease activity on MRI." Neurology 73(1): 32-38. 
 
Fewings, N. L., P. N. Gatt, F. C. McKay, G. P. Parnell, S. D. Schibeci, J. Edwards, M. A. Basuki, A. 
Goldinger, M. J. Fabis-Pedrini, A. G. Kermode, C. P. Manrique, J. L. McCauley, D. Nickles, S. E. 
Baranzini, T. Burke, S. Vucic, G. J. Stewart and D. R. Booth (2017). "The autoimmune risk gene 
ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis." Journal of 
Autoimmunity 78: 57-69. 
 
Galloway, A., A. Saveliev, S. Łukasiak, D. J. Hodson, D. Bolland, K. Balmanno, H. Ahlfors, E. Monzón-
Casanova, S. C. Mannurita, L. S. Bell, S. Andrews, M. D. Díaz-Muñoz, S. J. Cook, A. Corcoran and M. 
Turner (2016). "RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence." Science 
352(6284): 453-459. 
 
Hodson, D. J., M. L. Janas, A. Galloway, S. E. Bell, S. Andrews, C. M. Li, R. Pannell, C. W. Siebel, H. 
R. MacDonald and K. De Keersmaecker (2010). "Deletion of the RNA-binding proteins ZFP36L1 and 
ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia." Nature 
immunology 11(8): 717-724. 
 
Huang, J.-Y., W.-C. Su, K.-S. Jeng, T.-H. Chang and M. M. Lai (2012). "Attenuation of 40S ribosomal 
subunit abundance differentially affects host and HCV translation and suppresses HCV replication." 
PLoS pathogens 8(6): e1002766. 
 
Intlekofer, A. M., N. Takemoto, E. J. Wherry, S. A. Longworth, J. T. Northrup, V. R. Palanivel, A. C. 
Mullen, C. R. Gasink, S. M. Kaech, J. D. Miller, L. Gapin, K. Ryan, A. P. Russ, T. Lindsten, J. S. Orange, 
A. W. Goldrath, R. Ahmed and S. L. Reiner (2005). "Effector and memory CD8+ T cell fate coupled 
by T-bet and eomesodermin." Nat Immunol 6(12): 1236-1244. 
 
Jørgensen, P. B., A. H. Livbjerg, H. J. Hansen, T. Petersen and P. Höllsberg (2012). "Epstein-Barr 
virus peptide presented by HLA-E is predominantly recognized by CD8bright cells in multiple 
sclerosis patients." PloS one 7(9): e46120. 
- 73 - 
 
 
Junger, W. G., F. C. Liu, W. H. Loomis and D. B. Hoyt (1994). "Hypertonic saline enhances cellular 
immune function." Circulatory shock 42(4): 190-196. 
 
Kasper, L. H. and J. Shoemaker (2010). "Multiple sclerosis immunology: The healthy immune 
system vs the MS immune system." Neurology 74(1 Supplement 1): S2-S8. 
 
Kleinewietfeld, M., A. Manzel, J. Titze, H. Kvakan, N. Yosef, R. A. Linker, D. N. Muller and D. A. Hafler 
(2013). "Sodium Chloride Drives Autoimmune Disease by the Induction of Pathogenic Th17 Cells." 
Nature 496(7446): 518-522. 
 
Klutts, J. S., B. A. Ford, N. R. Perez and A. M. Gronowski (2009). "Evidence-Based Approach for 
Interpretation of Epstein-Barr Virus Serological Patterns." Journal of Clinical Microbiology 47(10): 
3204-3210. 
 
Lazarevic, V. and L. H. Glimcher (2011). "T-bet in disease." Nat Immunol 12(7): 597-606. 
 
Lazarevic, V., L. H. Glimcher and G. M. Lord (2013). "T-bet: a bridge between innate and adaptive 
immunity." Nat Rev Immunol 13(11): 777-789. 
 
Levin, L. I., K. L. Munger, M. V. Rubertone, C. A. Peck, E. T. Lennette, D. Spiegelman and A. Ascherio 
(2005). "Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial 
onset of neurological symptoms in multiple sclerosis." Jama 293(20): 2496-2500. 
 
Lucas, R., A. M. Hughes, M. J. Lay, A.-L. Ponsonby, D. E. Dwyer, B. Taylor and M. Pender (2011). 
"Epstein–Barr virus and multiple sclerosis." Journal of Neurology, Neurosurgery & Psychiatry: jnnp-
2011-300174. 
 
Lunemann, J. D., M. Tintore, B. Messmer, T. Strowig, A. Rovira, H. Perkal, E. Caballero, C. Munz, X. 
Montalban and M. Comabella (2010). "Elevated Epstein-Barr virus-encoded nuclear antigen-1 
immune responses predict conversion to multiple sclerosis." Ann Neurol 67(2): 159-169. 
Martyn, C., M. Cruddas and D. Compston (1993). "Symptomatic Epstein-Barr virus infection and 
multiple sclerosis." Journal of Neurology, Neurosurgery & Psychiatry 56(2): 167-168. 
- 74 - 
 
 
McKay, F. C., P. N. Gatt, N. Fewings, G. P. Parnell, S. D. Schibeci, M. A. I. Basuki, J. E. Powell, A. 
Goldinger, M. J. Fabis-Pedrini, A. G. Kermode, T. Burke, S. Vucic, G. J. Stewart and D. R. Booth 
(2016). "The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56 + cell 
dysregulation and is affected by immunomodulatory therapies." Clinical Immunology 163: 96-107. 
 
Munger, K. L., L. I. Levin, E. J. O’Reilly, K. I. Falk and A. Ascherio (2011). "Anti-Epstein-Barr virus 
antibodies as serological markers of multiple sclerosis: a prospective study among United States 
military personnel." Multiple sclerosis (Houndmills, Basingstoke, England) 17(10): 1185-1193. 
 
Nociti, V., G. Frisullo, A. Marti, M. Luigetti, R. Iorio, A. K. Patanella, A. Bianco, P. A. Tonali, R. L. 
Grillo, M. Sabatelli and A. P. Batocchi (2010). "Epstein-Barr virus antibodies in serum and 
cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating 
polyradiculoneuropathy and amyotrophic lateral sclerosis." J Neuroimmunol 225(1-2): 149-152. 
 
Parnell, G. P., P. N. Gatt, M. Krupa, D. Nickles, F. C. McKay, S. D. Schibeci, M. Batten, S. Baranzini, 
A. Henderson, M. Barnett, M. Slee, S. Vucic, G. J. Stewart and D. R. Booth (2014). "The autoimmune 
disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis 
and define a molecular subtype of disease." Clinical Immunology 151(1): 16-24. 
 
Parnell, G. P., P. N. Gatt, F. C. McKay, S. Schibeci, M. Krupa, J. E. Powell, P. M. Visscher, G. W. 
Montgomery, J. Lechner-Scott and S. Broadley (2014). "Ribosomal protein S6 mRNA is a biomarker 
upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by 
season." Multiple Sclerosis Journal 20(6): 675-685. 
 
Parnell, G. P., P. N. Gatt, F. C. McKay, S. Schibeci, M. Krupa, J. E. Powell, P. M. Visscher, G. W. 
Montgomery, J. Lechner-Scott, S. Broadley, C. Liddle, M. Slee, S. Vucic, G. J. Stewart and D. R. Booth 
(2014). "Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, 
downregulated by interferon treatment, and affected by season." Mult Scler 20(6): 675-685. 
 
Pearce, E. L., A. C. Mullen, G. A. Martins, C. M. Krawczyk, A. S. Hutchins, V. P. Zediak, M. Banica, C. 
B. DiCioccio, D. A. Gross and C.-a. Mao (2003). "Control of effector CD8+ T cell function by the 
transcription factor Eomesodermin." Science 302(5647): 1041-1043. 
- 75 - 
 
 
Pender, M. P. (2012). "CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, 
and Steps to Autoimmunity: A Unifying Hypothesis." Autoimmune Dis 2012: 189096. 
 
Pender, M. P., P. A. Csurhes, A. Lenarczyk, C. M. Pfluger and S. R. Burrows (2008). "Decreased T-
cell reactivity to Epstein-Barr virus-infected lymphoblastoid cell lines in multiple sclerosis." Journal 
of Neurology, Neurosurgery & Psychiatry. 
 
Pinnell, N., R. Yan, H. J. Cho, T. Keeley, M. J. Murai, Y. Liu, A. S. Alarcon, J. Qin, Q. Wang and R. Kuick 
(2015). "The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of Notch1 in T cell 
development and leukemia." Immunity 43(5): 870-883. 
 
Pinnell, N., R. Yan, Hyo J. Cho, T. Keeley, Marcelo J. Murai, Y. Liu, Amparo S. Alarcon, J. Qin, Q. 
Wang, R. Kuick, Kojo S. J. Elenitoba-Johnson, I. Maillard, Linda C. Samuelson, T. Cierpicki and 
Mark Y. Chiang (2015). "The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of 
Notch1 in T Cell Development and Leukemia." Immunity 43(5): 870-883. 
 
Ramagopalan, S. V., R. Dobson, U. C. Meier and G. Giovannoni (2010). "Multiple sclerosis: risk 
factors, prodromes, and potential causal pathways." The Lancet Neurology 9(7): 727-739. 
 
Rogers, L. M., J. D. Riordan, B. L. Swick, D. K. Meyerholz and A. J. Dupuy (2013). "Ectopic Expression 
of Zmiz1 Induces Cutaneous Squamous Cell Malignancies in a Mouse Model of Cancer." Journal of 
Investigative Dermatology 133(7): 1863-1869. 
 
Rubicz, R., R. Yolken, E. Drigalenko, M. A. Carless, T. D. Dyer, L. Bauman, P. E. Melton, J. W. Kent, 
Jr., J. B. Harley, J. E. Curran, M. P. Johnson, S. A. Cole, L. Almasy, E. K. Moses, N. V. Dhurandhar, E. 
Kraig, J. Blangero, C. T. Leach and H. H. H. Göring (2013). "A Genome-Wide Integrative Genomic 
Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 
1 (EBNA-1)." PLOS Genetics 9(1): e1003147. 
 
Shao, Y., A. Poirier, H. Ohshima, C. Malaveille, Y. Zeng and H. Bartsch (1988). "Epstein–Barr virus 
activation in Raji cells by extracts of preserved food from high risk areas for nasopharyngeal 
carcinoma." Carcinogenesis 9(8): 1455-1457. 
- 76 - 
 
 
Shapiro, L. and C. A. Dinarello (1995). "Osmotic regulation of cytokine synthesis in vitro." 
Proceedings of the National Academy of Sciences 92(26): 12230-12234. 
 
Sharma, M., X. Li, Y. Wang, M. Zarnegar, C. Y. Huang, J. J. Palvimo, B. Lim and Z. Sun (2003). 
"hZimp10 is an androgen receptor co‐activator and forms a complex with SUMO‐1 at replication 
foci." The EMBO journal 22(22): 6101-6114. 
 
Shiina, T., K. Hosomichi, H. Inoko and J. K. Kulski (2009). "The HLA genomic loci map: expression, 
interaction, diversity and disease." J Hum Genet 54(1): 15-39. 
 
Shuai, K. and B. Liu (2005). "Regulation of gene-activation pathways by PIAS proteins in the 
immune system." Nature Reviews Immunology 5(8): 593. 
 
Spitzer, A. (1982). The role of the kidney in sodium homeostasis during maturation, Elsevier. 
Stumpo, D. J., H. E. Broxmeyer, T. Ward, S. Cooper, G. Hangoc, Y. J. Chung, W. C. Shelley, E. K. 
Richfield, M. K. Ray, M. C. Yoder, P. D. Aplan and P. J. Blackshear (2009). "Targeted disruption of 
Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective 
hematopoiesis." Blood 114(12): 2401-2410. 
 
Sun, Y., X. Zuo, X. Zheng, F. Zhou, B. Liang, H. Liu, R. Chang, J. Gao, Y. Sheng, H. Cui, W. Wang, A. K. 
Andiappan, O. Rotzschke, S. Yang, L. Sun, F. Zhang, X. Zhang, Y. Ren and J. Liu (2014). "A 
comprehensive association analysis confirms ZMIZ1 to be a susceptibility gene for vitiligo in 
Chinese population." Journal of Medical Genetics 51(5): 345-353. 
 
Sundström, P., P. Juto, G. Wadell, G. Hallmans, A. Svenningsson, L. Nyström, J. Dillner and L. 
Forsgren (2004). "An altered immune response to Epstein-Barr virus in multiple sclerosis A 
prospective study." Neurology 62(12): 2277-2282. 
 
The International Multiple Sclerosis Genetics Consortium (IMSGC), Wellcome Trust Case Control 
Consortium 2 (WTCCC2), S. Sawcer, G. Hellenthal, M. Pirinen, C. C. A. Spencer, N. A. Patsopoulos, 
L. Moutsianas, A. Dilthey, Z. Su, C. Freeman, S. E. Hunt, S. Edkins, E. Gray, D. R. Booth, S. C. Potter, 
A. Goris, G. Band, A. B. Oturai, A. Strange, J. Saarela, C. Bellenguez, B. Fontaine, M. Gillman, B. 
- 77 - 
 
Hemmer, R. Gwilliam, F. Zipp, A. Jayakumar, R. Martin, S. Leslie, S. Hawkins, E. Giannoulatou, S. 
D’alfonso, H. Blackburn, F. M. Boneschi, J. Liddle, H. F. Harbo, M. L. Perez, A. Spurkland, M. J. 
Waller, M. P. Mycko, M. Ricketts, M. Comabella, N. Hammond, I. Kockum, O. T. McCann, M. Ban, 
P. Whittaker, A. Kemppinen, P. Weston, C. Hawkins, S. Widaa, J. Zajicek, S. Dronov, N. Robertson, 
S. J. Bumpstead, L. F. Barcellos, R. Ravindrarajah, R. Abraham, L. Alfredsson, K. Ardlie, C. Aubin, A. 
Baker, K. Baker, S. E. Baranzini, L. Bergamaschi, R. Bergamaschi, A. Bernstein, A. Berthele, M. 
Boggild, J. P. Bradfield, D. Brassat, S. A. Broadley, D. Buck, H. Butzkueven, R. Capra, W. M. Carroll, 
P. Cavalla, E. G. Celius, S. Cepok, R. Chiavacci, F. Clerget-Darpoux, K. Clysters, G. Comi, M. Cossburn, 
I. Cournu-Rebeix, M. B. Cox, W. Cozen, B. A. C. Cree, A. H. Cross, D. Cusi, M. J. Daly, E. Davis, P. I. 
W. de Bakker, M. Debouverie, M. B. D’hooghe, K. Dixon, R. Dobosi, B. Dubois, D. Ellinghaus, I. 
Elovaara, F. Esposito, C. Fontenille, S. Foote, A. Franke, D. Galimberti, A. Ghezzi, J. Glessner, R. 
Gomez, O. Gout, C. Graham, S. F. A. Grant, F. R. Guerini, H. Hakonarson, P. Hall, A. Hamsten, H.-P. 
Hartung, R. N. Heard, S. Heath, J. Hobart, M. Hoshi, C. Infante-Duarte, G. Ingram, W. Ingram, T. 
Islam, M. Jagodic, M. Kabesch, A. G. Kermode, T. J. Kilpatrick, C. Kim, N. Klopp, K. Koivisto, M. 
Larsson, M. Lathrop, J. S. Lechner-Scott, M. A. Leone, V. Leppä, U. Liljedahl, I. L. Bomfim, R. R. 
Lincoln, J. Link, J. Liu, Å. R. Lorentzen, S. Lupoli, F. Macciardi, T. Mack, M. Marriott, V. Martinelli, D. 
Mason, J. L. McCauley, F. Mentch, I.-L. Mero, T. Mihalova, X. Montalban, J. Mottershead, K.-M. 
Myhr, P. Naldi, W. Ollier, A. Page, A. Palotie, J. Pelletier, L. Piccio, T. Pickersgill, F. Piehl, S. 
Pobywajlo, H. L. Quach, P. P. Ramsay, M. Reunanen, R. Reynolds, J. D. Rioux, M. Rodegher, S. 
Roesner, J. P. Rubio, I.-M. Rückert, M. Salvetti, E. Salvi, A. Santaniello, C. A. Schaefer, S. Schreiber, 
C. Schulze, R. J. Scott, F. Sellebjerg, K. W. Selmaj, D. Sexton, L. Shen, B. Simms-Acuna, S. Skidmore, 
P. M. A. Sleiman, C. Smestad, P. S. Sørensen, H. B. Søndergaard, J. Stankovich, R. C. Strange, A.-M. 
Sulonen, E. Sundqvist, A.-C. Syvänen, F. Taddeo, B. Taylor, J. M. Blackwell, P. Tienari, E. Bramon, A. 
Tourbah, M. A. Brown, E. Tronczynska, J. P. Casas, N. Tubridy, A. Corvin, J. Vickery, J. Jankowski, P. 
Villoslada, H. S. Markus, K. Wang, C. G. Mathew, J. Wason, C. N. A. Palmer, H. E. Wichmann, R. 
Plomin, E. Willoughby, A. Rautanen, J. Winkelmann, M. Wittig, R. C. Trembath, J. Yaouanq, A. C. 
Viswanathan, H. Zhang, N. W. Wood, R. Zuvich, P. Deloukas, C. Langford, A. Duncanson, J. R. 
Oksenberg, M. A. Pericak-Vance, J. L. Haines, T. Olsson, J. Hillert, A. J. Ivinson, P. L. De Jager, L. 
Peltonen, G. J. Stewart, D. A. Hafler, S. L. Hauser, G. McVean, P. Donnelly and A. Compston (2011). 
"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis." 
Nature 476(7359): 214-219. 
 
- 78 - 
 
Tsurumi, T., M. Fujita and A. Kudoh (2005). "Latent and lytic Epstein-Barr virus replication 
strategies." Rev Med Virol 15(1): 3-15. 
 
Young, L. S. and A. B. Rickinson (2004). "Epstein-Barr virus: 40 years on." Nat Rev Cancer 4(10): 
757-768. 
 
Zheng, C. X., L. Yan, B. Nilsson, G. Eklund and B. Drettner (1994). "Epstein-Barr Virus Infection, 
Salted Fish and Nasopharyngeal Carcinoma: A case-control study in Southern." Acta oncologica 
33(8): 867-872. 
 
Zhou, Y., G. Zhu, J. C. Charlesworth, S. Simpson, R. Rubicz, H. H. Göring, N. A. Patsopoulos, C. 
Laverty, F. Wu and A. Henders (2016). "Genetic loci for Epstein-Barr virus nuclear antigen-1 are 
associated with risk of multiple sclerosis." Multiple Sclerosis Journal: 1352458515626598. 
 
  
- 79 - 
 
Chapter 4: CD40, LMP1 and MS 
4.1. Introduction: 
A member of the Tumour Necrosis Factor Receptor (TNFR) superfamily, CD40 is a 48kDa type I 
transmembrane protein crucial for the generation of effective immune responses (Elgueta, Benson 
et al. 2009, Peters, Stunz et al. 2009). Mainly expressed on the surface of B-cells, CD40 can be 
found on many cells; Antigen Presenting Cells (APCs) such as dendritic cells and B cells, 
macrophages, monocytes, microglia, and T cells; along with non -immune cells such as platelets, 
endothelial, epithelial neuronal and smooth muscle cells, keratinocytes and fibroblasts 
(Chatzigeorgiou, Lyberi et al. 2009, Peters, Stunz et al. 2009). The ligand for CD40, CD40L, also 
known as CD154, is transiently expressed on the surface of activated T-cells, and like its receptor, 
to a lesser extent on endothelial, epithelial and smooth muscle cells (Chatzigeorgiou, Lyberi et al. 
2009). CD40, like other TNFR superfamily members, can self-associate through a PLAD domain in 
the absence of its ligand (Chan, Chun et al. 2000), resulting in signalling. CD40 has multiple isoforms 
formed by alternative RNA splicing, where some isoforms can block its signalling, suggesting that 
alternative splicing of CD40 mRNA plays a role in its regulation (Tone, Tone et al. 2001). CD40 is 
also known to be involved in the development, maintenance and survival of neuronal cells, where 
adult mice deficient in CD40 exhibit neuronal dysfunction with gross brain abnormalities that occur 
with age (Tan, Town et al. 2002). 
 
CD40 was first discovered as a receptor found on B cells, and its importance was first shown in X-
linked Hyper IgM immunodeficiency (HIGM) patients, where there are defects in the CD40 gene or 
the CD40L gene (Lam and Sugden 2003). As low IgG, IgA and IgE with normal to high levels of IgM 
is characteristic of HIGM, it is likely that CD40-CD40L signalling is crucial in T-cell dependent Ig class 
switching of B-cells (Lam and Sugden 2003). Mice with no CD40-CD40L signalling have defects in Ig 
class switching, formation of germinal centres and establishment of B-cell memory (Lam and 
Sugden 2003). CD40-CD40L signalling results in the binding of TNFR Associated Factors (TRAFs) to 
the short cytoplasmic tail of CD40, specifically, TRAF2, TRAF3, TRAF5 and TRAF6, along with an 
indirect association with TRAF1, resulting in the activation of many different signals such as NFKB, 
JNK and p38 pathways (Peters, Stunz et al. 2009). This results in a multitude of effects, amongst 
which are transcription factor activation, cytokine and chemokine secretion, proliferation and 
differentiation of B cells into plasma cells and memory cells, activation of T cells, activation of the 
nuclear factor κβ (NF-κβ) signalling pathways, the Janus family kinase (JNK) and the mitogen and 
stress-activated protein kinase (MAPK/SAPK) cascades (Chatzigeorgiou, Lyberi et al. 2009, Elgueta, 
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Benson et al. 2009, Peters, Stunz et al. 2009) (Figure 4.1). It must be noted, however, that CD40L 
stimulation results in different outcomes compared to anti-CD40 antibody binding (Baccam and 
Bishop 1999). 
 
 
Figure 4.1: TRAF dependent CD40-CD40L signalling and their downstream effects. 
Pathway activation is determined by which TRAFs are recruited. Image taken from (Elgueta, 
Benson et al. 2009). 
 
EBV, LMP1 and CD40 
While in vivo infection of EBV causes asymptomatic infection in childhood, infectious 
mononucleosis in young adults and a lymphoproliferative disease in immunocompromised 
individuals, in vitro infection of EBV gives rise to immortalised B cell lines, called Lymphoblastic Cell 
Lines (LCL) (Lam and Sugden 2003). LMP1, a viral membrane protein expressed during active EBV 
infection, is a functional mimic to CD40 and is found to be crucial for the constant proliferation 
and immortalisation that occurs in LCL formation and EBV-associated lymphomas (Kilger, Kieser et 
al. 1998). Unlike EBNA-1, LMP1 is not expressed during latency phase 1, and is crucial for EBV entry 
into the lytic cycle and virus release, along with driving EBV infected cell proliferation (Kuppers 
2003). LMP1 is ligand independent, delivering amplified and sustained signals compared to the 
transient nature of CD40-CD40L signalling (Kilger, Kieser et al. 1998, Graham, Moore et al. 2009, 
Arcipowski, Stunz et al. 2014). Whether LMP1 can fully replace CD40-CD40L in B cells is debated. 
While LMP1 can induce B cell activation, differentiation and Ig class switching, it appears to block 
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germinal centre (GC) formation (Uchida, Yasui et al. 1999), though more recent research with 
transgenic expression of a chimeric CD40-LMP1 in mice suggests that GC formation does occur, 
but with B-cell hyperactivation, autoreactivity and abnormal lymphoid architecture (Stunz, Busch 
et al. 2004). As both CD40 and LMP1 activate the same pathways, namely Akt, ERK, JNK, STAT and 
both canonical and non-canonical NFKB signalling (Graham, Arcipowski et al. 2010), the differences 
between them are due to how much each pathway is activated and regulated.  
 
Figure 4.2: Signaling relationships between LMP1 and CD40 (Thorley-Lawson 2001) 
While the downstream signaling between LMP-1 and CD40 remains the same, the two 
proteins employ TRAFs in different ways along with direct recruitment of the TNFR-1 
associated death domain protein (TRADD) and receptor interacting protein (Thorley-
Lawson 2001). 
 
Unlike CD40, LMP1 can bind directly to TRAF1, in addition to TRAFs 2,3,5 and 6 (Graham, 
Arcipowski et al. 2010). In general, CD40 signalling is tightly controlled and intermittent, due to the 
transient nature of the expression of its ligand in T cells, TRAF3 negative feedback and degradation 
of TRAFs 2 and 3 (Graham, Arcipowski et al. 2010). For CD40, the recruitment of TRAF2 is crucial 
for subsequent polyubiquitination and proteasome dependent degradation of CD40 itself, along 
with TRAF3 (Graham, Moore et al. 2009). In contrast, TRAF2 is found to be dispensable in LMP1 
signalling, where the degradation of both TRAF2 and 3 is completely absent (Graham, Moore et al. 
2009). TRAF3 appears to be crucial in LMP1 signalling, as it is used as a positive mediator of 
signalling whereas it is a negative regulator in CD40 signalling (Xie, Hostager et al. 2004). In addition 
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to persistent signalling triggered by self-oligomerisation (Graham, Arcipowski et al. 2010), 
compared to CD40, LMP1 is a more potent activator of B cells specifically in JNK and NFKB 
signalling, upregulation of surface molecules, secretion of IL-6 and IgM (Brown, Hostager et al. 
2001).  
 
Lymphoblastoid cell line (LCLs) 
EBV infected B cells have five transcriptomes, four latency stages and a lytic stage.  B cells infected 
with EBV can be easily cultured as they are immortalised as LCLs. LCLs are models of the latency III 
program of EBV, where LMP1, LMP2a and b, EBNA1, 2, 3a, 3b and 3c are continuously expressed 
(Cameron, Fewell et al. 2008). Also called, the growth programme, in vivo, latency III cells are only 
found in EBV infected naïve B cells in the tonsil, in post-transplant lymphomas, some AIDS 
associated B-cell lymphomas and in some cells of Burkitt’s lymphomas (Kuppers 2003, Fields, Knipe 
et al. 2007). This stage is the most targeted by the immune system of the latency stages and as 
such is likely to be especially important in immune regulation and susceptibility to MS. 
 
CD40 and MS 
Several single nucleotide polymorphisms (SNPs) in the CD40 gene confer increased risk of MS, 
including rs1883832, located 1 base pair prior to the CD40 transcription start site (Australia New 
Zealand Multiple Sclerosis Genetics Consortium 2009, Beecham and IMSGC 2013). For rs1883832, 
the MS risk is allele is T, a minor allele that is also associated with increased risk of Crohn’s disease 
(Blanco-Kelly, Matesanz et al. 2010). The MS protective allele, C, is associated with an increased 
risk of Graves’ disease and rheumatoid arthritis (Blanco-Kelly, Matesanz et al. 2010, Field, 
Shahijanian et al. 2015). The minor T MS risk allele is associated with decreased CD40 mRNA 
expression in B-cells and differentiated DCs of healthy controls (Field, Shahijanian et al. 2015), 
indicating a protective function of CD40, where lower B cell expression of CD40 confers risk of MS. 
In addition, MS patient B-cells are found to have lower levels of CD40, at both the mRNA and 
protein levels, when compared to healthy controls (Field, Shahijanian et al. 2015). However, this 
finding is controversial, with other studies finding either no difference or increased CD40 levels in 
MS patients (Huang, Huang et al. 2000, Buck, Kroner et al. 2006). 
As stated above, CD40-CD40L interaction increases T and B-cell activation along with 
proinflammatory cytokine production, among which is IL-6, a cytokine implicated in MS 
pathogenesis (Bush and Bishop 2008, Dendrou, Fugger et al. 2015). This appears somewhat 
counterintuitive, given that lower expression of an inflammatory pathway is associated with 
increased risk of MS; an observation we have called the “CD40 paradox”. However, one potential 
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explanation for the CD40 paradox in MS is that it confers a competitive advantage to the host 
during EBV infection.  Here, LMP1, a continuous and more potent activator of B cells (Stunz, Busch 
et al. 2004), increases the risk of formation of autoreactive B-cells which can then confer the 
damage proinflammatory effects that may contribute to or increase risk to MS. We hypothesise 
that increased CD40 expression may result in increased CD40-CD40L signalling, creating 
competition for TRAF resources with LMP1.  
 
Aims: 
To genotype individuals for MS risk SNP rs1883832, and replicate the findings of Fields et al. (2015) 
in 15 samples, n=5 in each rs1883832 genotype in B cells. In this data the protective allele had 
higher expression. Next, to determine if CD40 is also upregulated for the protective genotype in 
LCLs (mRNA, protein) and to determine if CD40-CD40L signalling affects proliferation of LCLs. 
Finally, to determine if CD40 rs1883832 genotype predicts anti-EBNA-1 levels. 
 
Hypotheses: 
The CD40 protective allele has higher expression (mRNA, protein) in LCLs, resulting in an increased 
response to CD40L. This increased signalling through CD40 in turn competitively inhibits viral LMP1 
signalling. Consequently, proliferation is reduced in the presence of CD40L, especially for the 
rs1883832 protective genotype of C. Therefore, those with the protective genotype have better 
control over EBV infection, as indicated by lower anti-EBNA-1 antibody levels, and consequently, 
lower risk of MS. 
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4.2. Results: 
The protective allele of CD40 MS risk variant rs1883832, ‘C’, has been shown to have higher 
association with gene expression in blood (Gandhi et al, 2010) and in B cells (Field et al, 2015). 
mRNA expression in 15 controls by RTPCR using GAPDH as a housekeeping gene was assessed; 
although CC and CT genotypes had higher means, it was not statistically significant (Fig 4.3).   
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Figure 4.3: CD40 mRNA levels in healthy control B-cells measured by Q-RT PCR as 
normalised to GAPDH. No trend is apparent between genotypes (Each genotype n=5, 
measured in triplicate). Error bars represent median and interquartile range. 
 
 
CD40 mRNA and protein expression in LCLs  
CD40 mRNA expression was higher in LCLs for the protective allele (p=0.0317) (Fig 4.4). CD40 
protein was more highly expressed for the protective allele using flow cytometry. No significant 
associations of genotype with expression were identified (Fig 4.5) 
 
- 85 - 
 
C
C
C
T
T
T
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
C D 4 0
 rs 1 8 8 3 8 3 2
E
x
p
re
s
s
io
n
 l
e
v
e
l
*
 
Figure 4.4: CD40 mRNA expression levels as normalised to GAPDH in LCLs derived 
from the same healthy controls as in figure 4.1, organised according to rs1883832 
genotypes. Individuals with the MS risk genotype TT has lower CD40 mRNA compared to 
the protective genotype of CC. P=0.0317 (Mann-Whitney), n=5 for all genotypes, each 
measured in triplicate. Median and interquartile range represented by error bars.  
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Figure 4.5: Surface expression of CD40 measured by flow cytometry in LCLs, organised 
according to rs1883832 genotypes. No trend is apparent, median and interquartile range 
represented by error bars, n=5 for all genotypes. 
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CD40-CD40L signalling and proliferation of LCLs 
Although the evidence for higher expression of CD40 for the protective genotype was equivocal in 
the small sample size I have used, the evidence from other, larger studies suggest it may be the 
case (Field, Shahijanian et al. 2015). If CD40 expression is higher, then signalling in response to 
CD40L may also be higher.  This may compete with signalling through LMP1 and so reduce LCL 
proliferation under control of the LMP1 pathway.  I found that LCL proliferation, as measured by 
CSFE decay, was reduced in the presence of CD40L (Fig 4.6, P<0.0001, paired t test). The difference 
in proliferation on CD40L stimulation was highest for the protective allele (Fig 4.7, p=0.039, 
unpaired 2-tailed student’s T-test). 
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Figure 4.6: Inhibition of proliferation in LCLs by CD40L stimulation. Proliferation as 
measured with a flow-based proliferation assay, was inhibited in all individuals, n=15, 
P<0.0001 (Wilcoxon test). 
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Figure 4.7: Difference in the proliferation of LCL under CD40L stimulation compared 
to no stimulation, organised according to rs1883832 genotype (CC, n=5) (CC/TT, n=9) 
(P= 0.039) (Unpaired 2 tailed T-test) mean and standard deviation represented by 
error bars. 
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CD40 genotype and anti EBNA-1 IgG titres 
Individuals more susceptible to EBV infection have higher levels of antigen and so may have higher 
titres of antibody to the virus, with EBNA-1 being the most commonly used target antigen in assays. 
I confirmed higher titres of anti-EBNA-1 antibodies in patients with MS (p=0.0196).  If the 
protective CD40 allele inhibits LMP1 signalling, individuals with this variant may control EBV 
infection more successfully, and so have lower titres of the antibody to EBNA-1.  I found no 
evidence that this was so (Fig 4.8). 
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Figure 4.8: Anti EBNA-1 IgG titres organised according to CD40 rs1883832 genotype. 
Heterozygous healthy controls titres (n=21) are statistically significantly lower compared to 
their heterozygous MS counterparts (n=46) (p = 0.0196) (Mann-Whitney). A non-
statistically significant trend of decreasing IgG titres can be seen in healthy controls (CC: 
n=31, CT: n=21, TT: n=5), but not in MS patients (CC: n=70, CT: n= 46, TT: n=8). Error bars 
represent median with interquartile range.  
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4.3. Discussion: 
Previous studies have shown that protective variant of the T cell activation gene is more highly 
expressed. Rather than increase T cell activation, which should increase risk of autoimmunity, 
CD40 may have another function where high expression is beneficial in MS.  Since CD40 can 
potentially reduce signalling though the viral gene LMP1 by competition, higher expression of 
CD40 in EBV infected B cells (LCLs) may be protective against EBV and consequently MS.  We have 
found that the protective allele of CD40 is associated with higher expression of CD40 in LCLs (Fig 
4.4), and that culture of LCLs in the presence of CD40L reduces their proliferation (Fig 4.6).  The 
reduction in proliferation was highest for the protective genotype of CD40 (Fig 4.7).  Overall these 
data support our hypothesis that the protective allele of CD40 reduces susceptibility to MS through 
reducing susceptibility to EBV. 
 
However, some findings were not consistent with this hypothesis.  We did not find a genotype 
association with mRNA expression in B cells, with protein expression in LCLs, or with anti-EBNA-1 
titres in healthy controls or people with MS.  A likely explanation for this inconsistency is that we 
lacked sufficient statistical power to find such associations. 
 
MS risk genotype and CD40 mRNA expression in normal B-cells and EBV infected B 
cells 
Measurement of CD40 mRNA levels in the B cells of these individuals failed to confirm the 
observation of Field et al. (2015), where the CC genotype confers higher levels of CD40 than both 
the CT and TT genotypes, likely due to the small sample size. We found lower expression of CD40 
for the MS risk genotype TT in LCLs at the mRNA level (figure 4.4), indicating that either or both 
the infection with EBV and its transformation into a cell line changes mRNA expression. This is not 
surprising, given that B cells extracted from the peripheral blood of healthy controls would most 
likely be in a non-proliferative state. LCLs, as a cell line, would be in a much different state, though 
its proliferative capabilities could almost all be attributed to LMP-1.  
However, when surface CD40 expression was quantified using flow cytometry (figure 4.5), this 
statistical significance was not observed. The most likely reason for these discrepancies with 
published work is the low sample number of 5 in each cohort. Considering that converting B cells 
into LCLs required a minimum of 2-3 months, it is difficult to achieve larger cohort numbers in a 
master’s degree due to time constraints. In addition, numbers of TT individuals are very low, with 
all 5 healthy controls utilised in all experiments.  
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Activation of CD40 through CD40L reduces LCL proliferation 
LCL proliferation under CD40L stimulation was assessed to determine if it is inhibited, potentially 
counteracting LMP1 mediated cell proliferation and both CD40 and LMP1 use shared signalling 
molecules (Fig 4.2). All samples tested showed decreased proliferation under CD40L stimulation, 
at a concentration of 250ng/mL, consistent with the hypothesis that the two pathways interact. 
The most likely reason for this is for CD40 to bind TRAFs 2 and 3 when stimulated and eventually 
triggering the degradation of both, along with the inhibitory effects TRAF3 has on proliferation 
through CD40.  
 
Because CD40 signalling decreases proliferation, it may explain the paradox of CD40 in MS, where 
increased CD40 expression increases its signalling, moderating the effects of LMP1 which is known 
to create B-cell hyperactivation and autoreactivity (Stunz, Busch et al. 2004). In comparing 
proliferation of LCLs to its rs1883832 genotype, inhibition of proliferation with the CC genotype, 
which also confers increased CD40 expression (Field, Shahijanian et al. 2015), was strongest 
(p=0.039, Fig 4.7). The effect may be explained by the increased CD40 levels conferred by the C 
allele of rs1883832 (figure 4.4) (Field, Shahijanian et al. 2015). This supports the hypothesis that 
the CD40 protective allele has higher expression (mRNA, protein) in LCLs, resulting in an increased 
response to CD40L and competitively inhibiting viral LMP1 signalling. However, it is possible that 
the proliferation may be independent of the pathogenic effect that rs1883832 may contribute to 
MS, whereby CD40 levels are influenced by another genetic or environmental factor. 
 
Anti EBNA-1 titres and CD40 genotype 
The CD40 rs1883832 genotype was determined in healthy controls and MS patients (Figure 4.8) 
and genotype correlation with titre of antibodies to EBNA-1, as a measure of control of EBV 
infection (higher titre = less control). Titre was highest in MS patients, as expected.  There was no 
difference between genotypes for those with MS, and less anti EBNA-1 IgGs identified in those 
carrying a MS risk allele, T, for healthy controls. As the rate of incidence of the T allele in the 
population is very small, around 23% , despite examining 57 healthy controls (HC) and 124 MS 
patients (MS), only very low numbers (5 HC and 8 MS) of homozygous TT individuals were 
identified. The heterozygous (CT) individuals show increased anti EBNA-1 IgG in MS patients 
compared to healthy controls (p=0.0196), and this effect appears to be increased in the MS risk 
allele individuals (TT), though with no statistical significance, most likely due to a lack of power as 
individuals with the TT genotype are very rare. As EBNA-1 is a latency protein, its antibody titre is 
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not a good marker for active infection, and therefore it is possible that the T genotype of rs1883832 
confers decreased latency and increased active infection, something we have not measured for.  
 
Limitations of the Study 
As discussed above, all correlations were limited by statistical sensitivity to detect differences. 
Further, all genotype effects on CD40 expression were determined using cells from healthy 
controls, which may behave differently from those of people with MS. The latter would be difficult 
to obtain, and genotype effect in culture was presumed to be similar to those found in MS B cells.  
 
Future Work 
A larger sample size would be ideal in addition to obtaining MS patient PBMCs to transform into 
LCLs. Measurement of LMP-1 in LCLs would allow direct comparison with CD40 and proliferation 
with CD40L. Additionally, examination of the TRAFs that are likely to mediate the competition 
between CD40 and LMP1 such as TRAFs 2 and 3 is needed, particularly if any are MS risk genes. If 
further experimentation supports our hypothesis; whereby those with the protective genotype 
have better control over EBV infection and consequently, lower risk of MS, it may be that LMP-1 
could be a potential therapeutic target. 
 
Conclusion 
We have found that the protective allele of CD40 (rs1883832, CC) is associated with higher 
expression of CD40 in LCLs, and that culture of LCLs in the presence of CD40L reduces their 
proliferation, in a genotype dependant manner. Overall the data in this chapter supports our 
hypothesis that the protective allele of CD40 reduces susceptibility to MS through reducing 
susceptibility to EBV. However, some findings were inconsistent with this hypothesis, as we did 
not find a genotype association with mRNA expression in B cells, with protein expression in LCLs, 
or with anti-EBNA-1 titres in healthy controls or people with MS.  A likely explanation for this 
inconsistency is that we lacked sufficient statistical power to find such associations. 
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Chapter 5: HERV-W, EBV and MS 
Introduction 
Comprising approximately 1-8% of the human genome, Human Endogenous Retroviruses (HERV) 
can be termed as the “footprints” of previous retroviral infections that have been transmitted 
vertically through the germline (Nelson, Carnegie et al. 2003, Perron and Lang 2010). Though the 
majority of HERVs are defective through accumulation of mutations, some do transcribe viral 
products that are implicated in illnesses or provide a benefit (Nelson, Carnegie et al. 2003). A 
beneficial HERV product is the HERV group W envelope protein, syncytin, believed to be important 
in human placental morphogenesis (Mi, Lee et al. 2000).  
 
The multiple sclerosis-associated retrovirus (MSRV)/type W family of human endogenous 
retroviruses (MSRV/HERV-W) were discovered in the late 1980s, when leptomeningeal cells 
isolated from a patient with multiple sclerosis (MS) were shown to harbor a retrovirus, with 
reverse-transcriptase (RT) activity. Complete MSRV sequencing identified a new family of HERVs, 
which was named HERV-W from its tryptophan t-RNA binding site, identified in MSRV 5’ long 
terminal repeat (LTR) (Dolei and Perron 2009). The human genome contains around 70 gag, 100 
pro, and 30 env HERVW-related regions, and in silico expression data suggest that 22 complete 
HERV-W subfamilies are randomly expressed in various tissues (Dolei and Perron 2009). The 
existence of replication-competent and/or “exogenous” family member of HERV-W is supported 
by some lines of evidence but is yet to be confirmed (Dolei and Perron 2009).    
 
MSRV (Machnik, Skudrzyk et al. 2015) is an endogenous retroviral element repeatedly found in the 
cerebrospinal fluid (CSF), EBV-immortalised LCLs (Perron, Garson et al. 1997) and the brain tissue 
of MS patients (Schmitt, Richter et al. 2013). The presence of MSRV in the CSF of MS patients is 
also observed to be associated with increased disease severity (Sotgiu, Serra et al. 2002). However, 
the role of MSRV in the pathogenesis of MS is unclear and controversial, with conflicting reports 
of MSRV upregulation or lack of in the MS brain (Antony, Zhu et al. 2007, Mameli, Astone et al. 
2007, Antony, Deslauriers et al. 2011).  
 
A recent model proposes Human Endogenous Retrovirus-W (HERV-W) as the link between high 
EBV titre and MS (Mameli, Poddighe et al. 2012). Here, it is proposed that super-antigenic HERV-
W is activated by EBV infection in the brain, triggering toxic mechanisms against oligodendrocytes, 
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contributing to the neuropathology of MS (Mameli, Poddighe et al. 2012). In this chapter I 
investigated if there was evidence that HERV-W was dysregulated in MS. 
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Results 
5.1 MSRVenv PCR 
We sought to confirm the findings of Mameli (2007, 2009), where peripheral blood immune cells 
of MS patients are found to express HERVenv proteins. To begin we attempted to replicate their 
PCR findings, utilising the same primer set and Taqman probe as used by Mameli et al. (2009), 
however no difference was detected (figure 5.1; p = 0.453), in contrast to their findings of 5.8 fold 
increase of MSRVenv mRNA in MS patients compared to healthy controls (Mameli, Poddighe et al. 
2009). To confirm the accuracy of the primer-probe set, we then used a 10-fold higher 
concentration of cDNA, and thus a 10-fold increase in target, expected to result in a 10-fold 
increase in expression level comparable to GAPDH, our housekeeping gene, as calculated by the 2-
ΔCt method. However, a decrease of approximately 10-fold was detected (figure 5.2). This initially 
surprising result can be explained by examining the Ct levels; where although the GAPDH Ct levels 
were decreased by approximately 4 (increased product by 24, or 16) as expected, the MSRVenv Ct 
levels did not change (figure 5.3). This suggests a failure by the MSRVenv primer and probe set to 
detect the appropriate target. 
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Figure 5.1: No difference in MSRVenv mRNA levels between MS patients and healthy 
controls detected in whole blood PCR as normalised to GAPDH (p=0.4653) (Mann-
Whitney). PCR completed by Prudence Gatt. Error bars represent median and interquartile 
range. 
 
Further investigations into the primer set confirmed our belief of an unreliable primer set as 
exhibited by the high amounts of non-specific amplification suggested by testing the SYBR green 
melt curve of this primer set (figure 5.4); subsequently called MSRVenv 160 due to the 160-base 
pair product predicted. A possible reason to why the MSRVenv 160 primers did not work in our 
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samples was inefficient replication of products, with a significant proportion of the PCR reaction 
devoted to amplifying other non-MSRVenv targets.  
 
1
0
x
 H
C
1
0
x
 M
S
1
x
 H
C
1
x
 M
S
0 .0 0 0 1
0 .0 0 1
0 .0 1
0 .1
M
S
R
V
 e
n
v
 
Figure 5.2: More concentrated cDNA used in Q-PCR results in decreased amounts of 
MSRVenv levels as normalised to GAPDH. HC= healthy control, MS= MS patients. 10x 
and 1x refers to relative cDNA concentrations, 1x PCR completed by Prudence Gatt. 
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Figure 5.3 Ct’s of the Q-RT PCR of figure 5.2 shows differences in the mRNA of GAPDH 
to be out of proportion with MSRVenv between 10x and 1x mRNA, 1x PCR completed 
by Prudence Gatt. 
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Figure 5.4: The derivative melt curve of the original MSRVenv primers by Mameli et al. 
(2009), subsequently called the MSRVenv160 primer set, showing amplification of 
multiple products 
  
- 101 - 
 
5.2 Development of new primers 
Therefore, a new set of more specific primers was needed, and it was concluded that it may be 
better to create a new forward or reverse primer. As the reverse primer could only be based upon 
one published MSRVenv sequence (figure 5.5), it was concluded that constructing a new forward 
primer would be the best option. The difficulty with the new primer set is that it needed to be very 
specific due to MSRVenv’s close homology with host gene Syncytin-1, and at the same time cover 
the variations seen within the available MSRVenv sequences. Consequently, it was not possible to 
use a primer design program such as Primer3 or NCBI’s primer design tool. 2 new forward primers 
were derived using alignments and checked for self-complementarity and melting temperatures 
using Primer 3 and NCBI’s primer design tool. To ensure a very high level of specificity, we chose 
primers to cover a mismatch at the 3’ end (Ayyadevara, Thaden et al. 2000) between Syncytin-1 
and MSRVenv (figure 5.5). 
 
The 2 new forward primers, called MSRVenv 308 which had a predicted 308-base pair product, 
and MSRVenv 444, which has a 444-base pair predicted product when used with the original 
MSRVenv 160 reverse primer were tested by quantitative SYBR green PCR. The products were also 
run onto an agarose gel to confirm the predicted size and determination of primer dimers or non-
specific binding. The product sizes were as expected, with the MSRVenv 308 primer set produced 
a very strong band with no smudging and no non-specific binding, along with a lack of primer 
dimer, while MSRVenv 444 has a weak product with very strong primer dimer formation as 
indicated by the no template control (NTC) (figure 5.6). These results were consistent with the 
SYBR green melt curve, where MSRVenv 308 had a very clean peak in the derivative melt curve, 
indicating a lack of non-specific binding, whereas MSRVenv 444 and MSRVenv 160 were 
discounted for use by the multiple peaks in the SYBR green melt curve (figure 5.7), and strong 
primer dimer formation for MSRVenv 444 (figure 5.7).  
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Figure 5.5: Creating new forward primers. Yellow = new forward primer 1 
(MSRVenv444); blue = new forward primer 2 (MSRVenv308); purple = original forward 
MSRVenv primer; green = original MSRVenv Taqman probe; pink, original MSRVenv reverse 
primer, also used as a reverse primer with the new forward primers. Blue zig zag line 
denotes areas in sequences that are not shown. 
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Figure 5.6: Agarose gel of products of the new primers, compared to the original 
MSRVenv 160 primers. MSRVenv308 produced very bright, clean lanes indicating lack of 
primer dimer or non-specific binding. MSRVenv 160 and 444 produced much lower levels of 
product. 
 
 
 
Figure 5.7 The derivative SYBR green melt curve of all three MSRVenv primers; 
MSRVenv 160 (blue), 308 (pink) and 444(brown). 
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5.3 MSRVenv 308 PCR 
With a better quality MSRVenv primer set developed for use with the SYBR green PCR system, we 
re-attempted the original PCR; comparing MS patients with healthy controls to both determine if 
we could replicate the findings of Mameli et al. (2009) of increased MSRVenv expression in MS 
patients, and to choose a positive control for the HERVenv flow cytometry. We found no 
differences between MS and healthy controls (figure 5.8). With no statistically significant increase 
of MSRVenv compared to healthy controls, it may be concluded that in our cohort, that MSRVenv 
mRNA expression is not associated with MS. We also compared MSRVenv mRNA expression with 
anti EBNA-1 IgG levels and found no correlation between the two (r= -0.08672, p=0.4992) (Pearson 
r) (figure 5.9).  
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Figure 5.8: There are no differences of the expression level of MSRVenv as normalised 
to GAPDH between healthy controls (HC) (n=41) and MS patients (MS) (n=33) 
(p=0.3407) (Mann-Whitney). Each point done in triplicate.  
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Figure 5.9: No correlation was detected between MSRVenv 308 mRNA expression and 
anti EBNA-1 IgG levels (r= -0.08672, p=0.4992) (Pearson r). 
 
To confirm the identity of the resultant MSRVenv product a few of the MSRVenv 308 products 
were sequenced after removal of any leftover primers using ExoSAP. Comparison with the 
available Syncytin-1 and MSRVenv sequences on NCBI, confirms the detected product is MSRVenv, 
with the presence of a 12-base pair insertion only found in MSRVenv and absent in Syncytin-1 
(figure 5.9). Interestingly, we discovered five new variations in our MSRVenv product (Westmead 
MSRVenv), all found in a section of the sequence only seen in one published sequence, MSRVpV14, 
accession number AF331500.1 (figure 5.10), as the other published sequences terminate prior to 
this section. 
 
Prediction of the Westmead MSRVenv protein sequence was completed using the EMBL-EBI 
Transeq tool: WVLPFLGPLAALILLLLFGPCIFNLLVKFVSSRIEAVKLQMVLQMEPQMQSMTKIYHG 
PLDQPASPCSDVNDIKGTPPEEISTAQ. Interestingly, nucleotide comparison of the Westmead 
MSRVenv with MSRVpV14 shows 93% homology, but when the corresponding protein sequences 
were compared, the homology decreases to 87%.  
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MSRVenv and syncytin (ERVW-
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MSRVenv sequences 
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Key: 
Figure 5.10: Alignment of sequenced 
MSRVenev308 products with 
sequences available on NCBI.  
Red line demarcates Syncytin-1 mRNA 
above the line, MSRVenv below the line. 
Below the line are 3 Westmead 
MSRVenv 308 sequences, the bottom 3 
are available MSRVenv sequences on 
NCBI. 
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  = Variation found only in MSRV, not Syncytin 
  = 4 amino acid insertions in MSRVenv; absent in Syncytin (ERVW-1)  
  = Unique variations in Westmead MSRVenv amino acid sequences  
  = Variation between the MSRVenv protein avaliable on NCBI and Syncytin-1 precursor or Westmead MSRVenv protein. 
              = Unique variation in Healthy Control 176 (position 139 in mRNA) position 47, P is replaced with T. 
              = Predicted transmembrane section of syncytin-1 
 
Figure 5.11: Protein alignment with available Syncytin-1 and MSRVenv protein sequences available on NCBI.  
Three samples were used to translate to protein alignment. The first sequence is Westmead MSRVenv sequence, middle 2 are Syncytin-1 precursor, 
and bottom is the only available MSRVenv sequence on NCBI that encodes this section of MSRVenv.  
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5.4: Flow cytometry of HERVenv 
With the PCR showing no replicability of Mameli et al. findings (2009), we attempted to replicate 
this group’s flow cytometry experiment where peripheral blood immune cells of MS patients are 
found to express HERVenv proteins (Mameli, Astone et al. 2007). Utilising the RTPCR data we 
identified a healthy control with high levels of MSRVenv compared to the rest to use as a positive 
control. Using the only commercially available HERV antibody in Australia, we tested blocking 
using Rabbit IgG; as the HERV antibody used is a rabbit IgG, before attempting to titrate HERV 
antibody levels. No specific binding of the HERV antibody was detected (Figure 5.11).  
 
We therefore concluded that the HERVenv detected in (Mameli, Astone et al. 2007) is mainly due 
to non-specific binding, a phenomenon often found with monocytes (Andersen, Al‐Karradi et al. 
2016). On the other hand, it is possible that our samples do not express HERVenv. Another 
explanation for the non-specific binding is that according to the manufacturers, the antibody has 
not been optimised for flow cytometry usage, only immunostaining and western blots. However, 
given the paucity of papers identifying HERV-Wenv protein expression, it is likely that any HERV-
Wenv produced in PBMCs are in such low levels that it is undetectable by flow cytometry.  
As there is no other commercially available antibody to either MSRVenv or HERV-Wenv, 
combined with the lack of discernible difference between healthy controls and MS patients, we 
did not pursue this line of investigation further.  
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Figure 5.12: The HERVenv protein found by Mameli et al. (2007) is undetected by 
flow cytometry when blocked with IgG from HERV antibody animal of origin. A= 
HERV antibody stained and blocked with rabbit IgG, B= HERV antibody stained with no 
block, C= Isotype antibody stain and rabbit IgG blocked, D Isotype antibody stain with no 
block. Assay was performed 3 times, with 3 different samples, no repetition. 1 
representative sample shown. 
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5.5: Discussion 
MSRVenv, the envelope protein of the multiple sclerosis associated virus previously found to be 
overexpressed in the lymphocytes of MS patients (Mameli et l, 2009) were found in this study to 
be expressed at very low levels in the PBMCs of both MS and healthy controls. While unique 
sequences were found in both the healthy controls and MS patients at Westmead, both the lack 
of statistically significant difference between healthy controls and MS patient MSRVenv mRNA 
expression, and the lack of any correlation between MSRVenv mRNA and anti EBNA-1 IgG titres, 
do not suggest an association between MSRVenv, MS and levels of EBV infection in our cohort. 
MSRVenv was not detectable in our samples by flow cytometry but rather a high level of non-
specific binding of the only commercially available HERV-W antibody that was completely 
blocked by an appropriate reagent (rabbit IgG). Consequently, we found no evidence of 
association at the RNA level, along with no correlation with EBV activity, using anti EBNA-1 IgG 
titres as a proxy for EBV activity. Additionally, as we could not detect protein levels with the 
available reagents, protein quantification was not pursued further. 
 
The PCR primers used by Mameli et al. did not amplify the target sequence in our samples.  
Spanish healthy controls and MS EBV strains may be different, or in their cohort specifically.  The 
novel sequences found in the Westmead cohort indicates this is a possibility, although is more 
likely due to the paucity of sequence data for MSRV.  Future work may be facilitated by the 
increasing data available from whole genome sequencing on variation in MSRV sequences 
between individuals, and possible MS –specific strains. Improved sensitivity of flow cytometry 
antibodies may allow more accurate detection of MSRVenv expression in people with MS and 
controls.  
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Chapter 6: Summary 
Multiple Sclerosis (MS) affects more than 2.3 million people worldwide, (Browne, Chandraratna 
et al. 2013) and is a degenerative autoimmune disease characterised by demyelination of 
neurons in the CNS (Sospedra and Martin 2005). Disease onset typically occurs between the ages 
of 15 and 50 years old and results in permanent heterogeneous disability; including but not 
limited to loss of sensation, motor, autonomic, and neurocognitive ability (Sospedra and Martin 
2005, Haahr and Hollsberg 2006). MS is thought to arise in genetically susceptible individuals, 
elicited by environmental factors.  
 
Though the precise cause of MS is unknown, evidence has shown that gender, age, genetic and 
environmental factors play a crucial role (Ramagopalan, Dobson et al. 2010). Approximately 30- 
34% of disease risk is due to genetic factors (Dyment, Ebers et al. 2004, Marrie 2004, Dendrou, 
Fugger et al. 2015), with first degree relatives having a 3-5% recurrence risk as compared to the 
global prevalence of approximately 0.2% (Dyment, Ebers et al. 2004). While these numbers are 
still comparatively small, this equates to more than 15-35 times greater risk compared to the 
general population (Dyment, Ebers et al. 2004, Ramagopalan and Sadovnick 2011). 
 
Despite the large role that genetic factors play in MS pathogenesis, around 70% of MS risk cannot 
be explained by genetics (Ebers 2008); of which a large portion must then be due to 
environmental factors, in addition to other unknown events. There are two main environmental 
factors influencing MS risk, the first being Vitamin D/UV, and the second; infectious disease 
involvement, particularly, the Epstein Barr Virus. Virtually all MS patients are seroconverted to 
EBV compared to the general population, which have a seroconversion rate of 90-94% 
(Ramagopalan, Dobson et al. 2010, Jørgensen, Livbjerg et al. 2012). EBV is thought to play a role 
in MS pathogenesis. Increased levels of IgG antibodies to EBV Nuclear Antigen-1 (EBNA-1) after 
the age of 25 are associated with increased MS risk by 2 to 3 fold (Levin, Munger et al. 2005, 
DeLorenze, Munger et al. 2006), and MS patients are found to have increased levels of anti-EBNA-
1 IgGs, a finding that has been replicated across many cohorts (Munger, Levin et al. 2011, McKay, 
Gatt et al. 2016). 
 
Anti EBNA-1 IgG can be considered as an indicator of the magnitude of immune response to 
latent EBV infection, as EBNA-1 is the only viral protein consistently expressed throughout all four 
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stages of the EBV life cycle (Daikoku, Kudoh et al. 2004, Tsurumi, Fujita et al. 2005). In this project, 
we are able to confirm previous findings that MS patients have increased anti EBNA-1 IgG 
compared to healthy controls (Lunemann, Tintore et al. 2010, Nociti, Frisullo et al. 2010, Munger, 
Levin et al. 2011), As the ratio of anti EBNA-1 to total IgGs was higher in MS, this supports the 
hypothesis that in MS, there is an impaired or decreased control of EBV that contribute to MS 
pathogenesis by way of a combination of bystander damage, molecular mimicry and/or 
autoimmune B-cell survival.  
 
The MS risk genes of interest in this project are HLA-DR, ZFP36L2, ZMIZ1, RPS6, EOMES and 
TBX21. Of all of the MS risk genes, HLA-DR has the strongest association with MS, and of its 
variants, the DRB1*1501 allele confers the highest risk with an odds ratio of 3.1 followed by 
DRB1*1303 at an odds ratio of 2.4 (The International Multiple Sclerosis Genetics Consortium 
(IMSGC), Wellcome Trust Case Control Consortium 2 (WTCCC2) et al. 2011). Here, we found an 
association between anti-EBNA-1 IgG titres and the HLA-DR SNP rs2516049; where the more 
common MS risk allele has a dose dependent association with increasing anti EBNA-1 IgG 
production, and thus, increased MS risk. This association between MS, anti EBNA-1 IgG titres and 
the rs2516049 SNP is further supported by the much larger GWAS study published by Zhou et al 
(2016), with this SNP giving the strongest P value (p= 4.11x10-9) out of all the HLA SNPs tested.  
 
The ZFP36L2 SNP, tagged by rs2163226 suggests a trend of lower anti EBNA-1 IgGs with the risk 
allele for MS in healthy controls. As ZFP36L2 helps the genomic integrity of B-cells by maintaining 
quiescence after VDJ recombination (Galloway, Saveliev et al. 2016), this effect may be due to 
decreased levels of mature B- cells, and consequently, less EBNA-1 expression and production of 
its antibody. In MS patients, this effect is absent, which may be due to the increased 
inflammatory state in MS, therefore, it is unlikely that the MS risk conferred by rs2163226 is 
mediated through levels of EBV infection in the host. The absence of a correlation between anti 
EBNA 1 IgG levels with ZFP36L2 mRNA expression further suggests a lack of relationship between 
EBV and MS risk conferred by ZFP36L2 that can be seen in peripheral blood.  
 
A weak negative correlation was observed between ZMIZ1 gene expression and anti EBNA-1 IgG 
levels in healthy controls, indicating that higher levels of ZMIZ1 expression are associated with 
lower levels of EBV infection. ZMIZ1 is a member of the protein inhibitor of activated STAT (PIAS)-
like family of transcriptional coactivators which bind to STAT, Notch-1, NF-κB, SMAD and 
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androgen receptors (Sharma, Li et al. 2003, Shuai and Liu 2005). With both ZFP36L2 and ZMIZ1, 
it is difficult to develop specific hypotheses to explain how lower expression confers disease risk 
due to its many probable interactions and downstream effects as a transcriptional coactivator. 
However, as ZMIZ1 inactivation is also known to result in inhibition of T-cell development (Pinnell 
et al. 2015), it is possible that decreased ZMIZ1 expression leads to decreased T-cell maturation, 
and thus decreased control of EBV infection, leading to increased MS risk.   
 
RPS6KB1, an MS risk gene, controls the phosphorylation of ribosomal protein 6 (RPS6), a protein 
involved in the regulation of cell growth, and proliferation. It is known to be upregulated in MS 
(Parnell, Gatt et al. 2014, Fewings, Gatt et al. 2017), and as RPS6 expression has a weak positive 
correlation with anti EBNA-1, it is possible that the MS risk conferred by RPS6 is in some way 
mediated by EBV infection. The upregulation of RPS6 in MS patients may have increased the cell 
growth and proliferation of EBV infected B-cells, leading to increased levels of EBV infection, and 
thus increased MS risk. 
 
While EBV activity, as assayed by anti EBNA-1 antibody titre, is likely to be involved in MS 
pathogenesis, the role it plays in mediating the risk conferred by MS risk genes is not as clear cut. 
It is possible that EBV may contribute to the MS risk conferred by ZMIZ1 and RPS6, and perhaps, 
to a lower extent, ZFP36L2. ZMIZ1 is positively correlated with ZFP36L2; both are upregulated in 
MS patients and ZMIZ1 is also negatively correlated with RPS6, which is downregulated in MS 
patients (Fewings et al. 2017). As ZMIZ1, RPS6 and ZFP36L2 seem to interact with each other, a 
relationship between EBV and any one of the three genes may be reflected less prominently in 
the other 2. We saw no evidence in whole blood other MS risk variants conferred altered 
regulation of EBV infection; HLA-DR SNP rs9271366, EOMES SNP rs11129295, TBX21 SNP 
rs4794058, ZMIZ1 SNP rs1782645 and RPS6KB1 SNP rs180515 when compared to anti-EBNA-1 
IgG titres did not result in statistical significance, although this may be due to an absence of 
statistical power. 
 
Another gene of interest, CD40, is part of the Tumour Necrosis Factor Receptor (TNFR) 
superfamily (Elgueta, Benson et al. 2009), and mainly expressed on B cells, though it can also be 
expressed on DCs, monocytes, macrophages and platelets, along with myofibroblasts, 
fibroblasts, epithelial, and endothelial cells (Elgueta, Benson et al. 2009). The downstream effects 
of CD40 activation include but are not limited to T cell dependent B cell activation, differentiation 
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into plasma cells and memory B cells, Ig isotype switching, germinal centre formation and somatic 
hypermutation to enhance Ig affinity (Elgueta, Benson et al. 2009, Peters, Stunz et al. 2009). 
Several single nucleotide polymorphisms (SNPs) in the CD40 gene confer increased risk of MS, 
including rs1883832, located 1 base pair prior to the CD40 transcription start site (Australia New 
Zealand Multiple Sclerosis Genetics Consortium 2009, Beecham and IMSGC 2013). The minor T 
MS risk allele or rs1883832 is associated with decreased CD40 mRNA expression in B-cells and 
differentiated DCs of healthy controls (Field, Shahijanian et al. 2015), indicating a protective 
function of CD40, where lower B cell expression of CD40 confers risk of MS. Additionally, MS 
patient B-cells are found to have lower levels of CD40, at both the mRNA and protein levels, when 
compared to healthy controls (Field, Shahijanian et al. 2015). 
 
As CD40-CD40L interaction increases T and B-cell activation along with proinflammatory cytokine 
production (Bush and Bishop 2008, Dendrou, Fugger et al. 2015) this appears somewhat 
counterintuitive, given that lower expression of an inflammatory pathway is associated with 
increased risk of MS; an observation we have called the “CD40 paradox”. However, one potential 
explanation for the CD40 paradox in MS is that it confers a competitive advantage to the host 
during EBV infection.  Here, LMP1, a continuous and more potent activator of B cells (Stunz, Busch 
et al. 2004), increases the risk of formation of autoreactive B-cells which can then confer the 
damage proinflammatory effects that may contribute to or increase risk to MS.  
 
It has been suggested that in the context of EBV infection, CD40 may compete with EBV latent 
membrane protein 1 (LMP-1) for signalling molecules. LMP-1 is a functional mimic of CD40, with 
downstream effects similar to CD40, but signalling in an amplified and sustained manner 
(Kilger, Kieser et al. 1998, Graham, Moore et al. 2009).While in vivo infection of EBV causes 
asymptomatic infection in childhood, infectious mononucleosis in young adults and a 
lymphoproliferative disease in immunocompromised individuals, in vitro infection of EBV gives 
rise to immortalised B cell lines, called Lymphoblastic Cell Lines (LCL) (Lam and Sugden 2003). 
LMP1, a viral membrane protein expressed during active EBV infection, is a functional mimic to 
CD40 and is found to be crucial for the constant proliferation and immortalisation that occurs in 
LCL formation and EBV-associated lymphomas (Kilger, Kieser et al. 1998). 
Here, we have found that the protective allele of CD40 (rs1883832, CC) is associated with higher 
expression of CD40 in LCLs, and that culture of LCLs in the presence of CD40L reduces their 
proliferation, in a genotype dependant manner. This supports our hypothesis that the protective 
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allele of CD40 reduces susceptibility to MS through reducing susceptibility to EBV, by way of 
competition between LMP-1 and CD40 for resources, such as TRAFs 2 and 3. However, some 
findings were inconsistent with this hypothesis, as we did not find a genotype association with 
mRNA expression in B cells, with protein expression in LCLs, or with anti-EBNA-1 titres in healthy 
controls or people with MS.  A likely explanation for this inconsistency is that we lacked sufficient 
statistical power to find such associations. This is something that is difficult to remedy considering 
that converting B cells into LCLs required a minimum of 2-3 months, therefore it is difficult to 
achieve larger cohort numbers in a master’s degree due to time constraints. Further work in this 
area would require a much larger sample size, and examination of the TRAFs that are likely to be 
involved in the competition between LMP-1 and CD40, particularly if any are MS risk genes. 
 
Comprising approximately 1-8% of the human genome, Human Endogenous Retroviruses (HERV) 
can be termed as the “footprints” of previous retroviral infections that have been transmitted 
vertically through the germline (Nelson, Carnegie et al. 2003, Perron and Lang 2010). A beneficial 
HERV product is the HERV group W envelope protein, syncytin, believed to be important in 
human placental morphogenesis (Mi, Lee et al. 2000). Syncytin bears close homology with 
Multiple Sclerosis associated Retrovirus (MSRV) (Machnik, Skudrzyk et al. 2015), a viral element 
repeatedly found in the cerebrospinal fluid (CSF), EBV-immortalised LCLs (Perron, Garson et al. 
1997) and the brain tissue of MS patients (Schmitt, Richter et al. 2013). The presence of MSRV in 
the CSF of MS patients is also observed to be associated with increased disease severity (Sotgiu, 
Serra et al. 2002). However, the role of MSRV in the pathogenesis of MS is unclear and 
controversial, with conflicting reports of MSRV upregulation or lack of in the MS brain (Antony, 
Zhu et al. 2007, Mameli, Astone et al. 2007, Antony, Deslauriers et al. 2011).  
 
MSRVenv, the envelope protein of the multiple sclerosis associated virus previously found to be 
overexpressed in the lymphocytes of MS patients (Mameli, Poddighe et al. 2009, Mameli, 
Madeddu et al. 2013) were found in this study to be expressed at very low levels in the PBMCs 
of both MS and healthy controls. While unique sequences were found in both the healthy 
controls and MS patients at Westmead, both the lack of statistically significant difference 
between healthy controls and MS patient MSRVenv mRNA expression, and the lack of any 
correlation between MSRVenv mRNA and anti EBNA-1 IgG titres, do not suggest an association 
between MSRVenv, MS and levels of EBV infection in our cohort. MSRVenv was not detectable 
in our samples by flow cytometry but rather a high level of non-specific binding of the only 
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commercially available HERV-W antibody that was completely blocked by an appropriate reagent 
(rabbit IgG). Consequently, we found no evidence of association at the RNA level, along with no 
correlation with EBV activity, using anti EBNA-1 IgG titres as a proxy for EBV activity.  
 
Conclusions: 
We can confirm that anti EBNA-1 IgGs are increased in MS patients, independent of total IgG 
levels in the blood, as MS patients have very similar levels of total IgG to healthy controls. 
However, the spread of the data overlap of MS and controls precludes the use of anti EBNA-1 
levels are predictors of MS risk. We found a significant association between anti EBNA-1 IgG levels 
with rs2516049, an MS risk SNP for HLA-DR, the gene most strongly associated with MS risk. 
However, we found no significant association of the SNP most associated in MS; rs9271366. 
ZMIZ1, RPS6 and ZFP36L2 were associated with anti EBNA1 titres, and may contribute to the 
immune response to EBV. Serum sodium is not associated with anti EBNA-1 IgG levels, though as 
the human body seems to keep a very tight homeostasis on sodium levels, it may not be the best 
measure of dietary sodium intake and that urinary sodium output should be done instead.  
 
The MS protective allele of CD40 (rs1883832, CC) is associated with higher expression of CD40 in 
LCLs, and that culture of LCLs in the presence of CD40L reduces their proliferation, in a genotype 
dependant manner. This indicates that the protective allele of CD40 reduces susceptibility to MS 
through reducing susceptibility to EBV. However, we did not find a genotype association with 
mRNA expression in B cells, with protein expression in LCLs, or with anti-EBNA-1 titres in healthy 
controls or people with MS, likely due to a lack of power due to a small sample size.   
 
MSRVenv, the envelope protein of the multiple sclerosis associated virus previously found to be 
overexpressed in the lymphocytes of MS patients (Mameli, Poddighe et al. 2009, Mameli, 
Madeddu et al. 2013) were found in this study to be expressed at very low levels in the PBMCs 
of both MS and healthy controls. The lack of statistically significant differences between healthy 
controls and MS patient MSRVenv mRNA expression, and the lack of any correlation between 
MSRVenv mRNA and anti EBNA-1 IgG titres, do not suggest an association between MSRVenv, 
MS and levels of EBV infection in our cohort.  
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It must be considered however, that while anti EBNA-1 IgG is the main antibody associated with 
latent EBV infection and is used in many studies, it may not be the best measure of EBV 
dysregulation in the body as it only measures serological responses to EBNA-1. While EBNA-1 is 
expressed throughout all phases of the EBV life cycle, the antibody is known to be absent in some 
EBV positive patients (Miller, Grogan et al. 1987). Therefore, if EBV has reactivated in MS 
patients, then other antigens may need to be considered in combination with EBNA-1 as markers 
of EBV dysregulation. 
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